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2. Abstract 
 
Aims and Objectives: It was hypothesized that urinary incontinence has an impact on 
sexual function in women though the exact impact and its mechanism remains unproven.  
I also noted that patients who underwent treatment for urinary incontinence had an 
improvement in sexual function. This thesis aimed to analyze the association between 
urinary incontinence and sexual function in women. The impact of different treatment 
modalities for urinary incontinence and their effect on sexual function was measured. 
This was through a series of separate experiments.  
 
Methods: It is widely accepted that urinary incontinence impacts on sexual function but 
the pathophysiology remains unclear. A review of female sexual dysfunction (Paper 1) 
and the impact of pelvic floor problems on sexual function (Paper 2) was undertaken.  
 
As studies analyzing sexual function in women with pelvic floor disorders tend to cluster 
women with prolapse and incontinence it has been difficult to identify which of these has 
a greater impact on sexual function. A study was undertaken to compare sexual function 
in these 2 main disorders of the pelvic floor, prolapse and incontinence (Paper 3). The 
incidence of sexual dysfunction and comparison of symptoms in both groups were done 
using Mann-Whitney U test.  
 
The two most common causes for urinary incontinence are sphincter weakness and 
involuntary detrusor contractions, which usually manifest clinically as stress 
incontinence and overactive bladder. Traditional teaching has been that both are 
responsible for coital incontinence but there remains considerable controversy on the 
exact impact different types of urinary incontinence has. This was further explored in 
another study (Paper4). Data were collected as part of routine clinical care using an 
electronic pelvic floor questionnaire (ePAQ) and correlated with urodynamic findings. By 
correlating the different types of incontinence based on urodynamic diagnosis to sexual 
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function, the exact incidence of coital incontinence, penetration and orgasm 
incontinence were estimated.  
 
Various treatment modalities for both types of urinary incontinence were assessed and 
the impact these treatments have on sexual function studied. The chief forms of 
treatment for Stress incontinence are Pelvic Floor Muscle Training (PFMT) and surgical 
treatment. To assess the former a prospective cohort randomized controlled trial was 
conducted looking at the impact of electrical stimulation compared to standard PFMT 
alone in women with urinary incontinence and the impact this has on sexual function 
(Paper 7). This was a single centre two arm parallel group randomised controlled trial. The 
interventions compared were electric stimulation versus standard pelvic floor muscle 
training. Outcome measures included Prolapse and Incontinence Sexual function 
Questionnaire (PISQ) physical function dimension at post-treatment (primary); other 
dimensions of PISQ, SF-36; EQ-5D, EPAQ, resource use, adverse events and cost-
effectiveness (secondary outcomes). 
 
The impact of all continence surgery including the Tension free vaginal tape (TVT) on 
sexual function was evaluated by conducting a systematic review and meta-analysis 
(Paper 5). Observational studies and randomised controlled trials investigating the 
impact of surgical correction of stress urinary incontinence on sexual function were 
included. Surgical interventions included TVT, TVT-O, TOT, Burch and AFS. Studies which 
included patients undergoing concurrent prolapse surgery were excluded from the 
analysis. Coital incontinence was analyzed separately and OR with 95% CI calculated. 
The data were analysed in Review Manager 5 software. In addition to analyzing various 
treatment options we also compared the different types of midurethral tapes and their 
overall impact on sexual function.  
 
The mainstay of treatment for women with overactive bladder symptoms (OAB) is 
anticholinergics and this was assessed in a separate study. Women identified to have 
OAB and sexual dysfunction being commenced on anticholinergics were followed up to 
P a g e  6 | 187 
 
 
 
 
observe the impact of medical treatment on their sexual function (Paper 6).The ePAQ 
PF, PISQ 12 and PGI-I for Overactive bladder and Sexual function. Sexually active women 
with overactive bladder were included in the study and assessed using the ePAQ-PF, 
PISQ 12 and PGI-I for Ovaercative bladder and Sexual function.  Prolapse and voiding 
dysfunction were exclusion criteria for the study. All women were followed up for 6 
months and were treatment naïve. Sexual function before and after treatment was 
compared.  The data were analysed using SPSS.  
 
Results: The individual impact of pelvic organ prolapse (POP) and urinary incontinence 
on sexual function was found to be similar. Patient and partner avoidance in women 
with POP was greater than those with stress urinary incontinence (Paper 3). 
 
Worsening urinary incontinence has a deleterious effect on sexual function. However 
the type of urinary incontinence as established on Urodynamic diagnosis does not 
correlate with the nature of underlying sexual problems, orgasm or penetration 
incontinence (Paper 4).    
 
PFMT improved sexual function, but when comparing standard PFMT to electrical 
stimulation there was no difference in the outcomes (Paper 7).  
 
Surgical correction of SUI resulted in coital incontinence being significantly reduced. An 
analysis of overall impact on sexual function with all surgical continence procedures 
demonstrated an improvement, no change and deterioration in 31.9%, 55.5% and 13.1% 
respectively. These were similar when analyzing overall sexual function following mid 
urethral tapes in isolation (Paper 5). 
 
Anticholinergics and cure of overactive bladder did not however correlate to an 
improvement in sexual function (Paper 6).   
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Conclusions: Sexual dysfunction is complex and multifactorial. The prevalence of sexual 
dysfunction is greater in women with pelvic floor disorders and the various interventions 
for urinary incontinence have a variable impact.  
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5. Commentary 
 
5.1 Literature Review: Introduction and Background 
5.1.1 Female Sexual Dysfunction (FSD)  
Sexual problems are common among women but they become a dysfunction when they 
cause distress as opposed to a normal physiological response due to difficult 
circumstances. FSD is defined as a disorder of sexual desire, arousal, orgasm or 
sexual pain that results in significant personal distress. It is more prevalent in women 
(43%) than in men (31%)7. Furthermore it is associated with various psycho-
demographic characteristics, e.g. age, education, and poor physical and emotional 
health. FSD appears to be more common in women who have a history of sexual abuse 
or coercion8. It is believed that in the general population up to 60% of women aged less 
than 60 have some degree of sexual dysfunction9. An international survey (The Global 
Study of Sexual Attitude and Behaviours) investigated behaviours’, attitudes, beliefs, 
and satisfaction regarding sex, intimacy, and relationships among men and women aged 
40-80 years. In women, 34% of respondents had decreased sexual interest and 19% did 
not consider sexual intercourse to be pleasurable. In this same survey 23% of women 
reported reduced lubrication with a significant increase between 50 and 69 years 10. 
Surveys of patients in physicians' offices suggest  that each year, family practitioners will 
see several women or couples who present with sexual problems, and even more if the 
physician enquires about patients' sexual health. Surveys have also shown a very high 
prevalence of sexual concerns in women seeking routine gynaecological care11. 
Nusbaum et al questioned 1500 women attending a gynaecology clinic and found that 
98% of the respondents reported one or more sexual concerns. The most frequent was 
hypoactive sexual desire (87%) followed by orgasmic disorders (83%) inadequate 
lubrication (5%) and dyspareunia indicative of a sexual pain disorder (72%)8.  
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Paper 1 1 of this thesis is a review of Female Sexual dysfunction and looks at the 
underlying mechanisms and classification as well as the diagnosis and management of 
this condition.  
Since the publication of this paper there continues to be considerable debate into the 
classification of FSD but there has not been any updated classification universally 
accepted in clinical practice.  
Following the success of Sildenafil in male sexual dysfunction attempts to develop a 
similar drug for FSD have been ongoing. Flibanserin, a multifunctional serotonin 
agonist/antagonist, was developed as a non hormonal option designed specifically for 
the treatment of Hypo active sexual desire disorder but has failed to be established due 
to the marginal efficacy and side effect profile. The use of SSRI for the management of 
Persistent Genital arousal disorder described in this chapter seems counterintuitive as 
they cause severe sexual side effects including suppression of libido. However they may 
have a role where the condition is causing depression and in such cases it is necessary to 
weigh the pros and cons of such treatment. Another proposed treatment discussed in 
this chapter is the use of Alprostadil (Prostaglandin E1). Its use locally has been 
hypothesized to improve vulvar blood flow and may lead to an increase in overall sexual 
arousal and sexual satisfaction 12. 
5.1.2 Urinary Incontinence  
Urinary incontinence (UI) is defined by the International Continence Society as the 
“complaint of involuntary leakage of urine”. It is a common condition and 
epidemiological studies suggest that it affects up to 41% of the adult female population. 
UI impacts on different aspects of a woman’s life including social, psychological, 
occupational, domestic, physical and sexual well-being 13-16. The two most common 
pathophysiologies underlying urinary incontinence are sphincter weakness and 
involuntary detrusor contractions, which usually manifest clinically as stress urinary 
incontinence (SUI) and overactive bladder (OAB). Stress (urinary) incontinence is defines 
as the complaint of involuntary loss of urine on effort or physical exertion (e.g.sporting 
activities), or on sneezing or coughing.  Urgency (urinary) incontinence on the other 
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hand is the complaint of involuntary loss of urine associated with urgency. The 
corresponding urodynamic diagnosis are urodynamic stress incontinence (USI) and 
detrusor overactivity (DOA). USI is the involuntary leakage of urine during filling 
cystometry, associated with increased intra-abdominal pressure, in the absence of a 
detrusor contraction. DOA on the other hand is the occurrence of involuntary detrusor 
contractions during filling cystometry. These contractions, which may be spontaneous 
or provoked, produce a wave form on the cystometrogram, of variable duration and 
amplitude. The contractions may be phasic or terminal. If a relevant neurological cause 
is present, then neurogenic detrusor overactivity is noted, otherwise idiopathic 
detrusor overactivity should be the term used17. Women who have features of both 
have mixed incontinence18.  
 
Compared to the general population, women with UI complain of a deteriorating quality 
of life (QoL) both social and psychological problems, and sexual dysfunction in 
significantly greater numbers.  
Paper 2 2 of this thesis formed the literature review and analysed the previous reported 
literature of common urogynaecology conditions (prolapse and urinary incontinence) 
and their impact on sexual function.  
5.1.3 Pelvic Floor dysfunction and Sexual dysfunction  
Different problems of the pelvic floor can also impact on sexual activity in different 
ways. It is however difficult to tease out the exact relationship of pelvic floor 
dysfunction to sexual dysfunction specially since there is a high baseline prevalence. In 
recent years there has been an increasing interest in pelvic floor dysfunction and 
associated sexual problems particularly related to urinary incontinence.  
Prolapse and Urinary incontinence are both common pathologies affecting the pelvic 
floor however the issue of which of the two impacts on sexual function more remains 
unresolved.  In women with prolapse there is considerable debate about the impact of 
prolapse per se on sexual function. A review of literature shows conflicting results, with 
some studies showing a deterioration of function and others showing no impact 19. In 
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their observational study Handa et al looked at 1299 participants, of whom 495 (38.1%) 
had evidence of pelvic floor disorders. Sexual complaints were significantly more 
common among women with pelvic floor disorders (53.2% vs 40.4%, P < .01) and when a 
multiple regression model, urinary incontinence was significantly associated with low 
libido (odds ratio [OR] 1.96), vaginal dryness (OR 2.11), and dyspareunia (OR 2.04), 
independent of age, educational attainment, and race. In contrast, pelvic organ prolapse 
was not associated with any sexual complaint. A study by Weber et al20 comparing 80 
women with prolapse with or without incontinence and 30 controls (women with no 
prolapse) showed no difference in global sexual function score, vaginal dryness, 
dyspareunia, interest in sexual activity or satisfaction with their sexual relationship. They 
concluded that women with prolapse and urinary incontinence do not differ from 
continent women without prolapse in measures of sexual function and age is the most 
important predictor of sexual function. Burrows et al 21 came to similar conclusions in 
their retrospective study of 352 women with prolapse. They also found that prolapse 
severity did not impact on sexual function.  
 
The study by Barber et al22 comparing the impact of prolapse and incontinence on 
sexual function found completely the opposite results. In their review of 343 community 
dwelling women with either symptomatic prolapse or incontinence, they found that 
prolapse was more likely to influence sexual function than urinary incontinence. This 
study also demonstrated that treatment of prolapse was less likely to impact on change 
in sexual function whereas treatment of incontinence resulted in a mild improvement in 
sexual function. The impact of pelvic organ prolapse and its treatment is beyond the 
remit of this work.   
 
In women with UI, the symptoms per se, along with fear of odour, shame, 
embarrassment, loss of self-esteem and fear of, or actual occurrence of, incontinence 
are contributory factors to deteriorating sexual function. The most common sexual 
complaints in women with urinary incontinence are low desire, vaginal dryness, and 
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dyspareunia 19. However the problem with assessment of sexual function in the 
different studies reported in literature is that: 
1. Different tools have been used in different studies  
2. Studies cluster prolapse and incontinence under the same umbrella 
3. Study groups are small 
4. Different types of incontinence and varying severity of incontinence are clumped 
together  
5. Few studies make an attempt to establish what proportion of the sexual 
problems is related to urinary leakage.  
6. Even fewer studies look at the impact of either incontinence or its treatment on 
different aspects of the sexual cycle.   
 
Paper 3 3 of this thesis aims to test which of the pelvic floor disorders ie prolapse or 
urinary incontinence impacts on sexual function more and what aspects of sexual 
function are affected in each of these conditions. The electronic Pelvic floor assessment 
questionnaire (ePAQ PF) was used to compare the different aspect of sexual function in 
women with either prolapse or incontinence. This questionnaire is routinely 
administered to patients attending the Urogynaecology clinic as part of routine clinical 
care.  The ePAQ PF is a 129-item, interactive computer-based self-administered 
questionnaire which measures urinary, bowel, vaginal and sexual symptoms. It also 
assesses the impact of these individually. The questionnaire has four dimensions: 
urinary, bowel, vaginal and sexual. Responses to screening questions determine 
whether or not subsequent items are skipped. When patients are asymptomatic, sub-
questions on impact are hidden, thus minimising the burden of items not relevant. 
Patients can omit an entire dimension or decline to answer individual items if they so 
wish. It has been validated as a web-based clinical assessment system. It has been 
specifically designed to provide detailed, reliable and meaningful self-reported 
symptoms & quality of life data in women with pelvic floor disorders 23;24. Although 
designed initially as a clinical tool to facilitate patient assessment, ePAQ has been 
recognised by the British Society of Urogynaecology (BSUG) and the National Institute of 
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Clinical excellence (NICE) as a responsive & meaningful patient reported outcome 
measure (PROM). 
All questionnaire data are stored on a password protected secure server located with 
the NHS firewall & fully compliant with UK data protection regulation. The questionnaire 
asks patients if they are willing for their data to be used in anonymized research in 
approved and registered research. Patients who declined consent did not have their 
data used. This study was a retrospective review of the ePAQ database assessing 
patients on the waiting list for either prolapse or incontinence surgery. As key 
demographic data is not collected in the database, this was missing in the analysis and is 
a weakness of this study, but it remains the single largest study comparing sexual 
function in patients with prolapse or incontinence.   
 
5.1.4 Urinary Incontinence and Sexual dysfunction 
 
It is widely accepted that urinary incontinence impacts on sexual function but there 
remains considerable controversy on the pathophysiology of this impact on sexual 
function. Complaints of SUI, OAB, and lower urinary tract symptoms have negative 
impact on various domains of sexual function 13;25.This was reported in a cross-sectional 
study by Salonia et al 25. Sexual dysfunction was diagnosed in 99 out of 216 patients 
(46%) with urinary incontinence or lower urinary tract symptoms. Of these, 34 (34%) 
reported hypoactive sexual desire, 23 (23%) reported sexual arousal disorder; 11 
patients (11%) complained of orgasmic deficiency, and 44 (44%) suffered from sexual 
pain disorder (e.g., dyspareunia or non-coital genital pain). Women reporting low sexual 
desire commonly suffered from stress incontinence (47%). Forty-six percent of those 
complaining of orgasmic phase difficulties also reported troublesome urge incontinence. 
A group of 102 age-matched women (mean age 54; age range 19-63) not complaining of 
urinary symptoms were enrolled as cross-sectional controls and investigated in 
accordance with the Female Sexual Function Index (FSFI).The FSFI values in both groups 
scored as follows (patients versus controls; median value; p value): desire: 2.0 vs. 3.2 
(p<0.01); arousal: 2.8 vs. 3.6 (p=n.s.); lubrication: 3.2 vs. 4.4 (p=0.01); orgasm: 4.1 vs. 4.4 
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(p=not significant); sexual satisfaction: 2.7 vs. 4.0 (p<0.01); sexual pain: 1.8 vs. 4.0 
(p<0.001).  
 
In a recent Case control study by Filippe 26 women with urinary incontinence were more 
likely to be sexual abstinent than continent women and had less sexual desire, sexual 
comfort, and sexual satisfaction.  Sexual dysfunction is therefore highly prevalent in 
women attending urogynaecological services 27.  
 
5.2 The association of different types of urinary incontinence with sexual function  
 
Traditional teaching has been that urodynamic stress incontinence (USI) is associated 
with penetration incontinence and detrusor over activity with orgasm incontinence 28, 
however subsequent studies by Moran et al29 have failed to confirm this association. In 
their observational study USI was associated with high rates of penetration incontinence 
(80%), orgasm incontinence (93%) and a combination of the two (92%). In women with 
SUI prevalence of coital incontinence ranges from 11-70% 28-31. Among the different 
types of urinary incontinence, OAB has a particularly high association with sexual 
dysfunction in various studies 32 33, which could be indicative of an underlying 
psychosomatic disorder 34. However studies assessing overall prevalence of sexual 
dysfunction in women with OAB and the impact on Quality of life remains 
controversial35 whereas menopausal and partner status have been shown to be the 
better predictors36. 
 
Paper 4 4 of this thesis compares the various types of urinary incontinence based on 
urodynamic diagnosis and the association with leakage at different phases of the sexual 
cycle. To ensure the results were valid a sample size calculation was undertaken even 
though this was a retrospective study. The sample size used for the analysis was in 
excess of the numbers required hence making the results valid. Assessment of 
correlation of the results of the e-PAQ and UDS was performed retrospectively from the 
e-PAQ database.  
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5.3 Pelvic Floor Muscle Training (PFMT) 
5.3.1 Types of PFMT 
PFMT was defined as a programme of repeated voluntary pelvic floor muscle 
contraction with or without supervision by health care professionals. First described by 
Kegel in 1948 with a cure rate of 84% it became more popular as a treatment option for 
urinary incontinence in the 1980s. PFMT is now accepted as the first line treatment for 
urinary incontinence 37 and the National Institute of Clinical Excellence (NICE) 
recommend that a trial of supervised pelvic floor muscle training of at least 3 months’ 
duration should be offered to all women with stress or mixed UI prior to any surgical 
intervention 38. There is Grade 1A evidence that daily pelvic floor muscle training 
continued for 3 months is safe and effective with an improvement in urinary 
incontinence expected in 40–60% of women. The exact mechanism by which PFMT 
improves incontinence is unknown; however the aim of therapy is to improve the 
strength and efficacy of pelvic floor contraction.  
 
All types of PFMT are undertaken in conjunction with education regarding anatomy of 
the pelvic floor and lower urinary tract its physiology and the continence mechanisms.  
PFMT can be performed with or without adjunctive treatments such as electrical 
stimulation(ES), vaginal cones or biofeedback. In a single blind randomised control trial 
comparing standard physiotherapy to ES and vaginal cones, Bo 39 demonstrated that 
standard physiotherapy was as effective as ES or vaginal cones if not better.   
Other studies have shown ES to be safe and effective in the treatment of women with 
urinary incontinence both stress 40;41 and urgency41;42. In a recent Systematic review ES 
was shown to be as effective as a treatment option for different types of urinary 
incontinence43.  
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5.3.2 PFMT and Sexual function 
The current available limited evidence suggests that supervised PFMT has a beneficial 
effect on overall sexual function. The study by Zahariou et al44 was an observational 
study assessing the effectiveness of PFMT on sexual function and showed all domains of 
sexual function to be improved. Women included in the study had received supervised 
PFMT for 12 months. Beji 45 showed similar results with an improvement in sexual 
desire, performance during coitus and achievement of orgasm in women who received 
pelvic floor muscle rehabilitation. Bo 46 also showed physiotherapy improved some 
aspects of sex life, though various domains of sexual function were not assessed.  
 
Rivalta et al 47 looked at the impact of biofeedback, electrical stimulation, PFMT and 
vaginal cones in combination in 3 women with urinary incontinence and associated sexual 
dysfunction. Benefits were demonstrated however numbers were too small and the 
benefit of individual interventions difficult to assess.  
 
In patients with sexual dysfunction electrical stimulation has been shown to be of benefit 
particularly those with vulval pain disorders48;49. Giuseppe et al50 demonstrated that in 
women with UI and who scored low on the Female Sexual Function Index (FSFI) showed 
an improvement in urinary leakage and also in their sexual life following treatment by 
neuromuscular electrical stimulation. This was an observational study with relatively 
small numbers and made no comparisons with alternative forms of physiotherapy.   
 
There are different hypothesis as to why PFMT may improve sexual function. The pelvic 
floor muscles are directly responsible for the amount of sensation a woman feels during 
intercourse, and for the amount of grip felt by her partner. Rhythmic contractions of the 
pelvic floor contribute to arousal and a woman's ability to achieve orgasm. Women may 
be able to reach orgasm more easily, after a pelvic floor exercise program. Exercise 
improves muscle tone which means that the muscle is tighter, so is stretched more by an 
erect penis. Strong, firm muscles have more nerve endings, and more nerve endings mean 
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more sensations during coitus. Exercise improves circulation, and this is particularly 
important for the smaller muscles of the pelvic floor, which are responsible for engorging 
the clitoris when women are aroused.  
 
Paper 7 of this thesis was a randomised control trial (RCT) comparing the clinical and cost 
effectiveness of electric stimulation plus standard pelvic floor muscle training to standard 
pelvic floor muscle training (PFMT) alone in women with urinary incontinence and sexual 
dysfunction.   
The sample size recruited to the study was adequate however the number of women 
who completed the study with adequate follow up was insufficient. There was a lack of 
compliance to appointments and as a consequence patient number required for study 
completion were not met. As the missing outcomes would seriously impede the ability 
to make correct inferences from the RCT, multiple imputation was undertaken. Multiple 
imputation is an advanced method of dealing with missing data in statistical analysis, 
which can be a common problem of medical research. This allowed the sample size to 
be preserved. This was in preference to Complete case (CC) analysis as this would have 
reduced sample size and led to reduced statistical efficiency of estimates while 
increasing the potential for bias.  
Interestingly even though no clinical benefit was identified in comparing standard PFMT 
to electric stimulation plus standard PFMT, the health economics evaluations 
demonstrated that the electrical intervention was cost effective.  This conclusion is 
driven by a very small incremental cost associated with the addition of electrical 
stimulation.  There is also a small and statistically significant gain in QALYs measured via 
the EQ-5D. 
The protocol and ethics approval are attached in appendix 3.  
 
5.4 Surgical Treatment of stress incontinence and Sexual dysfunction:  
5.4.1 Types of surgery for Stress urinary incontinence 
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The chief forms of surgical treatment for Stress urinary incontinence (SUI) include 
colposuspension, autologous fascial slings, midurethral tapes and bulking agents.  
Burch Colposuspension was described in 196151. The initial description was attachment 
of the paravaginal fascia to the arcus tendineus. However, this was later changed to 
attachment to Cooper's ligaments.  
 
The autologous fascial sling also known as the pubovaginal sling (PVS) was popularized 
by McGuire and Lytton in 197852. They reported an 80% success rate in patients with 
intrinsic sphincter deficiency. Though this was shown to have a greater success than the 
Burch colposuspension the morbidity associated with this procedure was greater 53.  
In 1996 Ulmsten 54 first described the Tension Free vaginal tape (TVT) and this has 
revolutionised the management of stress incontinence. This operation was followed 
some years later55 by another midurethral sling operation which utilises the obturator 
route ie Transobturator tape  described by de Leval in 2003 . 
 
Following a multicentre RCT comparing the Colposuspension to TVT 56-58, the former is 
now very infrequently performed. The most common surgical procedure for SUI is the 
midurethral sling of which the ‘gold standard’ is the retropubic sling.  
 
Bulking agents or Injectables have also been used to manage SUI. Their application has 
been limited by placement, durability, antigenicity, and other compatibility issues. 
In women with SUI, the impact of treating incontinence on sexual function is 
controversial. Surgical treatment in these patients may be curative of their coital 
incontinence but has the potential to cause undesired effects on sensation, blood flow, 
and the anatomy. These effects can affect sexual arousal and orgasm or cause 
dyspareunia. 
5.4.2 Colposuspension/Fascial Sling and Sexual Function 
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Before the introduction of minimally invasive suburethral sling procedures, Burch 
colposuspension was regarded as the “gold standard” for the surgical correction of SUI. 
There is some data regarding the impact of colposuspension on sexual health. Moran59 
evaluated 55 women with SUI who reported coital incontinence before undergoing 
colposuspension. Preoperative coital leakage occured in 65% with penetration, in 16% 
with orgasm, and 18% with both. After surgery, 81% of the women reported no coital 
incontinence. This study did not assess other aspects of sexual health and did not use a 
questionaire to assess other components of sexual function. Baessler et al30 showed 
similar improvements in coital incontinence following a colposuspension. In the study by 
Baessler et al questionnaires were used for more formal assessment of women however 
patients underwent both prolapse surgery and continence surgery concomitantly hence 
it is difficult to say what proportion of symptoms were contributed to by resolution of 
prolpase and what proportion were related to the incontinence symptoms.  There are 
very few studies assessing the impact of fascial slings on sexual function. In their RCT 
comparing colposuspension to autologous fascial slings, Brubaker et al14 did not find a 
difference with either of the two surgeries in terms of outcomes for sexual function but 
did find that the improvements in sexual function were directly related to the success of 
surgery. 
5.4.3 Midurethral tapes and Sexual function  
 
The impact of midurethral slings, specifically tension-free vaginal tape (TVT) on female 
sexual function is variable. Different studies have shown different outcomes, with some 
suggesting deterioration60-63  of sexual function, some an improvement31;64-66  whereas 
others were equivocal67-70  .  Deterioration in function may be associated with 
dyspareunia 61, loss of libido or partner associated discomfort. There have also been 
anecdotal reports of anorgasmia after TVT probably related to passage of the trochar 
and subsequent injury to the dorsal nerve of the clitoris71. However, there seems to be a 
consensus that TVT reduces coital incontinence rates by three - to sixfold 56;61;67.  
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The alternative approach ie the obturator may adopt the inside out or the outside in 
approach. The Obturator approach appears to have a similar beneficial effect71;72   on 
sexual function comparable to the retropubic approach (TVT)73. In a comparison of the 
outside in and the inside out technique of the Obturator sling, reports are conflicting 
with one study suggesting the inside out (TVT-O) to be better72and another study 
showing the outside in technique (TOT) to be superior71 for stress incontinence but no 
difference has been demonstrated on sexual function in the largest randomised control 
trial comparing the two methods by Abdel Fatatah et al74.   
 
Paper 5 5 of this thesis is a systematic review analysing all procedures used for SUI and 
their impact on sexual function followed by analysis of midurethral slings ie Tension Free 
Vaginal Tapes (TVT) and Obturator tapes (TOT/TVT-O) analysed separately as these are 
now the gold standard. A comparison of the different midurethral slings ie retropubic 
(TVT) versus the obturator approach was also made and meta-analysis conducted.  
As most studies were observational studies the MOOSE guidelines for conducting a 
meta-analysis of observational studies was followed 75. The MOOSE checklist contains 
specifications for reporting of these studies. To assess the quality of the non-
randomised studies included in the meta-analysis the Newcastle Ottawa Scale was used 
to rate each observational study included. The results need to be viewed with caution as 
there was significant heterogeneity of the studies.  
 
5.5 Impact of treatment of OAB on sexual function:  
 
For urgency incontinence, the main treatment includes bladder retraining and 
pharmacotherapy (anticholinergics). In sexually active women with overactive bladder 
and concurrent sexual dysfunction, sexual quality of life, PISQ (Pelvic Organ 
Prolapse/Urinary Incontinence Sexual Questionnaire) scores, and anxiety states were all 
improved with corresponding improvement in OAB scores by treatment with 
anticholinergics33;36;76 . In the study by Sand et al33 2878 subjects with overactive bladder 
were treated with transdermal oxybutynin for 6 months or less. The impact of overactive 
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bladder on sexual function before and after treatment was assessed via item responses 
from the King's Health Questionnaire and Beck Depression Inventory-II. 586 (23.1%) 
women at baseline, reported that overactive bladder had an impact on their sex life. Coital 
incontinence in 569 (22.8%) decreased after treatment to 438 (19.3%). Effects of 
overactive bladder on subjects' sex lives improved in 19.1% (worsened in 11.2%), and the 
effect on relationships with partners improved in 19.6% (worsened in 11.9%). Reduced 
interest in coitus, reported by 52.1% at baseline, improved significantly. (all P < .0001). In 
a similar study by Rogers76 overactive bladder (OAB) symptoms and sexual and emotional 
health in sexually active women with OAB/urgency urinary incontinence treated with 
tolterodine extended release was assessed. Sexually active women with OAB symptoms 
were randomized to placebo or tolterodine ER. Tolterodine ER (n = 201; mean +/- SD age, 
49 +/- 12 years) reduced UUI episodes (P = 0.0029), total (P = 0.0006) and OAB (P < 0.0001) 
micturitions, and pad use per 24 h (P = 0.0024), and was associated with improvements 
in SQOL-F (P = 0.004), PISQ total (P = 0.009), and HAD Anxiety (P = 0.03) scores versus 
placebo (n = 210; mean +/- SD age, 47 +/- 12 years). OAB symptoms improved with 
tolterodine ER as did the scores of sexual health and anxiety measures in sexually active 
women with OAB 
 
Paper 6 of this thesis assesses the impact of anticholinergics on sexual function in 
women with urgency symptoms. A range of anticholinergics were used and the changes 
in sexual function compared to alteration in OAB symptoms. The main shortcoming of 
this study was that the sample size failed to be achieved. This was because the inclusion 
criteria was women who were treatment naïve but it was subsequently realized that in 
secondary care this was very unlikely to be the case as patients had already trialed one 
and sometimes more lots of anticholinergics before being referred to the hospital. So 
the study had to be conducted as a pilot feasibility studyand remains underpowered to 
answer the whetehr anticholinergics impact on sexual function of women with 
overactive bladder symptoms. It was recognized that if conducted again this study 
would be better carried out in primary care.  
The protocol and ethics approval are attached in appendix 3.  
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7. Published Papers 
7.1 Paper 1: Female Sexual Dysfunction 
Swati Jha, Ranee Thakar 
Abstract 
In recent years, Female Sexual Dysfunction (FSD) which has a detrimental effect on a 
woman’s quality of life is increasingly being recognised. It includes a range of disorders 
and therefore, adequate screening and diagnosis of patients is necessary before 
appropriate treatment can be commenced. As the etiology of FSD is often multi-
factorial, arising from a multitude of organic pathologies in addition to having an 
underlying psychological basis, the treatment is often multidisciplinary. An 
understanding of the etiopathogenesis is therefore imperative to management. In the 
past 20 years major changes have occurred in our understanding, conceptualization and 
treatment of sexual dysfunction. In this article we look at the prevalence, classification, 
etiology and management of FSD. 
Introduction 
Female sexual dysfunction (FSD) is a common problem which has detrimental effects on 
a woman’s quality of life. Sexual problems are common among women but they become 
a dysfunction when they cause distress as opposed to a normal physiological response 
due to difficult circumstances. Laumann et al (1) found that SD is more prevalent in 
women (43%) than in men (31%). Furthermore it is associated with various psycho-
demographic characteristics, e.g. age, education, and poor physical and emotional 
health. FSD appears to be more common in women who have a history of sexual abuse 
or coercion(2). It is believed that in the general population up to 60% of women aged 
less than 60 have some degree of sexual dysfunction(3). A recently conducted 
international survey (The Global Study of Sexual Attitude and Behaviors) investigated 
behaviors, attitudes, beliefs, and satisfaction regarding sex, intimacy, and relationships 
among men and women aged 40-80 years. In women, 34% of respondents had 
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decreased sexual interest and 19% did not consider sexual intercourse to be pleasurable 
(4). In this same survey 23% of women reported reduced lubrication with a significant 
increase between 50 and 69 years. Surveys of patients in physicians' offices suggest  that 
each year, family practitioners will see several women or couples who present with 
sexual problems, and even more if the physician inquires about patients' sexual 
health(5). Surveys have also shown a very high prevalence of sexual concerns in women 
seeking routine gynecological care. Nusbaum et al (2) questioned 1500 women 
attending a gynaecology clinic and found that 98% of the respondents reported one or 
more sexual concerns. The most frequent was hypoactive sexual desire (87%) followed 
by orgasmic disorders (83%) inadequate lubrication (5%) and dyspareunia indicative of a 
sexual pain disorder (72%).  
The articles which form the basis of this review were identified by an electronic search 
of the Cochrane Library (2010), MEDLINE (1966-2010) and EMBASE (1980-2010) using a 
combination of medical subject headings and text words. Keywords included, ‘female 
sexual dysfunction; difficulty with orgasm; female pain syndromes; loss of desire; sexual 
problems; vaginismus; psychosexual counseling'. Studies were evaluated if they 
assessed the definition, incidence, aetiology, diagnosis and management of FSD.  
Definition and classification 
FSD is defined as a disorder of sexual desire, orgasm, arousal and sexual pain that results 
in significant personal distress. In 1966 Masters and Johnson(6) reported that the 
normal female sexual response cycle consists of four successive phases -excitement,  
plateau, orgasm and resolution. This hypothesis was subsequently modified by Kaplan 
and the  excitement phase was further subdivided into desire and arousal, thereby 
eliminating the plateau phase. These models assume a linear progression from an initial 
awareness of sexual desire to one of arousal with a focus on genital swelling and 
lubrication, to orgasmic release and resolution. 
 
More recently the Diagnostic and Statistical Manual of Mental Disorders, 4th edition  
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(DSM – IV) classified FSD into 4 groups (7). The resulting diagnostic categories which 
included 4 groups ie sexual desire disorder, sexual arousal disorder, orgasmic disorder 
and pain disorders, reflected this linear and rather genitally focused model of sexual 
function. Each of these diagnoses is independent of the others e.g a patient with sexual 
desire may still be arousable and capable of orgasm. Thus, relatively discrete, non-
overlapping phases of sexual response were portrayed and discrete dysfunctions 
defined.  
 
However, evidence to date shows that many facets of women's sexual function are at 
variance with this model. Basson et al described a nonlinear model of the sex response 
cycle, showing  overlapping phases of the sexual response in a variable sequence that 
blends the responses of  the mind and the body(8). An international committee was 
convened by the American Foundation of Urological Disease to revise and expand 
definitions of women's sexual dysfunction (9). The committee relied on empirical and 
clinical research as well as clinical experience. Literature searches provided the 
background to extensive collaboration from September 2002 to February 2003. Informal 
pilot testing of the committee’s conclusions in clinical practice, plus presentation to a 
large international audience, led to further revisions over the next 6 months, acceptance 
by the Second International Consensus of Sexual Medicine(10). This revised and new 
classification (DSM IV TR [Text revision]) is shown in Table 1 and includes 5 main groups.  
 
Sexual Interest/Desire Disorder 
 
There are absent or diminished feelings of sexual interest or desire, absent sexual 
thoughts or fantasies and a lack of responsive desire. Motivations (here defined as 
reasons/incentives) for attempting to have sexual arousal are scarce or absent. The lack 
of interest is considered to be beyond the normative lessening with life cycle and 
relationship duration. 
 
Arousal Disorder      
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Subjective Sexual Arousal Disorder: Absence of or markedly diminished feelings 
of sexual arousal (sexual excitement and pleasure) from any type of sexual stimulation. 
Vaginal lubrication or other physical response still occur. 
Combined Genital and Subjective Arousal Disorder: Absence of or markedly 
diminished feelings of sexual arousal (sexual excitement and pleasure) from any type of 
sexual stimulation as well as complaints of absent or impaired genital sexual arousal 
(vulval swelling, lubrication). 
Genital Sexual Arousal Disorder: Complaints of absent or impaired genital sexual 
arousal. Self report may include minimal vulval swelling or vaginal lubrication from any 
type of sexual stimulation and reduced sexual sensations from caressing genitalia. 
Subjective sexual excitement still occurs from nongenital stimuli. 
 
Orgasmic Disorder 
 
Despite the self-report of high sexual arousal/excitement, there is either lack of 
orgasm, marked diminished intensity of orgasmic sensations or marked delay of orgasm 
of any kind of stimulation. 
 
Sexual Pain disorder 
 
Dyspareunia 
Recurrent or persistent pain with attempted or complete vaginal entry and/or penile 
vaginal intercourse 
Vaginismus 
Persistent or recurrent difficulties of the woman to allow vaginal entry of a penis, a 
finger, and/ or any object, despite the woman’s expressed wish to do so. There is often 
(phobic) avoidance and anticipation/fear/experience of pain, along with variable 
involuntary pelvic muscle contraction. 
 
Persistent Sexual Arousal Disorder 
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Spontaneous intrusive and unwanted genital arousal (eg tingling, throbbing, 
pulsating) in the absence of sexual interest and desire. The arousal is unrelieved by one 
or more orgasms and the feelings of arousal persist for hours or days. 
Constant modifications in the classification have resulted in confusion amongst different 
bodies and make it difficult to compare studies looking at FSD due to these changing 
criteria. In addition any system of classification attempts to classify FSD into distinct 
groups though quite often clinically they are very difficult to categorise as such.  
Etiology 
Throughout a woman’s life changes in sexual function occur. These normative changes 
are related to age and the menopause, pregnancy, parturition and breastfeeding. There 
are longitudinal studies showing a decline in desire and interest in sex with both the 
menopause and aging(11;12). Despite this the actual frequency of any partnered sexual 
activity may or may not change given that women have many reasons to engage in sex 
other than desire(1;13). It has also been shown that even years after menopause, an 
increase in desire and interest is consistently reported with a new relationship (14).  
There is also a reduction in sexual desire and frequency of intercourse related to 
pregnancy (15). These have been linked to women’s fear of causing a miscarriage or 
harm to the fetus. Fatigue, physical discomfort, and feeling less attractive are other 
reasons. The latter reasons have also been implicated in breastfeeding mothers (15). 
Data on the impact of childbirth on sexual function is conflicting. There is a dearth of 
scientifically reliable data about the impact of childbirth on sexual function and the 
association with the different modes of delivery. It is widely reported that postpartum 
dyspareunia is associated with the mode of delivery with assisted vaginal delivery being 
predominantly incriminated with at least a twofold increase in dyspareunia when 
compared to spontaneous vaginal delivery(16;16). Though a study by Buhling et al(17) 
found the highest dyspareunia after operative vaginal delivery, and least with elective 
C/S, this decreased uniformly in each group by 6 months. Operative vaginal deliveries 
had a persistent rate of dyspareunia of 14%, but there was no difference between the 
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spontaneous vaginal delivery group with an intact perineum and C/S (3.4% dyspareunia 
at 6 months). Interestingly, at 3 months postpartum, all of the patients reported 
“enjoyment at sexual intercourse” regardless of the mode of delivery. Women with an 
intact perineum or first-degree perineal tear 6 months postpartum were more likely to 
experience orgasm(17;18) than those with either second, third, or fourth-degree 
perineal tear. 
Emotions for the partner and the relationship with their partner during intercourse 
together with general emotional well being were identified as the strongest predictors 
of sexual health by Bancroft et al (19). They conducted a telephone survey of 987 white 
or black/African American women aged 20-65 years, with English as first language, living 
for at least 6 months in a heterosexual relationship. The participation rate was 53.1%. 
Weighting was applied to increase the representativeness of the sample. A total of 
24.4% of women reported marked distress about their sexual relationship and/or their 
own sexuality. Feeling emotionally close to their partner during sexual activity 
decreased the odds of ‘slight distress’ by 33% relative to ‘no distress’ and ‘marked 
distress’ by 43%. Physical aspects of sexual response in women, including arousal, 
vaginal lubrication, and orgasm, were poor predictors. In general, the predictors of 
distress about sex did not fit well with the original DSM-IV (7) criteria for the diagnosis 
of sexual dysfunction in women. 
Traditionally psychological and interpersonal factors have been implicated and non 
sexual distractions of daily life may preclude arousal (20). Sexual distractions also play 
an important role and include concerns related to being insufficiently aroused, reaching 
orgasm, male partners delayed ejaculation, fear of unwanted pregnancy or STD and lack 
of privacy (19-21). Mental well being has been shown to be a robust predictor of sexual 
desire and responsivity in longitudinal (11) and cross sectional (22) studies of 
menopausal women. Women who defined themselves as being in good mental health 
were much less likely to report distress about their sexual relationship compared to 
women who had lower self rated mental health scores(19). Healthier women were 59% 
less likely to report distress about their relationship. Studies have shown a high 
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correlation of desire complaints with measures of low self image, mood instability and 
tendency towards worry and anxiety (23).Differences between a group of women with a 
desire disorder without clinical depression and a control group of healthy women with 
no problems was significant for most scales in the Narcissism Inventory(23).  Women 
with desire disorders had anxiety issues, low self esteem, emotional instability and 
neuroticism. Sexual arousal and orgasm problems on the other hand were more 
prevalent in women who could not tolerate loss of control generally.(23) 
Recent studies have shown that socioeconomic factors place a person at higher risk too. 
A particular risk factor is poor educational background or low socioeconomic class (1). 
Memories of past negative sexual experiences, including coercive or abusive 
relationships and expectations of negative outcome from dyspareunia or partner sexual 
dysfunction all adversely impact on sexual function (24).  
With advancing research on FSD it has been identified that the primary medical 
conditions causing FSD can be a hormonal, anatomical, vascular and neural. During 
sexual arousal, blood flow to the clitoris and labia increase, leading to engorgement of 
these organs which in turn results in protrusion of the glans clitoris and eversion and 
engorgement of the labia minora. This is associated with increased blood flow to the 
vagina and uterus leading to increased secretion from the uterus and Bartholins glands, 
which lubricates the vagina. Further lubrication comes from transudate from the vaginal 
walls. As intact sensation is therefore important in arousal, poorer levels of sexual 
functioning may be expected in diabetic women with peripheral neuropathy. Vascular 
compromise may result in decreased lubrication and/ or subsequent dyspareunia. 
Sexual Dysfunction after pelvic surgery may be due to either interruption of the vascular 
supply or neurological innervations. Orgasm on the other hand requires an intact 
sympathetic nervous system hence orgasmic disorders are common in women with 
spinal cord injuries. Commonly associated causes are shown in Table 2. Therefore 
though psychological and interpersonal factors can not be undermined, with a better 
understanding of the condition it is now known that a number of illnesses can cause FSD 
too. Chronic diseases such as diabetes mellitus, chronic kidney disease, cancer, spinal 
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cord injury, lupus, rheumatic diseases, Parkinson's disease, fibromyalgia and chronic 
pain have all been identified to impact on sexual function adversely. A number of drugs 
have also been implicated in the causation of FSD and are shown in Table 3. 
Hormonal balance is essential to maintaining sexual function. Estradiol, Nitric Oxide(NO) 
and  Vasointestinal polypeptides (VIPs) (25) have all been identified as playing a role and 
helping to maintain integrity of vaginal mucosal epithelium and promote lubrication. 
There appears to be a lack of direct correlation between estrogen levels and sexual 
symptoms(26) and estrogen at baseline levels is required to make vasointestinal 
peptides and NO effective. NO is a major neurotransmitter allowing the congestion of 
clitoral tissue(27). VIPs have a similar mechanism of action and increase blood flow 
through the vagina(25). Generation of NO and VIPs is impaired in postmenopausal 
women(28) and estrogen therapy causes up regulation of vascular estrogen 
receptors(29). Endothelial dependent flow mediated vasodilatation in healthy women, 
which is mostly mediated by these neurotransmitters is enhanced by even short term 
administration of estrogen. This is achievable with even local estrogen therapy which 
can not only prevent but also reverse mild to moderate atrophy. Estrogen replacement 
therapy in postmenopausal women has therefore been shown to improve vaginal 
lubrication and sexual desire(30;31).  
Testosterone is the predominant androgen in women. The adrenal glands and ovaries 
are the major source for testosterone synthesis. Circulating androstenedione, which is 
also a major source of testosterone, is derived from the adrenal glands and ovaries. 
Decreasing levels of testosterone are associated with decreased libido, arousal, sexual 
response, sensation and orgasm and therefore declines after the menopause(32;33). 
Testosterone also influences the central nervous system and affects sexual behaviour 
and is also believed to be beneficial in improving sexual desire in women who go 
through a surgical menopausal(34). Of concern however is the lack of long term safety 
data for testosterone supplementation in premenopausal women and results from 
randomized controlled trails have been conflicting(35). The hormone tests which may be 
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considered in women with FSD depending on the underlying condition are shown in 
Table 4.  
Clinical Evaluation 
Gynaecologists have varying levels of experience and expertise both in the identification 
of and subsequent management of FSD. Occasionally women present directly with 
sexual dysfunction. However, more often women present with more covert symptoms 
of pelvic pain, distress about menses, general dissatisfaction with a contraceptive 
precaution, and expression of distaste for the genital area or dissociation at the time of 
genital examination. A sympathetic doctor will be alert to these clues and will ask open-
ended questions to explore these issues. A series of screening questions(36) as shown in 
table 5 help identify women wishing further treatment for underlying dysfunction. 
Women expect their doctors to be able to discuss sexual problems, but some doctors 
feel uncomfortable talking about sex and may not see it as part of their clinical role. 
Taking even a brief sexual history during a new patient visit is very effective and 
indicates to the patient that the discussion of sexual concerns is appropriate and is a 
routine component of an office visit. Many health-related conditions, life events, or 
developmental milestones put patients at higher risk for sexual problems and provide 
opportunity to inquire about associated changes in sexual function. Urogynaecology 
surgeries or problems, menopause and depression, for example, are risks for the 
development of sexual problems, and physicians can normalize the frequency with 
which women find that medical issues give rise to sexual issues. It can be helpful to link 
a woman’s current reproductive stage or presenting issue such as surgery to her sexual 
function. (37). 
 
Physician discomfort in broaching issues of FSD may be related to a number of reasons 
and has been detailed in the study by Humphery et al(38) and Roos et al(39). Table 6 
lists a few causes. The decision to treat depends very much on the level of individual 
expertise and the complexity of the dysfunction as well as underlying pathophysiology. 
Some sexual problems are best treated by specialists such as a sex or marital therapist, 
P a g e  42 | 187 
 
 
 
 
alone or in the context of a multidisciplinary approach. Referrals are more likely to be 
accepted by patients when the physician normalizes both the nature of the patient’s 
problem and the process of referral to a specialist(37). When a sexual problem is 
identified during initial screening, it should be determined whether (a) the concern can 
be addressed during the current appointment, (b) a follow-up visit is needed to allow 
more time to address the concern adequately, or (c) the sexual problem is beyond the 
physician’s scope of training and the patient should be referred to a specialist. It is 
always helpful to legitimize the sexual problem and to attend to patient discomfort by 
deferring sensitive questions to a subsequent visit or by supplying alternative 
terminology for patients who seem too embarrassed to provide explicit sexual 
details(40). 
 
A thorough sexual history should include medical, reproductive, surgical, psychiatric, 
social, and sexual information(41-43). Relevant content would include a past medical 
history, current health status, reproductive history, endocrine system review, thyroid 
conditions, and psychiatric illness. The current use of medicines, including prescription 
drugs, over-the-counter medications, and alternative medicines should also be 
identified.  A detailed clinical examination is important to making a diagnosis and 
establishing the cause of FSD. Physical examination should include a pelvic examination 
to search for evidence of vaginal atrophy, dryness, and pain triggering spots. For 
professionals working in a clinical environment, time is of the essence. There may not be 
time to practically include sexual function in a clinical encounter. To help with the time 
issue, some clinicians use validated research instruments designed to define the degree 
of sexual dysfunction. This monitors baseline sexual problems and the response to 
treatment. One such questionnaire is the Female Sexual Function questionnaire which 
assesses desire lubrication and orgasmic potential(44) though there are several others 
routinely used in clinical practice(45) (38;46-50). Some patient reported outcomes 
(PROs) assess all phases of sexual function (e.g., Female Sexual Function Index), while 
others focus on specific dysfunctions such as female sexual desire disorders and arousal 
disorders. Sexuality questionnaires play an integral role in the diagnosis and treatment 
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of male and female sexual dysfunctions. They are used to (1) identify/diagnose 
individuals with a particular dysfunction, (2) assess the severity of the dysfunction, (3) 
measure improvement or satisfaction with treatment, (4) examine the impact of the 
dysfunction on the individual’s quality of life (e.g., relationship satisfaction, mood, 
sexual confidence), and (5) study the impact of the dysfunction on the partner and his or 
her quality of life(51).  
 
When obtaining a sexual history, depending on the environment and time constraints, it 
is important to collect relevant information in a timely manner. If the patient has seen a 
clinician prior to the appointment, and the clinician seems concerned about the 
patient's sexual wellness, has a professional demeanor, and seems comfortable and 
understanding, it will make the sexual interview much more relaxing, honest, and 
helpful. Assessment of sexual function can be a part of the review of systems and should 
take place in a private setting in which confidentiality is assured. Establishing a rapport 
and putting patients at ease helps to make the environment conducive for discussion of 
sexual problems as the patient is being asked the most intimate, detailed questions of 
private life. It is important to ensure the patient is in a comfortable position, relaxed, 
face-to-face to the clinician, and in a private setting. The patient should be clothed to 
eliminate the anxiety and sense of vulnerability that are commonly experienced when 
sitting in an examination gown(36;52). It is imperative that physicians not assume the 
gender of sexual partners, nor that the woman’s sexual behavior is limited to an 
identified partner or spouse. The implication that the physician does not hold pre-
conceived notions may give patients the courage to discuss a sexual concern at a later 
time. The practitioner should feel comfortable using sexual terminology, and be ready to 
listen actively as patients are more likely in turn to feel comfortable reporting their 
sexual concerns. The use of eye contact is vital in gaining the woman's trust and 
confidence. Physicians may benefit by practicing the use of explicit sexual terminology in 
order to reduce embarrassment, hesitation in delivery, or other signs of discomfort. A 
balance can be found between terminology that is not so formal as to be distancing and 
so informal as to be offensive or inappropriate.  
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While speaking to women with FSD, it is best to mirror the patient's sexual vocabulary 
so she can relate and understand the discussion. Wherever possible, the patient should 
be permitted to set the pace and the tone of conversation. Often, a question may need 
to be asked several times, in different ways, to get an accurate answer. It is important to 
ask the patient if she would like to speak with the clinician about these issues. For some 
women this is not a concern, and for others it is a major life event. Giving the patient 
permission to discuss the issues is the first step in problem solving. Some general 
leading questions may be necessary to initiate the conversation, and are shown in table 
7(10). More specific questions can follow, once the conversation is initiated. It may be 
worth asking the patient her thoughts as to why she may be experiencing these 
problems. Educating patients about sex and correcting any myths or misconceptions 
they may have is time well spent. If these suggestions do not correct the situation, the 
issues may be more deeply rooted, or combined with other psychopathology, and may 
not be treated easily in the medical office setting.  
Management 
Management requires an understanding of psychosexual function and an ability to 
communicate about sexual matters. The clinician should be alert to non-verbal 
communications that indicate anxiety. Treatment should be individualised for each 
couple and to the underlying cause of FSD. Educating the patient and the partner about 
normal physiological response and anatomy is often necessary. In addition,physiological 
changes with aging and or disability and vascular dysfunction should be explained as 
well as the clear correlation between the patient’s general health and sexual function. 
Prescription medication may need to be tapered or even avoided where possible. 
Cessation of smoking and excessive alcohol consumption may also be beneficial.  
Disorders of desire are difficult to treat as and one reason that desire disorders remain 
elusive is that desire is a relatively complex concept that requires delineating the 
components for the patient and the clinician. Treatments include individual and/or 
couples psychotherapy/sex therapy, hormone therapy (e.g., exogenous testosterone 
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replacement or Tibolone, a synthetic steroid with selective estrogenic, androgenic, and 
progestogenic properties for postmenopausal women), and centrally acting 
pharmacologic agents that may have a positive impact on sexual function inhibiting 
serotonergic activity, facilitating dopaminergic activity, or binding to melanocyte 
receptors. To date, there are no pharmacologic treatments that are approved for the 
treatment of any female sexual disorder except the testosterone patch (Intrinsa; Warner 
Chilcott) which has been approved and used in but only in postmenopausal women. 
However, a number of treatments are currently in clinical trials. Postmenopausal 
women on the other hand may benefit from estrogen replacement therapy as this 
increases clitoral stimulation, decreases coital pain and treats vaginal atrophy. The 
literature on the use of testosterone in postmenopausal women remains controversial 
but it may have a beneficial role in women who have been through a surgical 
menopause following a hysterectomy and bilateral salpingoopherectomy(53;54). 
Sildenafil(Viagra) which has been of such great benefit in men with sexual dysfunction is 
beneficial in only a select group of women(55). The use of Sildenafil in women is 
however an unlicensed use as it does not yet have FDA approval. Where the cause of 
FSD is surgically correctable, this should be considered.   
 
Although there has been little evidence-based research on treatment for female sexual 
arousal disorder, treatment generally follows the work of Masters and Johnson(6) who 
taught patients to attend adequately to sexual sensations (sensate focus) using 
masturbation training while working to improve communication with their partners. 
Success rates using these strategies are reportedly quite good. Estrogen therapy, 
systemic or local, is often an effective treatment for arousal disorder that is acquired 
after menopause and can improve vaginal blood flow and lubrication. Over-the-counter 
lubricants and/or long-acting vaginal moisturizers may also be helpful when lubrication 
has been diminished. Other topical pharmacologic treatments that are being studied 
include the use of androgens, alprostadil, L-arginine, and Zestra.  
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Disorders of orgasm are often ‘situational’. These women can achieve orgasm readily 
and reliably with some specific forms of stimulation. For example, women are often 
reliably orgasmic with manual stimulation, but not with intercourse. In fact, intercourse 
is not a particularly reliable method for many women to achieve an orgasm. The most 
effective treatment is a cognitive-behavioral approach in which a woman learns to be 
comfortable with her body and then her own sexuality by altering negative attitudes 
and decreasing anxiety. The behavioral treatments include directed masturbation, 
sensate focus exercises, and systematic desensitization (56). Homework assignments 
that women can do in the privacy of their own homes are given with the goal of helping 
them to discover what stimulation is pleasing and effective. Eliminating myths that 
masturbation is bad is an important theme in treatment. Masturbation is an extremely 
effective way for the woman who has never achieved orgasm to experience her first 
climax. In privacy, without the pressure of performing for, or pleasing a partner, the 
woman is free to explore her own body and responsiveness. Another effective 
component of treatment is permission-giving by a clinician. 
 
Identification of the initiating and maintaining factors is fundamental to the diagnosis of 
dyspareunia. The differential diagnoses include vaginismus, atrophy, inadequate 
lubrication, and vulvodynia. Urethral disorders, cystitis, and interstitial cystitis can also 
present with painful intercourse. Less common etiologies are adhesions, infections, 
endometriosis, and pelvic congestion. Dyspareunia can be described as involving pain on 
entry or deep pain. Painful entry is most typical of vulvodynia, inadequate lubrication, 
and vaginismus. A physical examination often reproduces the pain when the vagina is 
touched with a cotton swab or insertion of a finger.  The psychobiology of sexual pain 
should be addressed with a comprehensive, integrated, and patient-centered 
perspective.  
 
For vaginismus, the most effective treatment is a combination of cognitive and 
behavioral psychotherapeutic approaches. The goal is to desensitize a woman to her 
panic and help achieve a sense of control over a sexual encounter or a pelvic exam and 
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an understanding that she is in no danger of experiencing pain, thereby feeling safe and 
calm. In response, her body can then learn to relax and the vaginal muscle contractions 
will no longer be a necessary automatic defense; essentially, she will feel in more 
control of her muscles. One of the most commonly used treatment techniques is 
systematic desensitization. In this case, women are first taught deep muscle relaxation 
and then to very gradually insert objects (usually dilators) of increasing diameter into 
the vagina. Refractory vaginismus may respond to botox injections into the 
puborectalis(57).  
 
The management of Persistent Sexual Arousal Disorder is unclear though there are 
anecdotal reports of treatment with high dose SSRIs(58). As patients feel isolated and 
embarrassed, the knowledge that the clinician is aware of the condition can be of help. 
With complex cases, it may be appropriate to refer the patient to a sex therapist or 
other clinician that specializes in FSD. 
 
Psychosexual counseling 
 
Sex therapists are trained to identify situations that require intensive therapy and to 
make appropriate medical referrals when necessary. On the first visit, a comprehensive 
interview will be conducted. An extensive history is recorded, with questions about 
upbringing and memories of family and social life(36). Because religious beliefs are 
connected closely with sexual attitudes, religious beliefs will be discussed. Questions 
regarding overall health, medications, and past medical history will also be included. 
Social issues, in reference to relationships, self-esteem, history of sexual abuse and 
trauma will be discussed. A comprehensive psychiatric history and assessment are 
conducted to help determine if psychiatric issues need to be addressed. After the 
evaluation is completed, the therapist will suggest what might be contributing to the 
problem and suggest a treatment plan. The treatment plan can be altered on a regular 
basis, depending on what is happening in treatment. Usually treatment is conducted 
with the partner unless circumstances dictate differently. Treatment focuses on 
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identification and examination of feelings, both from past and present experiences. The 
goal is to gain insight into maladaptive behaviors, improving communication between 
partners, and teaching new ways to deal with issues. Because most sexual dysfunctions 
are regarded as a couple's issue, the therapist might focus on the couple's strengths 
rather than weakness. If the patient is not in a current relationship, the therapist may 
work on individual strengths. "Homework" assignments are given at the end of a 
therapy session in order for the couple, or individual, to practice what was discussed in 
session. Assignments are geared towards teaching patients new skills. Some examples of 
these may be teaching the art of giving and receiving pleasure, extending mutual 
pleasuring (abandoning self-to-self pleasure), turning the idea of sexual obligation into 
pleasure, learning to focus on sensations rather than anxieties and fears, discovering 
harmful patterns in sexual relationships, and encouraging the patient to be open and 
honest about needs and frustrations in the relationship. Couples may even be asked to 
deliberately avoid orgasm, penetration, or even touching sexual organs for a period of 
time.  
 
Further details of psychosexual counseling are beyond the scope of this review.  
Conclusion 
Female sexual dysfunction is a common problem. Most dysfunctions are thought to be 
psychogenic, but our understanding increases as more studies are completed, providing 
new outlook on the etiology of FSD. The initial discussion with the patient is of utmost 
importance, as some problems can be handled without referral. With more complex 
issues, referral to a qualified sex therapist can help deal with the problem (19) 
There continue to be gaps in the body of information that clinicians need to diagnose 
and classify the condition hence the condition remains underreported and poorly 
managed. The new revised expanded definitions of FSD aim to emphasise the contextual 
nature of the condition and identification of the overlap of the phases. It is hoped in 
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future that with a further understanding of how psychological states affect biological 
responses we will have a greater understanding of the condition.   
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Figure 1. Sex response cycle, showing responsive desire experienced during the  
sexual experience as well as variable initial (spontaneous) desire(56).  
(published with the permission of the American College of Obstetricians and Gynecologists) 
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Tables 
Table 1 DSM-IV classification of FSD 
 
  
      1.  Sexual Desire Disorders 
 -Hypoactive sexual desire disorders 
             -Sexual aversion disorder 
2 Female sexual arousal disorder  
3 Orgasmic disorder  
4 Sexual pain disorders 
- Dyspareunia  
- Vaginismus  
- Other sexual pain disorders 
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Table 2. Risk factors contributing to FSD 
  
  
Genital Tract atrophy 
Genital surgery 
Neurological disease 
 Stroke 
 Spinal Cord injury 
 Parkinsonism 
Endocrinopathies 
 Diabetes 
 Hyperprolactinemia 
 Liver and adrenal failure 
Sexual abuse 
Peripheral Vascular Disease 
Psychological factors, life stressors 
Interpersonal, relationship disorders 
Medications 
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Table 3 Suggested Hormonal investigations for FSD  
Estradiol or FSH if symptoms of deficiency  
Serum testosterone 
DHEAS (Dehydroepiandrosterone acetate 
sulphate) 
Free Testosterone 
TFT 
Prolactin 
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Table 4 Drugs causing FSD 
 
Alkylating agents 
 Cyclophosphamide 
Antiandrogens 
 Cimetidine 
 Spironolactone 
Anticonvulsants 
Anticholinergics 
Antiestrogens 
 Tamoxifen 
 Raloxifen 
 GnHR analogues 
Antihistamines 
Antihypertensives 
 Diuretics 
 B blockers 
 Calcium Channel Blockers 
Drugs of Abuse 
 Alcohol 
 Sedatives and hypnotics 
Metoclopramide 
Metronidazole 
Oral contraceptives 
Sympathomimetic amines 
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Table 5 Medical reluctance to obtain a sexual History 
 
 
 
  
Lack of training 
Lack of practice 
Fear of ‘opening the flood gates’ 
Covert presentation of the problem 
Lack of time 
Lack of effective treatments 
Associated stigma 
Embarrassment of doctor, patient or both 
Sensitive subject 
Difficult subject 
Gender 
Age 
Culture 
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Table 6 Frequently asked questions to establish FSD 
 
Are you having any sexual difficulties at this time?" 
Are you having difficulties with desire for sex?" 
Do you feel a sense of arousal when engaging in sexual 
behavior or when thinking about sexual matters?" 
Do you have difficulties with lubrication, either be coming wet 
or staying wet?" 
Do you have difficulties achieving orgasms?" 
Do you have pain during or after sex?" 
Do you have problems when your partner attempts 
penetration?" 
It is not uncommon for women with hypertension, diabetes, or 
heart disease to experience difficulty with sexual functioning. 
Is this a problem for you?" 
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7.2 Paper 2: Problems associated with sexual activity 
 
Swati Jha 
 
Female sexual dysfunction (FSD) is defined as a sexual desire, sexual arousal, orgasm 
and/or sexual pain disorder which causes personal distress (Table 1). FSD is a relatively 
common health issue for women with a community prevalence of 30% to 50% (1). The 
wide range of the reported percentages depends on the impact of different concomitant 
factors on sexual function, such as interpersonal, emotional relationship and well-being, 
and psychological factors. Studies have shown that FSD and other sexual problems have 
been linked to a “diminished quality of life, low physical satisfaction, low emotional 
satisfaction, and low general happiness”(2). Women’s sexuality and sexual function are 
very complex issues, strongly modulated by psychosocial situation and this necessitates 
a biopsychosocial approach for understanding the basis of dysfunction which has been 
dealt with elsewhere in this text book.  Physiological events such as pregnancy, 
childbirth, menopause, aging as well as gynecological conditions like infertility, prolapse, 
urinary incontinence, and gynecological cancers, have an impact on sexual well-being. 
The interaction of these conditions with sexual health needs to be better understood to 
deal effectively with the problems as a whole.  
 
Sexual dysfunction is highly prevalent in women attending urogynaecological services 
with a prevalence of 50% -64%(3-5). Furthermore, urogynaecological surgery represents 
an important but underestimated cause of FSD. Different problems of the pelvic floor 
can impact on sexual activity in different ways. Interest in and publications about female 
sexual dysfunction (FSD) are very recent (3). 
 
In this chapter we review the correlation of common urogynaecological conditions on 
sexual activity and the impact of their treatment.  
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URINARY INCONTINENCE (UI)  
 
Urinary incontinence is a common condition and epidemiological studies suggest that it 
affects up to 41% of the adult female population(6). It is a health burden, and impacts 
on social, psychological, occupational, domestic, physical and sexual well being (7-10). 
Women reporting LUTS or urinary incontinence (UI) complain of a deteriorating quality 
of life (QoL) in terms of social and psychological problems, and also of sexual 
dysfunctions in significantly greater numbers than the general healthy population, as 
reported in a recent cross-sectional study(11). Table 2 shows the prevalence of urinary 
incontinence during sexual activity as shown in different population groups.  
 
Complaints of stress urinary incontinence (SUI), overactive bladder (OAB), and lower 
urinary tract symptoms have negative impact on all domains of sexual function(7;11). In 
this population of women, the symptoms per se, along with fear of odour, 
embarrassment, shame, loss of self-esteem and fear of, or actual occurrence of, 
incontinence are contributory factors. The most common sexual complaints in women 
with urinary incontinence are low desire, vaginal dryness, and dyspareunia(12).  
 
Even in community dwelling women aged over 55, 5% were not sexually active due to 
urinary incontinence, and 25% of these sexually active women reported a negative 
influence of urine loss on their sex life(13). 
 
In women with SUI prevalence of coital incontinence ranges from 11-70%(14-18). 
Traditional teaching has been that urodynamic stress incontinence(USI) is associated 
with penetration incontinence and detrusor overactivity with orgasm incontinence(16), 
however subsequent studies by Moran et al(17)have failed to confirm this association. 
In their observational study USI was associated with high rates of penetration 
incontinence(80%), orgasm incontinence (93%) and a combination of the two(92%).  Jha 
et al(18) co-related different urodynamic diagnosis to orgasm or penetration 
incontinence and found no association.  
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Among the different types of urinary incontinence, OAB has a particularly high 
association with sexual dysfunction in various studies(19-21), which could be indicative 
of an underlying psychosomatic disorder(22). However studies assessing overall 
prevalence of sexual dysfunction in women with OAB and the impact on Quality of life 
remains controversial(23) whereas menopausal and partner status have been shown to 
be the better predictors(24). 
 
Till recently the impact of treating incontinence on sexual function has been 
controversial. Before the introduction of minimally invasive suburethral sling 
procedures, Burch colposuspension was regarded as the “gold standard” for the surgical 
correction of SUI. There is some data regarding the impact of colposuspension on sexual 
health. Moran et al.(25) evaluated 55 women with SUI who reported coital incontinence 
before undergoing colposuspension. Preoperative coital leakage occured in 65% with 
penetration, in 16% with orgasm, and 18% with both. After surgery, 81% of the women 
reported no coital incontinence. Baessler et al (14) showed similar improvements in 
coital incontinence following a colposuspension.  
 
The impact of midurethral slings, specifically tension-free vaginal tape (TVT) on female 
sexual function has been unclear. Different studies have shown different outcomes, with 
some suggesting deterioration(26-29) of sexual function, some an improvement (30-32) 
whereas others were equivocal(33-36) .  Deterioration in function may be associated 
with dyspareunia(29), loss of libido or partner associated discomfort. There have also 
been anecdotal reports of anorgasmia after TVT probably related to passage of the 
trocar and subsequent injury to the dorsal nerve of the clitoris (37). However, there 
seemed to be a consensus that TVT reduces coital incontinence rates by three - to 
sixfold(29;33;38).  
 
The Obturator approach appeared to have an overall beneficial effect (37;39) on sexual 
function comparable to the retropubic approach (TVT) (40). In a comparison of the 
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outside in and the inside out technique, reports are conflicting with one study 
suggesting the inside out (TVT-O) to be better (39) and another study showing the 
outside in technique (TOT) to be superior(37).  
 
Jha et al(41) conducted a systematic review of all continence procedures and the impact 
of treating urinary incontinence on sexual function. They found that coital incontinence 
was significantly reduced following continence surgery. However though the pooled 
results suggest  a 2 to 3 times greater likelihood of improvement compared to 
deterioration in sexual function, at least half of all women undergoing surgery for stress 
incontinence are likely to experience no change in sexual function. There was no 
difference is sexual function following the two most commonly performed procedures 
for SUI ie the TVT and TOT/TVT-O.  
 
In sexually active women with overactive bladder and concurrent sexual dysfunction, 
sexual quality of life, PISQ (Pelvic Organ Prolapse/Urinary Incontinence Sexual 
Questionnaire) scores, and anxiety states were all improved with corresponding 
improvement in OAB scores by treatment with anticholinergics (42;43). Treatment of 
OAB has also been shown to improve with both percutaneous tibial nerve 
stimulation(44) and Sacral nerve stimulation too(45).  
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PELVIC ORGAN PROLAPSE (POP) 
Pelvic organ prolapse (POP) is a common medical problem in parous women and 
particularly with advancing age. As life expectancy increases, this is acquiring greater 
significance, and 20% of women on Gynecology waiting lists in the UK are awaiting 
prolapse surgery demonstrating the enormity of this virtual pandemic. The incidence of 
prolapse requiring surgical correction in women who have had a hysterectomy is 3.6 per 
1000 person years of risk; the cumulative risk is 1% at 3 years and 5% at 17 years after a 
hysterectomy(46).  
 
A review of literature shows conflicting results on the impact of prolapse on sexual 
function, with some studies showing a deterioration of function and others showing no 
impact (12).In their observational study looking at 1299 participants, 495 (38.1%) had 
evidence of pelvic floor disorders. Sexual complaints were significantly more common 
among women with pelvic floor disorders (53.2% vs 40.4%, P < .01) and when a multiple 
regression model, urinary incontinence was significantly associated with low libido (odds 
ratio [OR] 1.96), vaginal dryness (OR 2.11), and dyspareunia (OR 2.04), independent of 
age, educational attainment, and race. In contrast, pelvic organ prolapse was not 
associated with any sexual complaint. A study by Weber et al (47) comparing 80 women 
with prolapse with or without incontinence and 30 controls (women with no prolapse) 
showed no difference in Global sexual function score, vaginal dryness, dyspareunia, 
interest in sexual activity or satisfaction with their sexual relationship. They concluded 
that women with prolapse and urinary incontinence do not differ from continent 
women without prolapse in measures of sexual function and age is the most important 
predictor of sexual function. Burrows et al (48) came to similar conclusions in their 
retrospective study of 352 women with prolapse. They also found that prolapse severity 
did not impact on sexual function. The study by Barber et al(49) comparing the impact 
of prolapse and incontinence on sexual function found completely the opposite results. 
In their review of 343 community dwelling women with either symptomatic prolapse or 
incontinence, they found that prolapse was more likely to influence sexual function than 
urinary incontinence. This study also demonstrated that treatment of prolapse was less 
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likely to impact on change in sexual function whereas treatment of incontinence 
resulted in a mild improvement in sexual function. 
 
Other studies have shown prolapse causes several problems with sexual function 
including discomfort, urinary incontinence (40%) (both orgasm and penetration), 
obstruction and dryness during intercourse. Women with prolapse were more likely to 
have urinary and or fecal incontinence during sexual activity, more dyspareunia and 
fewer orgasms. They were also more likely to report negative emotional reactions 
associated with sex and higher rates of embarrassment leading to avoidance of sex (50). 
Presence of both prolapse and incontinence has a cumulative negative effect on sexual 
function, with libido, sexual excitement, and orgasm being significantly affected. 
Increasing severity of prolapse is associated with symptoms related to urinary 
incontinence, voiding, defecatory, and sexual dysfunction, which do not necessarily 
correlate with the location of prolapse and therefore are not compartment-specific(51).  
 
The problem with assessment of sexual function in the different studies reported in 
literature is that 
1. Different tools have been used in different studies  
2. Studies cluster prolapse and incontinence under the same umbrella 
3. Study groups are small 
4. Different types of prolapse clumped together (different compartments, diff 
grades)  
 
There are a multitude of studies reporting on the impact of prolapse surgery on sexual 
function but the results are very conflicting with some being equivocal reporting no 
impact of prolapse correction on sexual function and others demonstrating a 
deterioration of sexual function following prolapse treatment. The cause of sexual 
dysfunction following vaginal surgery may be classified as organic and/or 
psychosocial(52). Organic causes are anatomical, physiological, vascular, neural and 
hormonal. Psychosocial factors on the other hand such as life stressors, anxiety and 
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depression must be borne in mind. Altered perception of genital health after surgery, 
both by the woman and her partner, with associated apprehension and fear of damage 
to the internal organs, can also be contributory factors for a negative impact on sexual 
function. 
 
The verdict is still open on the impact that prolapse has on sexual function, and larger 
epidemiological studies are required to substantiate or refute the currently available 
conflicting evidence. This will also be partly achieved by the long term follow up of 
randomized controlled trials. When counseling women with a prolapse and particularly 
before treatment, these factors should feature in the discussion and aid decision 
making. This allows more realistic expectations from the treatments available, and 
avoids disappointment when those goals are not met. There remain many unanswered 
questions, but it is important to remember that the presence of anatomical defect does 
not imply dysfunction. The goal of pelvic surgery should be restoration of anatomic 
support without deleterious effects on visceral and sexual function. Data is currently 
limited on quality of life and sexual function following both traditional and graft-
reinforced anterior vaginal prolapse surgery and further research is required to 
determine whether surgical technique and type of graft used impact surgical outcome 
and complications before introduction into routine clinical practice. Women should be 
counselled and managed depending on current best available evidence.  
 
Current treatment options for vaginal wall prolapse include pelvic floor muscle training 
(Physiotherapy), use of topical HRT, use of mechanical devices (ring or shelf pessaries) 
and surgery, with or without mesh reinforcement. The impact of these different forms 
of treatment for prolapse on sexual function are discussed here.  
  
Physiotherapy 
In their Systematic Review looking at the benefits of pelvic floor muscle training (PFMT), 
Hagen et al(53) identified some benefit on sexual function in women with mild prolapse. 
But even more reassuringly women who were currently performing PFMT scored 
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significantly better on several aspects of sexual function (54;55). and is therefore to be 
encouraged in women.  
  
Oestrogen therapy 
There are no studies looking at the impact of oestrogen therapy in women with prolapse 
or its impact on sexual function. However several studies have shown an individual 
improvement in symptoms of atrophic vaginitis which may negatively impact on sexual 
function even in the absence of prolapse, hence may be considered for that indication.  
  
Pessaries 
There are a variety of pessaries available, made of rubber, plastic, or silicone-based 
material. The commonest pessaries are the rings and shelf, but other types being 
increasingly used are the inflatable, the doughnut and the Gellhorn all of which have 
slightly different uses and specifications. A recent study by Kuhn et al (56), 
demonstrated desire, lubrication, and sexual satisfaction significantly improved with 
pessary use, though orgasm remained unchanged (Figure 1).  
 
A comparison of sexual function in women with pessaries or surgery(57) for the 
treatment of POP found a significant improvement in sexual function in both groups 
though there was increased frequency of intercourse in the surgery group (54% vs 46%; 
p = 0.028), which was not significant when controlled for age. 
 
Lowenstein et al (58) on the other hand found greater improvement following surgery 
than use of pessaries and this appeared to be related to altered self-perceived body 
image.  
  
Surgery  
Richard TeLinde said, “Every surgeon of extensive and long experience will have to 
admit that he is not entirely and absolutely satisfied with the long term results of all his 
operations for prolapse and allied conditions” and this is further substantiated by the 
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repeat surgery rates for recurrent prolapse being in the region of 30 %(59). White in 
1908 said “Plastic gynaecology remains the last unsolved problem of surgical 
gynaecology” and this remains true even in the 21st century.  
 
Surgical correction of prolapse depends largely on the compartment which is affected. 
So for vaginal wall prolapse it may involve an anterior colporrhaphy/ anterior vaginal 
wall repair, posterior colporrhaphy/ posterior vaginal wall repair or a vaginal 
hysterectomy. For a vaginal vault prolpase surgical correction may require a sacro-
spinous fixation, an abdominal sacro-colpopexy or an Infracoccygeal procedures which 
may involve the use of trocar systems (eg Apogee, Post I-Stop).   
  
Though Weber et al(35) identified a decrease in the vaginal dimensions after surgery for 
prolapse, this was associated with either no alteration in sexual function or a mild 
improvement. Dua et al had similar conclusions following Anterior or posterior 
repair(60). When an anterior repair was combined with a posterior repair Anterior 
vaginal repair does not appear to impact adversely on postoperative sexual function or 
cause dyspareunia. Nevertheless, there are very few data confirming this paradigm. 
Weber (61) compared three surgical techniques for cystocele repair, the dyspareunia 
rate reduced from 30% preoperatively to 22% postoperatively.  
 
An anterior repair (with or without a vaginal hysterectomy for prolapse does not impact 
adversely on sexual function (60;62). Both Colombo (63) and Van Geelen (64) found that 
anterior repair when compared to a Burch colposuspension for a cystocele did not 
predispose to dyspareunia. Though it was associated with significant vaginal shortening 
when compared to the Burch, this did not appear to impact on function unless 
combined with a posterior repair.  
 
Combining a posterior vaginal wall repair with anterior colporrhaphy may however 
increase dyspareunia rates and there may be a place for doing the two procedures 
separately where feasible. This would also indicate that a prophylactic posterior repair 
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should be avoided at the time of an anterior repair in sexually active women. This was 
also shown in the study by Dua et al(60). 
   
Studies looking at posterior vaginal wall defect are more confusing and whereas earlier 
studies suggest dyspareunia and problems with intercourse (65) with a posterior repair 
this is not substantiated in more recent studies and this could be due to a recognition of 
the problem and a change in technique(66). Levator ani plication is frequently 
implicated as the cause for dyspareunia due to post operative mid-vaginal narrowing 
(65;67;68). In contrast, improvement in dyspareunia have been reported with site-
specific defect or midline plication procedures (69-71). In sexually active women 
therefore levator plication should be avoided where possible and surgical techniques 
aimed at avoiding narrowing of vaginal introitus adopted.   
  
Vault prolapse surgery may be associated with postoperative dyspareunia and FSD. 
However, as this procedure often involves a concomitant repair, it is methodologically 
difficult to ascertain which specific procedure is causing sexual dysfunction. . Maher et 
al(72) in their systematic review comparing sacrocolpopexy to sacrospinous fixation 
showed lower dyspareunia rates with the abdominal approach but a longer operating 
time, a longer time for recover),and greater expense. Baessler and Schuessler found that 
sacrocolpopexy was actually curative in women with dyspareunia and ceased in all but 
one of the nine patients among 33 consecutive women presenting with prolapse-related 
dyspareunia preoperatively(73). Postoperative dyspareunia is reported to be between 
8% and 16% after sacrospinous fixation(74-76). When combined with a repair vaginal 
narrowing, excessive colpectomy occurring due to a concomitant repair procedures was 
identified as the most common cause of postoperative dyspareunia(77) but vaginal 
narrowing and pudendal nerve injury have also been implicated. A sacrocolpopexy has 
also been shown to be superior to a vaginal mesh. Kuhn et al (78) demonstrated that 
following a sacrocolpopexy the domains of sexual desire, arousal, lubrication, 
satisfaction, and pain improved significantly but orgasm remained unchanged. There 
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was no vaginal shortening postoperatively. Therefore in sexually active women a 
sacrocolpopexy is the preferred procedure.  
 
Iliococcygeal fixation is also performed for vault prolapse. In a matched case-control 
study comparing sacrospinous to ileococcygeal fixation, Maher et al(79) found no 
significant difference in the percentage of women who were sexually active (58% vs 
55%), who had dyspareunia (14% vs 10%), or buttock pain (19% vs 14%). It is well 
recognized that bilateral ileococcygeal fixation may result in shortening of the vagina by 
2–3 cm. In sexually active women with vault prolapse and a short vagina, bilateral 
ileococcygeal fixation is contraindicated, as it may cause severe postoperative 
dyspareunia.    
  
Mesh 
The aims of using mesh in the repair of vaginal wall prolapse are to add additional 
support and to reduce the risk of recurrence, particularly for women with recurrent 
prolapse or with congenital connective tissue disorders (such as Ehlers–Danlos or 
Marfan’s syndromes). A study by Abdel Fatah et al(80) looking at the complications of 
mesh reinforcement identified some very severe complications and therefore the need 
for caution when using synthetic materials in the absence of clear cut indications. 
Further reports on problems with the use of meshes have resulted in a distinct decline 
in mesh usage.  
  
Some studies have shown very high dyspareunia rates following mesh reinforcement for 
prolapse surgery. Milani, R. et al. (81) also demonstrated that though the use of mesh 
was associated with high success rates there was a very high rate of dyspareunia of 20% 
when used for anterior repair and 63% when used for posterior repair. This warrants 
extensive counseling and caution when using meshes in women who are sexually active. 
These results are further borne out by other studies though some studies are equivocal 
and some even demonstrate an improvement following the use of mesh in vaginal 
repair.  
P a g e  73 | 187 
 
 
 
 
 
Maher et al in their systematic review(72) analysed sexual function and dyspareunia in 
women undergoing surgery in the anterior compartment, posterior compartment and 
apical compartment using mesh. The studies included in their systematic review were 
women who had mesh reinforced colporrhaphy versus standard repair. They found no 
difference in the dyspareunia rates for native tissue anterior or posterior repair and 
mesh reinforced anterior or posterior repairs. However the commonest cause of 
complaints following mesh reinforced repair according to the FDA report of 2011(82;83) 
was pain or dyspareunia (590/1503,38.6%). This has resulted in withdrawal from the 
market of some of the products including those by Bard and Ethicon.  
 
  
  
 
P a g e  74 | 187 
 
 
 
 
URINARY TRACT INFECTIONS (UTI) 
 
The association of lower urinary tract symptoms (LUTS) and sexual dysfunction is widely 
accepted. The incidence of urinary tract infections (UTIs) in women who are become 
sexually active is about 3% per annum and about 4% of all LUT infections in this group are 
thought to be related to sexual activity and 60% in recurrent cases(84).Honeymoon 
Cystitis refers to LUTS occuring after sexual intercourse. Bacteria are often pushed 
mechanically up the urethra and into the bladder during coitus. If they are not voided 
soon after, they multiply and may cause infection. The relative risk of UTI increased from 
1.0 for unmarried women who had not been sexually active in the previous week to 9.0 
for women who had had intercourse seven times during that period(85). The term 
'honeymoon' was applied because, in the past, this was expected to be the time of first 
intercourse. The male urethra, being substantially longer, is not susceptible to the same 
problem. Some women are particularly sensitive to postcoital urinary tract dysfunction 
due to the development of a relatively high urethral pressure following intercourse. Of 
course, the condition of post-coital female lower urinary tract infection occurs at many 
times beyond the traditional 'honeymoon' - from the onset of sexual activity into old age. 
This is further illustrated by the fact that nuns have a lower prevalence of bacteriuria than 
other populations of women in early adult life(86). Following intercourse urinary bacterial 
count is significantly raised in 30% of women(87) and Nicolle et al(88) reported that both 
symptomatic and asymptomatic bacteriuria was more frequent the day after intercourse. 
Several behavioral factors have been shown to enhance the risk of UTI following sexual 
intercourse. These include deferred voiding after intercourse (89), frequent intercourse 
(84), low fluid intake (90), and deferred voiding after the initial urge to micturate (91). In 
addition reduced lubrication and the use of spermicide coated condoms, and spermicides 
either alone or in conjunction with diaphragm have also been incriminated (92).  
Contraceptive diaphragms by reducing urinary flow and spermicidal cream and the use of 
spermicidal-lubricated condoms can sometimes result in vaginal and urethral irritation 
hence the association. These risk factors were shown to have a detrimental effect in a 
large prospective study by Hooton and co-workers who examined a variety of risk factors 
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for UTI in young women (93). 
 
The initial management of postcoital UTIs includes several simple measures which may 
be effective. Close attention to perineal hygiene, change of coital technique, use of a 
vaginal lubricant, and avoidance of the contraceptive diaphragm may all be successful 
first-line measures. Women should be encouraged to drink fluid before anticipated sex to 
facilitate postcoital voiding. Ingestion of products containing cranberry (as juice or a 
supplement) has long been thought to afford protection against UTIs (94). Cranberries 
contain two substances (proanthocyanidines and fructose) which are thought to inhibit 
adhesion of infecting bacteria, particularly type 1 and type P fimbriated Escherichia coli, 
to the uroepithelium(95). A systematic review of the literature considered the role of 
cranberry in the setting of recurrent UTIs and found the relative risk of developing a UTI 
over 6 months while taking cranberry to be reduced to 0.61 (CI 0.4–0.91) compared to 1.0 
for placebo or no treatment(96). The role of cranberry in prophylaxis against infection 
following intercourse, however, has yet to be established. 
 
For women who do not respond to simple measures, regular or intermittent antibiotic 
prophylaxis is usually effective(97;98). A recent systematic review of the literature found 
evidence that in women with recurrent UTIs associated with sexual activity, postcoital 
ciprofloxacin is equally as effective as a continuous daily prescription and should be 
considered in this setting(99). There is evidence that local application of estrogen could 
be protective against infection in the context of recurrent UTIs in young women who are 
on oral contraceptives (100). When simple measures fail to alleviate postcoital cystitis, 
further investigation including investigation for atypical organisms such as Mycoplasma 
hominis and Ureaplasma urealyticum, is often worthwhile. Chlamydia causing acute 
urethritis should also be ruled out. Underlying abnormalities such as voiding difficulties 
and vesicoureteric reflux should always be considered, and imaging of the renal tract with 
ultrasonography, intravenous urography or videocystourethrography may be necessary. 
It is also sometimes appropriate to perform a cysto-urethroscopy and or magnetic 
resonance imaging to exclude a urethral diverticulum or an intravesical foreign body such 
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as a calculus.  
BLADDER PAIN SYNDROME (BPS) 
Bladder pain syndrome previously known as Interstitial cystitis/painful bladder 
syndrome (IC/PBS) is a chronic, debilitating disease of unknown etiology characterized 
by urinary frequency, urgency, nocturia, suprapubic pressure, and pain The true 
prevalence of the condition ranges from 10 to 500 cases/100,000 women depending on 
the strictness of the criteria used for the diagnosis (101;102). Studies suggest that most 
women with IC experience not only pelvic pain, but also dyspareunia, sexually related 
distress, and significant declines in desire and orgasm frequency (103-107). The 
prevalence of sexual dysfunction in these women is higher than previously estimated 
and substantially affects quality of life and sexuality (108). Sacco et al (105) showed that 
BPS was associated with the greatest impairment of FSF among women with LUTS. 
Because multiple factors contributing to sexual dysfunction (including biopsychosocial 
comorbidities such as stress, abuse, or chronic illness) can be present in women with IC, 
a variety of treatments might be required. It is also important to consider that some 
typical IC treatments, such as antidepressants and opioids used to manage pelvic pain, 
can exacerbate sexual dysfunction. Hypertonic pelvic floor dysfunction is prevalent in 
patients with IC (104) and contracted muscles can result in dyspareunia, vulvodynia, and 
vaginismus. The association between IC and syndromes such as vestibulodynia and 
spontaneous or provoked vulvodynia is commonly reported(109). The magnitude of the 
association between vulvar and bladder symptoms is variable. This has obvious negative 
implications on sexual function and sexual functioning is in fact one of the strongest 
predictors of poorer quality of life (QOL) in patients diagnosed with refractory interstitial 
cystitis/painful bladder syndrome (IC/PBS) (110). 
Several Studies have demonstrated an improvement in the dyspareunia and other levels 
of sexual function when PBS symptoms are alleviated either by intravesical injections of 
lidocaine, heparin, and sodium bicarbonate (111) or other pharmacological treatments 
(112) such as pentosan polysuphate and hyaluronic acid(113). The pelvic floor muscles 
play an important role in female responsiveness and sexual function; thus, therapies 
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aimed at treating the pelvic floor might be even more efficacious in improving sexual 
function, the woman’s self-esteem, and her relationship with her partner.  Some 
therapies that have been reported to be helpful include pelvic floor therapy, 
biofeedback, neuromodulation, and botulinum toxin type A(114). 
FAECAL INCONTINENCE (FI)  
Anal incontinence is reported to affect 8% of women in the general population (115). 
Faecal incontinence is known to cause sexual dysfunction and this may be associated 
with anal sphincter injury related to birth trauma (116;117)or due to other causes such 
as neurological disorders. Fecal incontinence of solid stool and depression related to 
fecal incontinence were correlated with poorer sexual function but does not prevent 
women from engaging in sexual activity thereby demonstrating that it is an important 
aspect of their lives(118).   
Corrections of faecal incontinence irrespective of the mode of repair was associated 
with an improvement in sexual function in most studies (117;119). But patients who had 
undergone an overlapping sphincteroplasty versus an end-to-end sphincteroplasty 
reported pain during intercourse 24% vs 4% of subjects (P = .04). Sacral nerve 
stimulation which is increasingly being used for the treatment of fecal incontinence has 
been shown to be of benefit(120;121). However some studies actually suggest an 
equivocal impact on sexual function following a repair(122). Trowbridge (123) in his 
study showed that sexual function scores were not correlated with continence scores.  
PREGNANCY CHILDBIRTH AND PERINEAL TRAUMA  
Data on the impact of childbirth on sexual function is conflicting. There is a dearth of 
scientifically reliable data about the impact of childbirth on sexual function and the 
association with the different modes of delivery.  
It is generally accepted that pregnancy itself is associated with reduced interest in sex, 
ranging from 57% to 75%(124-128). Sexual interest usually improves postpartum, but 
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23–57% of women still report reduced sexual interest at 3 months, and 21–37% at 6 
months (125;129).Generally speaking women are less likely to be sexually active during 
pregnancy, particularly in advanced pregnancy(125) with only 26% having intercourse in 
the third trimester. This could be due to a reduction in the ability to reach orgasm with 
60% of women experiencing orgasm through the second trimester (126) declining to 
50% in the third trimester (125). Sexual function, which declined through pregnancy was 
not recovered postpartum (P = 0.017). The main predictor for poor sexual function in 
early pregnancy, was impaired body image, while in the postpartum period, worse 
urinary symptoms correlated with poor sexual function scores (130). Interestingly 
though sexual practices changed during pregnancy they returned to early pregnancy 
levels in the postpartum period.  
It is widely reported that postpartum dyspareunia is associated with the mode of 
delivery with assisted vaginal delivery being predominantly incriminated (117;131-133) 
with at least a twofold increase in dyspareunia when compared to spontaneous vaginal 
delivery. Barret et al. reported that women delivered by C/S were significantly less likely 
to report dyspareunia at 3 months postpartum than those with vaginal delivery(129). 
However, the same authors in a subsequent study, by employing a larger cohort with 
longer follow-up found dyspareunia was equivalent in both groups(134). This has been 
further substantiated in other studies which have failed to show that a CS has a 
protective effect on sexual function(135;136).Though a study by Buhling et al (137) 
found the highest dyspareunia after operative vaginal delivery, and least with elective 
C/S, this decreased uniformly in each group by 6 months. Operative vaginal deliveries 
had a persistent rate of dyspareunia of 14%, but there was no difference between the 
spontaneous vaginal delivery group with an intact perineum and C/S (3.4% dyspareunia 
at 6 months). Interestingly, at 3 months postpartum, all of the patients reported 
“enjoyment at sexual intercourse” regardless of the mode of delivery (137). Perineal 
trauma with or without operative instrumental delivery was an important precursor of 
dyspareunia and the greater the tear even, with spontaneous vaginal delivery, the lower 
the sexual desire (138;139). Women with an intact perineum or first-degree perineal 
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tear 6 months postpartum were more likely to experience orgasm (117) than those with 
either second-, third-, or fourth-degree perineal tear. 
Postpartum, sexual desire and the ability to reach orgasm do improve but the main 
problems encountered and impacting on sexual function are sexual arousal, excitement 
and lubrication (129). The risk of vaginal dryness and lubrication problems is increased 
with prolonged breast-feeding, which results in vaginal atrophy secondary to hypo-
oestrogenism. The latter is easily corrected with topical estrogens or nonhormonal 
lubricants.  
Owing to the inconsistencies in the definition of FSD and use of heterogeneous and 
invalid tools for evaluation in most of the studies, it is difficult to draw a scientifically 
sound conclusion about the impact of mode of delivery on sexual health. Reports on the 
negative effect of vaginal childbirth on sexual health led to the concept of elective 
Caesarean section (C/S) to preserve sexual function. Many health care professionals also 
advocate this approach with 7–24% of obstetricians and 4.4% of midwives preferring 
elective C/S for themselves or their partner (140-142). Interestingly, urogynaecologists 
scored even higher, with 45.5% opting for primary elective C/S (142).  
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HYSTERECTOMY  
Hysterectomy is the commonest major gynaecological operation in the UK. Theoretically 
it poses a risk not only to the intricate pelvic nerve plexus and damage to the autonomic 
nerve endings of the cervico-vaginal fascia hence impacting on orgasm or sensation 
during intercourse, but may also cause distortion of pelvic anatomy by shortening the 
vagina thereby resulting in dyspareunia. Historically, the uterus, “hystero”, was believed 
to be the center of female sexuality and may also have culture-dependent psychological 
effects leading to loss of self-esteem, female identity, and consequent FSD. 
 
Following hysterectomy an overall improvement (143) in the different aspects of sexual 
function ie frequency of sexual relations, dyspareunia, orgasm, vaginal dryness, and 
sexual desire were noted. The route of hysterectomy appears to play no role. A 
prospective study by El-Thouky et al (144) compared hysterectomies performed 
abdominally, vaginally or laparoscopically found that patients reported significantly 
lower rates of deep dyspareunia (18.8%, 19.7%, and 26.3% reduction respectively) after 
surgery than before the operation, regardless of the routes and technique used. This 
was not substantiated in the study by Ayoubi et al (145) who found greater 
postoperative delay in resuming sexual activity after abdominal hysterectomy (62.4+/-
9.3 days) than after vaginal (45.2+/-6.7 days) hysterectomy. They also found 
deterioration of sexual function occurred more frequently after abdominal 
hysterectomy (24%) than after vaginal (13.5%) or laparoscopic (8.5%) hysterectomy. 
 
The belief that the cervix is necessary to achieve orgasm or that total abdominal 
hysterectomy (TAH) leads to local innervation damage with subsequent impairment of 
sexual function is not supported by current evidence. This belief was held for several 
years following a study by Kilkku et al which found women had a lower libido and 
orgasm following a TAH (146) when compared to a STAH. However the same group 
subsequently reported an improvement in dyspareunia rates irrespective of the type of 
hysterectomy. Subsequent larger studies specifically comparing subtotal (STAH) and 
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total abdominal hysterectomy(147) have also failed to identify a difference in sexual 
function. A study(148) looking at the long term follow up of women following a vaginal 
hysterectomy versus a Manchester Fothergill repair showed no difference in sexual 
function between the two groups which further dispels this myth.  
 
 
 
 
 
CONCLUSION 
In spite of the common presentation of sexual dysfunction in association with pelvic 
floor disorders, overall assessment by clinicians remains low and a recent survey of the 
members of the British Society of Urogynaecology (BSUG) demonstrated that only half 
of all clinicians routinely asked about FSD in the clinic and similar numbers at the 
postoperative follow up visit(149). Similar trends have been seen amongst the US 
clinicians and a recent survey of members of the American Urogynecologic Society 
(AUGS) has shown that 77% and 76% of AUGS members enquired of FSD, respectively in 
similar situations (150). Lack of time, uncertainty about therapeutic options and older 
age of the patient were cited as potential reasons for failing to address sexual 
complaints as part of routine history. Clinicians dealing with women with these 
conditions need greater training to manage FSD in association with the underlying 
pathology. 
 
Currently available evidence of pelvic floor problems and their impact on sexual function 
is conflicting. Greater and more robust research into different urogynaecology 
conditions impacting on sexual function and their treatment is required. Assessment of 
patients with urogynaecology problems firstly requires a history and direct enquiry into 
sexual function, but also requires the development of standardized tools with well 
defined end point to assess the severity of the problem.  
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Figure 1: Ring Pessary in situ: No interference with sexual activity 
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Table 1 Classification of Female Sexual Dysfunction (DSM IV TR {Text revision}) 
(151) 
1. Sexual Desire/Interest Disorders 
2. Sexual Arousal Disorders 
- Genital Arousal disorder 
- Subjective Arousal disorder 
- Combined Arousal disorder  
     3.  Orgasmic Disorder  
     4.  Dyspareunia and Vaginismus 
     5.     Persistent Sexual Arousal Disorder 
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Table 2 Studies showing prevalence of urinary incontinence during sexual 
intercourse 
 
Authors Design and setting Symptoms analysed % with UI during 
intercourse 
Bo et al(152) RCT of women with 
SUI; Norway 
Urinary Incontinence 
during intercourse 
using BFLUTS 
33%  
Clark et 
al(153) 
48 women undergoing 
UDS;USA 
Incontinence and other 
urinary symptoms 
during intercourse 
56% 
Espuna, Pons 
M et al(154) 
633 Sexually active 
women 
Coital incontinence.  36.2% 
Gordon et 
al(155) 
100 consecutive 
women attending a 
clinic; Israel 
Psychiatric assessment 
of sexual function 
16% 
Hilton(16) 324 sexually active 
women; UK 
Standardised 
Questionnaire 
24% 
Jackson et 
al(156)  
RCT of HRT in women 
with SUI; UK 
Urinary Incontinence 
during intercourse 
using BFLUTS 
10% 
Jha et al(15) Women with 
Urodynamic Stress 
Incontinence 
undergoing TVT; UK 
ePAQ questionnaire 68% 
Jha et al (18) Women with Urinary 
incontinence 
undergoing 
urodynamics 
ePAQ questionnaire 60% 
Lam et 
al(157) 
2631 (random) women 
selected: 511 had SUI; 
Denmark  
When they have SUI 2% of general 
group; 12% of 
women with SUI 
Lemack et 
al(26) 
56 women; USA UI with intercourse 11% 
Moller et 
al(158) 
4000 randomly 
selected women from 
the community; 
Denmark 
UI with intercourse 8%= sometimes 
1.7%=weekly 
0.4%=daily 
Nygaard et 
al(159) 
224 random women: 
Gynaecology 
outpatient; USA 
UI with penetration/ 
orgasm 
12.9% 
Weber et 
al(35) 
81 sexually active 
women undergoing 
surgery; USA 
UI with intercourse 22% 
P a g e  86 | 187 
 
 
 
 
Vierhout et 
al(160) 
196 sexually active 
women attending clinic 
UI with intercourse 34% 
Visser et al 
(13) 
Community dwelling 
women 
UI with intercourse 26% 
Xu et al 
(161) 
55 women with USI 
undergoing TVT 
UI with intercourse 21.8% 
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7.3 Paper 3. Prolapse or incontinence, what affects sexual 
function the most? 
 
Swati Jha, Deepa Gopinath 
Abstract  
Introduction and Hypothesis 
Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) adversely affect sexual 
function in women. Comparative studies between the two subgroups are few and 
results are conflicting. The aim of this study was to compare the effect of POP and SUI 
on sexual function of women undergoing surgery for these conditions.   
Methods 
The study population comprised women with POP or SUI in a tertiary referral hospital in 
UK. Women who underwent SUI surgery had no symptoms of POP and had 
urodynamically proven stress incontinence. Patients with POP had > stage 2 prolapse, 
without bothersome urinary symptoms. Pre-operative data on sexual function were 
collected and compared using an electronic pelvic floor assessment questionnaire 
(ePAQ). The incidence of sexual dysfunction and comparison of symptoms in both 
groups were done using Mann-Whitney U test.  
Results: 
343 women undergoing surgery either for SUI or POP were included. Patients were age 
matched with 184 undergoing SUI surgery (age range 33-77years) and 159 POP surgery 
(age range 27-78years) (p= 0.869). The overall impact of POP and SUI was not 
significantly different in the two subgroups (p=0.703). However, both patients (73% vs 
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36%; p=0.00) and partners (50% vs 24%; p= 0.00) avoid intercourse significantly more in 
cases with POP compared to SUI. This did not have a significant impact on quality of life.  
Conclusions: 
The impact of bothersome SUI or POP on sexual function was found to be similar but 
patient and partner avoidance in women with POP was greater than those with SUI.                                                                                     
 
Introduction  
 
Pelvic organ prolapse (POP) and stress urinary incontinence (SUI) are disorders of the 
pelvic floor that affect about a third of community dwelling women with significant 
impact on woman’s quality of life[1, 2] . Sexual problems have been well known in 
women attending a urogynaecology clinic ranging from 37%- 64% [3, 4]. Sexual 
problems commonly described in women with POP or SUI include disorders of desire, 
arousal, orgasm and dyspareunia. Disorders in the male partner are also seen including 
premature ejaculation and erectile dysfunction [5]. A community based survey found no 
difference between sexual activity and satisfaction compared to women without pelvic 
floor dysfunction [6]. 
 
There is conflicting evidence in literature regarding the effect of POP and SUI on sexual 
function. Patients with prolapse may have coexistent urinary symptoms and vice versa 
due to the close anatomical relationship and also similar underlying pathophysiology. 
Most studies therefore report on women with mixed symptoms of both POP and SUI. 
Some studies report no difference in the sexual function in women with prolapse or 
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incontinence [7], others report prolapse is more likely to affect sexual relations than 
incontinence[8] [9]. whereas some studies found women with urinary incontinence 
were more likely to report low libido, vaginal dryness and dyspareunia [10]. All these 
studies have been in patients with both prolapse and urinary symptoms making it 
difficult to differentiate if there are any actual differences in sexual function in these 
two subgroups. Also, most studies failed to use validated questionnaires casting doubt 
on the validity of findings. 
 
The aim of this study was to evaluate female sexual function in two subsets of patients 
bothered by POP and stress urinary incontinence, without overlap of symptoms in order 
to reduce the confounding bias due to these factors. 
 
Materials and methods 
 
This was a retrospective cohort questionnaire based study conducted at a tertiary 
hospital in the UK. All patients attending the urogynaecology department complete an 
electronic pelvic floor assessment questionnaire as part of routine clinical care prior to 
being reviewed by a clinician. The electronic pelvic floor assessment questionnaire 
(ePAQ), a validated symptom specific and quality of life questionnaire was used for this 
purpose [11]. Pre-operative data on sexual function were collected on all sexually active 
women who underwent surgery for SUI or POP, in the period from January 2008 to 
December 2012. A post hoc power analysis was performed and the available sample size 
had a greater than 80% power of detecting 3 point differences at the 5% (two-sided) 
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level with standard deviation of 5 points. This instrument provides symptoms 
assessment in four dimensions: urinary, bowel, vaginal and sexual. Patients who had 
concurrent prolapse and urinary incontinence were excluded from the study. Women 
scheduled for surgery were selected rather than those opting for conservative 
treatment (physiotherapy or ring pessary) as it identified a cohort of women who were 
more bothered or were likely to have greater severity of prolapse or incontinence. All 
ePAQ data were collected preoperatively. Women undergoing SUI surgery had no 
symptoms of POP on clinical examination. This was further confirmed by the ePAQ 
scores which showed a negative screen for the prolapse item in these patients. They all 
had urodynamically proven SUI without any detrusor overactivity. Patients with POP had 
a stage 2 prolapse or more (Ba or C at or beyond 0 on POP-Q), without any bothersome 
urinary symptoms including urinary incontinence.  These patients were screened as 
negative for the impact of stress urinary incontinence on urinary domain related quality 
of life item on ePAQ. It is not routine practice in our unit to do a stress reduction test, so 
data on occult stress incontinence was not available.   
 
The sexual dimension on ePAQ has five domains which include urinary, bowel, vaginal, 
dyspareunia and general sex life. Within both groups, both item and bother scores from 
ePAQ were collected for domains urinary and vaginal for analysis. These scored on an 
ordinal scale from 0 to 3, where 0 represents “Never” and 3 represents “All the time”. 
SUI and POP have been shown to impact on sexual function in different ways[12]. In the 
SUI group, scores were collected for the items including overall impact due to 
incontinence, penetration and orgasm incontinence as well as post coital urinary tract 
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infections (UTI). In the POP group, the items dryness of the vagina, discomfort and pain, 
lack of sensation, tightness and obstruction were measured. A comparison of the two 
subgroups in terms of overall impact, avoidance of intercourse by patient and partner 
and patient anxiety were done. All analysis was done on SPSS version 19 and non-
parametric data was compared using Mann-Whitney U test and demographic data was 
compared using student’s t-test. 
 
This project was registered as a service evaluation project with Sheffield Teaching 
Hospitals NHS Foundation Trust. Data used for this study were only from patients who 
answered “Yes” to the final two items of the questionnaire: 
“(D2a) Are you willing to allow confidential use of your answers in order to evaluate the 
care you receive? 
(D2b) Are you willing to allow confidential use of your answers in order to check how 
this questionnaire is working?” 
 
Results 
 
One hundred and eighty four women who underwent a mid-urethral sling (TVT) 
procedure and were sexually active, completed ePAQ preoperatively. The age range was 
between 33 to 77 years with a median age of 49. One hundred and fifty nine women in 
the prolapse group who underwent pelvic floor repair which included anterior repair 
and or posterior repair, with or without a hysterectomy were sexually active and 
completed ePAQ. The age range of these women was 27y to 78y with a median age of 
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59. Though the median age of patients with prolapse appeared to be higher than 
patients with stress urinary incontinence, this was not found to be statistically 
significant (p=0.869). 
 
On comparison of the overall incidence of interference of sexual activity due to POP and 
SUI symptoms, the incidence was found to be higher in the POP group (n=113;71%) 
compared to SUI group (n=98;53%). However the mean ePAQ scores were similar for 
POP (1.56+1.05) and SUI (1.62+1.07) and did not reach any statistical significance (p = 
0.703). On comparing the avoidance of sexual activity, 116 patients with POP avoided 
sexual activity (73%) compared to 66 women with SUI (36%)  (p=0.000). However, the 
mean impact scores for avoidance of sexual activity were similar in these two groups 
(p=0.609).With respect to avoidance of sexual activity by the partner due to patient’s 
symptoms, the incidence was higher in the POP group (n=80, 50%) compared to SUI 
group (n=44, 24%). This again did not reach statistical significance with respect to 
impact on quality of life (p=0.820). Patient anxiety was found to be similar in POP 
(n=121, 76%) and SUI (n=116, 63%) groups respectively. These results are shown in 
table: 1. 
 
In the SUI group, 40% (74/ 184) complained of orgasm incontinence and 31 %( 57/184) 
complained of penetration incontinence. Thirty per cent (55/184) women reported post-
coital UTIs. With respect to the impact of specific items, the impact of urinary leakage 
during sex (1.62 +1.07) was the highest, followed by impact of post coital UTI 
(1.42+0.94).  In the POP group, 53% (84/159) complained of dryness in the vagina, 60% 
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(95/159) complained of lack of sensation, 56% (89/159) had vaginal discomfort, 18% 
(29/159) complained of tightness and 59% (94/159) complained of obstruction. Out of 
the specific vagina items, the highest impact score(1.36+1.18) was for the feeling of 
vaginal obstruction due to POP and the tightness of the vagina caused the least impact 
on sexual activity(0.42+0.84). Specific symptoms in the subgroup affecting sexual 
function are shown in Table 2. 
 
Discussion  
 
Women with bothersome POP and SUI have a similar impact of their pelvic floor 
symptoms on sexual function. Patient and partner avoidance of intercourse was greater 
in women with POP compared to women with SUI but this did not impact on quality of 
life.  
 
This is the largest study looking at specific pelvic floor problems and their comparative 
impact on sexual function. The study by Barber et al[8] only had 32 patients with 
prolapse and 29 patients reporting lower urinary tract symptoms including urinary 
incontinence. Similarly the study by Weber[7] only reported on 80 women. They 
reported that when prolapse interfered with sexual intercourse, women had 
significantly more advanced prolapse and more incontinence episodes than when POP 
did not interfere with intercourse. Other studies with larger sample sizes [6, 9, 10, 13, 
14] had a mixed population looking at women with both pelvic organ prolapse and 
urinary incontinence to varying degrees, and sometimes not needing any treatment. It is 
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difficult to therefore extrapolate from these studies the exact effect of these individual 
symptoms on sexual function or indeed compare the two. Another strength of our study 
is that all patients included had significant symptoms, as they were on a waiting list for 
surgery and therefore were significantly bothered by their pelvic floor symptoms.  
 
A study by Ozel[15] looked at patients who suffered SUI with and without POP. This 
study found that women with POP in conjunction with SUI  are more likely to report 
decreased libido, decreased sexual excitement, and difficulty achieving orgasm during 
intercourse when compared to women with UI alone impact on sexual function. Sample 
size was significantly less than in our study and this study presupposes that SUI causes a 
baseline level of sexual dysfunction.  
 
Our data was similar to that reported by Ellerkmann [16]and Barber [8] which found 
that women with bothersome POP avoided intercourse. This could be because POP 
causes objective symptoms during intercourse which is apparent both to the patient and 
the partner hence why they are more reluctant to engage in sexual activity. In addition 
the presence of prolapse may affect a woman’s self-image resulting in a reluctance to be 
intimate with her partner. For partners the avoidance may be related to a fear of 
causing worsening of the prolapse and their partner’s symptoms.  
 
The main weakness of our study is that this was a retrospective study so it is difficult to 
comment on other factors that may impact on sexual function such as the number of 
women who were menopausal, proportion of women on HRT or local oestrogen 
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replacement therapy. In addition we did not have any data on the partner and their 
sexual status with regard to inherent problems that may impact on sexual function. In 
the POP group we excluded women with stress urinary incontinence, we did not exclude 
women with micturition or urgency symptoms as this data was not available, This may 
be considered a shortcoming however we feel these symptoms were more likely to be 
related to the prolapse. There is also the absence of a control group to compare the 
baseline incidence of sexual dysfunction in the general population compared to our 
study group. It could be argued that the sexual problems patients in the study group 
suffered may not be linked exclusively to their pelvic floor problems.  
 
The results of our study enhances the understanding of sexual dysfunction in women 
with pelvic floor dysfunction. It also dispels several myths related to these conditions 
including the fact that POP per se results in a greater impact of various aspects of sexual 
function to a greater degree than SUI, and this does not appear to be the case.  Our 
study allows better counselling of women deciding to proceed with surgery for these 
conditions and allows us to give them more realistic expectations of what symptoms are 
related to individual pelvic floor problems. The role of conservative treatments such as 
pelvic floor muscle training cannot be underestimated[17]. We have previously reported 
on the impact of surgical treatment of POP [18, 19] and SUI [20, 21] on sexual function 
and results are very reassuring and similar to those reported by other authors[22].  This 
study also emphasizes the need for healthcare professionals to assess sexual health in 
women with bothersome POP and SUI. It has been demonstrated that there is definite 
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scope for improvement in this regard [23]. Irrespective of age, patients are bothered to 
varying degrees by the impact of these conditions on their sexual function.  
Sexual dysfunction is very complex and the impact of pelvic floor problems is unlikely to 
be a linear effect. Natural history of sexual dysfunction in these women needs to be 
further explored taking into account all the variables that might affect sexual function. 
Larger well designed studies looking at demographic and childbirth data as well as 
hormone status are required to understand the pathophysiology of sexual dysfunction 
in women with pelvic floor disorders and identify preventative as well as therapeutic 
strategies.  
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Figures 
 
Figure: 1 Items in the sexual dimension section of ePAQ 
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Tables 
Table: 1 Impact of urinary incontinence and POP on sexual function. 
 
Item POP(n=159) 
Incidence 
(%) 
SUI(n=184) 
Incidence (%) 
POP ePAQ 
scores 
Mean + SD 
SUI ePAQ 
scores 
Mean + SD 
p value 
ePAQ scores 
Incidence and 
overall impact 
on sexual 
activity 
71% 53% 1.56(1.05) 1.62(1.07) 0.703 
Patient avoids 
intercourse 
73% 36% 1.34(1.09) 0.90(0.92) 0.000 
Impact of 
patient 
avoidance 
67% 51% 1.55(1.07) 1.61(1.00) 0.609 
Partner avoids 
intercourse 
50% 24% 0.85(1.01) 0.42(0.76) 0.000 
Impact of 
partner 
avoidance 
45% 24% 1.11(1.11) 1.18(1.20) 0.820 
Patient anxiety  76% 63% 1.43(1.11) 1.33(1.13) 0.4114 
 
 
Mann-Whitney U test for calculation of p value  
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Table: 2 Incidence of bladder specific and prolapse specific symptoms that influences 
sexual function. 
 
Subgroup Symptom Incidence 
(%) 
Mean  impact 
score 
SUI 
(n=184) 
Orgasm incontinence 40%  0.79 + 1.18 
Penetration incontinence 31% 0.66 + 1.16 
Post-coital urinary tract 
infections 
30% 1.42 + 0.94 
POP 
(n=159) 
Dryness in the vagina 53% 1.05 + 0.97 
Lack of sensation 60% 1.21 + 1.03 
Discomfort 56% 1.19 + 1.04 
Tightness 18% 0.42 + 0.84 
Obstruction 59% 1.36 + 1.18 
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7.4 Paper 4 Incontinence during intercourse: myths unravelled. 
 
Swati Jha, Katie Strelley, Stephen Radley 
 
ABSTRACT 
Introduction 
This study aimed to establish the prevalence of urinary leakage during intercourse, the 
extent to which urinary leakage impacts on sex life and the correlation between 
different urodynamic diagnosis and coital leakage.    
Methods  
480 women attending between 1st January 2006 & December 2010 with urinary 
incontinence and subsequently undergoing urodynamic assessment were included. Data 
were collected as part of routine clinical care using the electronic Pelvic floor 
Assessment Questionnaire (ePAQ) and correlated with urodynamic findings. 
Results 
60% of women with urinary incontinence reported leakage during intercourse. Overall 
quality of life in women with urinary incontinence was strongly correlated to the impact 
of urinary symptoms on sex life. Parameters of sexual function were no different in 
women with different urodynamic diagnosis. 
Conclusion 
Worsening urinary incontinence has a deleterious effect on sexual function. Urodynamic 
diagnosis does not correlate with the nature of underlying sexual problems, orgasm or 
penetration incontinence.  
 
Introduction 
 
The association between different types of urinary incontinence and coital incontinence 
is poorly understood. Past studies[1] have demonstrated that detrusor overactivity 
(DOA) is associated with orgasm incontinence and urodynamic stress incontinence (USI) 
is associated with penetration incontinence. Subsequent studies failed to demonstrate 
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this association. However these later studies included small numbers[2], were 
observational, used non validated outcomes[3]  and were based on symptoms rather 
than urodynamic findings which have a poor correlation to underlying diagnosis.  
 
The aim of this study was to establish the prevalence of urinary leakage during 
intercourse in women presenting with a complaint of urinary incontinence and the 
extent to which urinary leakage impacts on sex life. We also established the impact and 
association of different types of urinary incontinence ie USI, DOA and mixed 
incontinence on different parameters of sexual function.   
 
Methods 
 
Patients attending the Urogynaecology Unit between 1st January 2006 & July 2010 
referred with urinary incontinence and subsequently undergoing urodynamics formed 
the study group. Patients with prolapse on clinical examination (POP- Q Aa -2 or less and 
Ap -2 or less), and those with voiding dysfunction or hypersensitivity on urodynamic 
studies were excluded from the analysis. Patients who had had previous prolapse or 
incontinence surgery were also excluded. All patients had a bladder capacity in excess of 
350 mls, and patients with low compliance were excluded as this could be an indicator 
of underlying detrusor overactivity. As part of unit policy none of the patients 
undergoing urodynamics were on anticholinergics for at least 2 weeks preceding the 
investigation. Patients with UTI were also excluded as patients with evidence of UTI on a 
mid-stream urine did not undergo the test.  
 
Data were collected as part of routine clinical care using a standardised, validated pelvic 
floor questionnaire and were analysed and correlated with urodynamic outcomes. The 
Electronic Pelvic Floor Assessment Questionnaire (ePAQ)[4] is a comprehensive web-
based pelvic floor questionnaire which includes 4 dimensions (Urinary, Bowel, Vaginal 
and Sexual). Each dimension has questions on frequency and severity of various 
symptoms and their associated bother and provides 19 psychometrically robust & 
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clinically meaningful domain scores (Figure 1). Each score is transformed on a range 
from 0 (indicating best health status) to 100 (worst health status). The domain score is 
calculated using the simple formula: Domain Score = total of raw scores for each item in 
the domain / maximum possible score × 100. ePAQ items record symptoms on a 4 point 
scale (Never=0, Occasionally=1, Most of the time=2 & All of the time=3). The impact 
attributed to these symptoms is also recorded on a 4-point scale: (Not a problem=1, A 
bit of a problem=1, Quite a problem=2, A serious problem=3).  
 
The sexual dimension of this questionnaire identifies the impact of different pelvic floor 
problems individually on sexual function. The sexual dimension provides 3 domain 
scores for the different aspects of pelvic floor symptomatology that may impact on 
sexual function: (1) Urinary, (2) Bowel & (3) Vaginal. The 2 final sexual domain scores are 
(4) Dyspareunia and (5) General sex life (Figure 1). For the purposes of this study we 
were interested in the impact of urinary symptoms and their impact on sexual function.  
The score for the urinary domain of the sexual dimension is derived from 4 items shown 
below. Each item is scored on an ordinal scale from 0-3, where 0 represents ‘Never’ and 
3 represent ‘All of the time’. These 4 items included;  
(1) Overall impact of bladder problems on sex life 
(2) Anxiety related to bladder problems during sex 
(3) Avoidance of sex by the patient because of her bladder problems 
(4) Partners avoiding sex because of the patient's bladder problems 
Items not contributing to this score also included incontinence during intercourse, 
orgasm incontinence, penetration incontinence & post-coital UTI. For the purposes of 
this study the association of different urodynamic diagnosis on each of these 8 
parameters was evaluated.  
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Sample size calculations were done. 480 women were identified as fulfilling the 
inclusion and exclusion criteria. Assuming a 5% margin of error and 95% confidence 
intervals with unknown responses, 218 responses were required to make this a valid 
study. As data was available for a larger number ie 350 we used all the data available. 
 
Women were given the opportunity of completing ePAQ, prior to their outpatient 
consultation. Only women who gave consent for their data to be used for non clinical 
purposes were included. Data were anonymised and exported to SPSS for analysis.   
 
Urodynamic investigations were performed in accordance with the guidelines for Good 
Urodynamic Practice proposed by the International Continence Society (ICS)[5]. The 
diagnosis of DOA, USI, Mixed incontinenence and normal urodynamics were in keeping 
with the terminology recommended by the ICS[6]. 
  
Pearson’s Rank Correlation was used to establish the association between severity of 
urinary incontinence and its impact on sex life. Kruskal-Wallis test was used to compare 
the different parameters of sexual function with different urodynamic diagnoses ie 
Urodynamic stress incontinence(USI), detrusor overactivity (DOA), Mixed incontinence 
(USI + DOA) and normal urodynamics. Chi square test was used to compare orgasm and 
penetration incontinence in different urodynamic diagnosis.   
 
This study had approval as a service evaluation project by Sheffield Teaching Hospitals. 
As data was obtained from a database and all data used had patient approval formal 
ethical approval was not required.  
 
Results 
 
480 women attending the Urogynaecology Unit between 1st January 2006 & July 2010 
referred with urinary incontinence and subsequently undergoing urodynamics formed 
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the study group. 350 women completed the sexual domain of the ePAQ questionnaire 
and fulfilled the inclusion criteria and data from their ePAQ and UDS was analysed.  
The overall frequency of different urodynamic diagnosis is shown in table 1. 211/350 
(60%) of women undergoing urodynamics and 12/31 (38%) of women with normal 
urodynamics had leakage during intercourse. Pearsons rank correlation demonstrated 
that overall quality of life in women with urinary incontinence was strongly correlated to 
the impact of urinary symptoms on sex life (r = 0.659, p < 0.01).  
 
The 130 women who did not complete the sexual dimension of the questionnaire were 
older than those who did and the most commonly cited reason was sexual inactivity. 
The frequency of the different urodynamic diagnoses was no different in those who did 
not complete the sexual dimension compared to those who did. The mean age of 
women who completed the questionnaire was 48.3 years(Standard deviation = 9.62). 
 
The parameters of sexual function were no different with different urodynamic 
diagnosis. Table 2 shows the results of the Kruskal-Wallis test comparing different 
parameters of sexual function in the different UDS diagnosis (USI, DOA and mixed). In 
women clinically presenting with incontinence but normal urodynamic diagnoses, all 
parameters were equally affected except incontinence with intercourse. In women with 
normal urodynamics incontinence with intercourse was less likely (p =0.035).  
 
The prevalence of orgasm incontinence alone with no penetration incontinence (n= 56) 
was not significantly different in women with USI (34/201;16%), DOA (11/67; 16%), 
mixed incontinence (7/51; 14%) and normal urodynamics (4/31,13%). Likewise there 
was no significant difference in the prevalence of penetration incontinence with no 
orgasm incontinence (n=51) in women with underlying USI (30/201; 15%), DOA (11/ 67; 
16%) and Mixed incontinence (9/51; 18%). In women with normal urodynamics 
penetration incontinence alone was unlikely (1/31; 3%; P < 0.005).  
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Comparisons of the underlying urodynamic diagnosis of USI, DOA mixed incontinence 
and normal urodynamics in women with coital incontinence, orgasm incontinence and 
penetration incontinence in women is shown in table 3.  
 
Discussion and Conclusions 
 
Incontinence during intercourse is a common problem in women with urinary 
incontinence and in our study is reported in 60%. The different parameters of sexual 
function ie, overall impact on sexual function, incontinence with intercourse, 
penetration incontinence, orgasm incontinence, patient avoidance, partner avoidance, 
anxiety  and postcoital infections are not influenced by the underlying urodynamic 
diagnosis.  The presence of specific symptoms ie orgasm or penetration incontinence in 
isolation is not prognostic of underlying urodynamic diagnosis. Worsening urinary 
incontinence significantly impacts on and causes a deterioration in sex life. 
 
This is the largest study looking at sexual symptoms using a validated questionnaire and 
underlying urodynamic diagnosis. In addition to orgasm and penetration incontinence 
other parameters of sexual function were also analysed. Data were collected as part of 
routine clinical care[7] using an electronic questionnaire hence patients were likely to 
volunteer symptoms rather than be too embarrassed to discuss them. Other factors that 
might impact on sexual function ie prolapse, painful bladder syndrome, previous surgery 
and voiding dysfunction were excluded from the analysis.  
 
The chief weakness of our study is that we do not have demographic data on the parity 
or ethnicity and therefore it is difficult to establish the impact if any of these variables.   
 
The main study cited when discussing coital incontinence in women with urinary 
incontinence is the paper by Hilton[1] in 1988. The prevalence of coital leakage in our 
study was significantly higher (60%vs 24%). This could be because patients are more 
willing to discuss this symptom. Also as this complaint was elicit by an electronic 
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questionnaire rather than during the face to face consultation it is likely patients would 
be more willing to divulge this information[8]. As with the Hilton study we found that 
USI was found in the majority of women presenting with coital, penetration or orgasm 
incontinence. This is probably related to the fact that this is the most common 
indication for urodynamics and, as with the Hilton study, most women with abnormal 
urodynamics had USI. However the overall prevalence of the different symptoms in the 
individual groups in our study was not different. This is in contradiction to the Hilton 
study which showed orgasm incontinence in the absence of penetration incontinence to 
be more strongly associated with DOA and the converse to be true for USI. The study we 
present has much larger numbers and uses a validated questionnaire for symptom 
assessment.    
 
A subsequent study by Moran et al [3] showed a much lower incidence of coital 
incontinence ie 10.6% compared with our study. They showed genuine stress 
incontinence (previously used terminology for urodynamic stress incontinence) was 
present in 79.8% of women with urinary leakage during penetration, in 93.2% with leak 
on orgasm and in 92.0% who leaked on both. The weakness of this study was its failure 
to use a validated questionnaire and failure to identify/exclude other confounding 
variables such as prolapse, previous surgery, voiding problems and a sensory bladder.  
 
A more recent study by El Azab et al [2] found a similar prevalence of coital incontinence 
in women with urinary incontinence to our study (66 % vs 60). As in our study, they did 
not find an association with orgasm incontinence and DOA. Their study was however 
much smaller (90 patients) and included patients with prolapse which may have 
influenced their results as prolapse can independently impact on sexual function[9,10].  
Unlike our study, ElAzab et al only asked about coital, penetration and orgasm 
incontinence rather than other parameters of sexual function.  
 
Our study further substantiates the importance of asking women about sexual problems 
when they present with urinary incontinence as it is a very common symptom, but 
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unless asked women will not volunteer this information[11]. Our study also dispels the 
belief traditionally held in relation to coital incontinence and found that urodynamic 
diagnosis is not linked to underlying sexual problems, orgasm or penetration 
incontinence.  
 
The exact mechanism of coital incontinence remains unclear. It has been hypothesised 
that the absence of smooth muscle sphincter seen in men and known to prevent reflux 
ejaculation predisposes women to coital incontinence if they suffer from urinary 
incontinence. The mechanism of coital leakage in women with normal urodynamics is 
poorly understood however in view of the limitations of the test it is likely that women 
[12] with normal investigations had a mild underlying urodynamic diagnosis rather than 
a negative one.  
 
The prevalence of coital incontinence in women without urinary incontinence has been 
poorly studied and further research into this area may shed more light on the exact 
pathophysiology of this condition and its treatment. Another area of considerable 
controversy is the impact of treatment of urinary incontinence on coital incontinence 
and this also requires further research.   
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Table 1 Incidence of UDS Dx in study population (Total 350)  
 
Urodynamic Diagnosis N        (%)                   
Urodynamic stress 
incontinence 
201    (58) 
Detrusor overactivity  67     (19) 
Mixed incontinence  51     (14) 
Normal  31      (9) 
 
 
Table 2: Comparison of different parameters of sexual function with different 
Urodynamic Diagnosis. (Kruskal-Wallis test) 
 
 USI/DOA/Mixed (Significance) 
Overall impact .575 
Incontinence with sex .698 
Orgasm incontinence .718 
Penetration incontinence .406 
Patient avoids intercourse .084 
Partner avoids intercourse .125 
Anxiety .871 
Postcoital infections .802 
 
USI= urodynamic stress incontinence; DOA= detrusor overactivity 
 
 
Table 3 Underlying urodynamic diagnosis in women with specific symptoms 
 
Urodynamic 
Dx 
Penetration 147 
(% ) 
Orgasm 153 (%) No leakage 139 
(%) 
Leakage with 
intercourse 
211 (%) 
USI 85 (58%) 89 (58%) 73 (53%) 128 (61%) 
DOA 28 (19%) 28 (18%) 31 (22%) 36  (17%) 
Mixed 27 (18%) 25 (16%) 16 (11%) 35  (16%) 
Normal 7 (5%) 11 (8%) 19 (14%) 12  (6%) 
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Figure 1: Summary of e-PAQ response  
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7.5 Paper 5.  Impact of Incontinence surgery on Sexual Function: 
a Systematic Review and meta-analysis 
 
Swati Jha, Mostafa Metwally, Manjunath Ammembal 
 
Abstract  
Introduction: Urinary incontinence has an adverse impact on sexual function. The 
reports on sexual function following the treatment of urinary incontinence are 
confusing.  
Aims: To investigate the impact of surgery for stress incontinence on coital incontinence 
and overall sexual function.  
Outcome Measures: Changes in sexual function and coital incontinence following 
surgery for urinary incontinence.  
Methods: Cochrane Incontinence Group Specialized Register of Controlled Trials, The 
Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE were searched 
for trials of incontinence surgery assessing sexual function and coital incontinence 
before and after surgery. 
Observational studies and randomised controlled trials investigating the impact of 
surgical correction of stress urinary incontinence on sexual function were included. 
Surgical interventions included TVT, TVT-O, TOT, Burch and AFS. Studies which included 
patients undergoing concurrent prolapse surgery were excluded from the analysis.  
Data extraction and analysis was performed independently by two authors. Coital 
incontinence was analysed separately and OR with 95% CI calculated. The data were 
analysed in Review Manager 5 software.  
Results: 
21 articles were identified which assessed sexual function and/or coital incontinence 
following continence surgery in the absence of prolapse. Results suggest evidence for a 
significant reduction in coital incontinence post surgery (OR 0.11; 95% CI 0.07, 0.17).  
Conclusions 
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Coital incontinence is significantly reduced following continence surgery. There were 
several methodological problems with the quality of the primary research particularly 
related to heterogeneity of studies, use of different outcome measures and the absence 
of well-designed randomised controlled trials. 
 
Introduction  
 
It is now widely accepted that Urinary incontinence has an adverse impact on sexual 
function resulting in coital incontinence (1-4) and a variety of other symptoms with a 
negative impact on all domains of sexual function(5;6). In this population of women, the 
symptoms per se, along with fear of odour, embarrassment, shame, loss of self-esteem 
and fear of, or actual occurrence of, incontinence are contributory factors. Studies have 
found that women with Urinary incontinence report less frequent sexual activity (5;7) 
and this may restrict sexual activity for fear of incontinence. Amongst the most common 
sexual complaints in women with urinary incontinence are low desire, vaginal dryness, 
and dyspareunia (8). These are similar to the problems seen in women with sexual 
dysfunction in the absence of urinary incontinence.  
 
The reports on response of sexual function following the treatment of urinary 
incontinence are confusing. Some studies suggest deterioration (9-12) of sexual 
function, some an improvement (3;13-16) whereas others are equivocal(17-20).  
 
The aim of this review was to assess the impact of surgery for stress incontinence on 
coital incontinence and overall sexual function. Women undergoing surgery for stress 
incontinence may be bothered by the impact it has on different aspects of their life. 
Sexual function is an important aspect of well-being and some women undergoing 
surgery for stress incontinence do so in the hope it will improve their sexual function. 
These may be unrealistic expectations. The current evidence is confusing and does not 
guide clinicians on the advice they should be giving women prior to incontinence 
surgery to predict future outcome with regard to sexual function. This study will assist in 
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counselling women about more realistic expectations of changes in sexual function 
following surgery. It also provides information on the aspects of sexual function that is 
likely to be altered by surgery as well as those that will probably remain unchanged.  
 
Methods 
 
The methods followed the guidelines issued by the Meta-analysis of Observational 
Studies in Epidemiology (MOOSE)(21).  
  
Inclusion and Exclusion Criteria 
 
Sexually active women with stress incontinence either in isolation or in combination 
with detrusor overactivity (mixed incontinence) proven on Urodynamic studies and 
undergoing surgery for their stress incontinence were included. Studies where sexual 
function was assessed were included. Patients acted as their own controls. Articles 
which included patients with concurrent prolapse were excluded from the review.  
 
Search strategy 
 
A systematic computerized search was conducted on published literature from eight 
databases in May 2009. The databases searched (inclusive dates) were Medline (1950–
2009), Embase (1980–2009), Cochrane library (1991–2009), Science Citation Index 
(1900–2007), Social Science Citation Index (1900–2009), CINAHL (1982–2009) and 
Medline In-Process and Other Non-Indexed Citations. 
 
No date or language restrictions were used. The search strategy used combinations of 
search terms related to sexual function, interventions for incontinence and outcomes 
for sexual function. Search terms used related to sexual function were ‘sexual function’ 
and ‘coital incontinence’. Terms relating to the intervention were ‘TVT’, ‘TVT-O’, 
‘Colposuspension’ and ‘Autologous fascial sling’. Terms related to outcome measures 
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were ‘change’, ‘improvement’ and ‘deterioration’.  The following databases were 
searched: Cochrane Incontinence Group Specialized Register of Controlled Trials, The 
Cochrane Central Register of Controlled Trials, MEDLINE, and EMBASE for trials of 
incontinence surgery assessing sexual function and coital incontinence before and after 
surgery. The search was conducted by the ScHARR.  
 
Assessment of methodological quality 
 
Studies were predominantly cohort studies. Two randomised controlled trials were 
identified which analysed sexual function in different continence procedures. The RCTs 
however used change in SUI as the primary outcome measure rather than sexual 
function, hence these studies were analysed for the purposes of this systematic review 
based on the individual procedures performed and outcome with regards to sexual 
function. We carried out crude event rate analysis of the RCTs by treating each arm as a 
case series.    
  
Interventions 
 
The type of interventions included commonly performed procedures for Urodynamic 
stress incontinence ie Tension free vaginal tape (TVT), transobturator tape (TOT), 
colposuspension and autologous fascial sling as these are approved as being evidence 
based in their efficacy. Studies looking at procedure no longer in use and not proven to 
be beneficial were excluded ie bulking agents and minitapes were not included in the 
analysis.   
 
Outcomes 
 
The studies varied significantly in the reporting of sexual function. Whereas some 
studies used a Sexual function questionnaire some reported on the change in overall 
status as a binary outcome ie better, worse or no change and other studies reported on 
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specific symptoms of sexual function. Questionnaires used included the PISQ 31 and 12 
(Prolapse and Incontinence Sexual Function Questionnaire), FSFI (Female Sexual 
Function Index), Lemack, BFLUTS (Bristol Female Lower Urinary Tract Symptoms 
questionnaire) and the ePAQ (electronic - Pelvic floor assessment Questionnaire). To 
combine the results from the different studies it was agreed that using a binary 
outcome ie improvement, no change and deterioration was appropriate as this data 
could be extracted from all studies including those that used both validated and non 
validated questionnaires for assessment of sexual function.  
 
Some studies did not report on the impact of incontinence on sexual function 
preoperatively. Studies which reported on pre and postoperative data formed part of 
the meta analysis.  
 
Data Extraction and analysis 
 
Two authors (SJ and KA) independently screened the titles and abstracts of the papers 
resulting from the initial search to determine if they met the inclusion and exclusion 
criteria. Where there was doubt the full paper was reviewed. The methodological 
quality of each study was assessed using the Newcastle-Ottawa scale. All relevant raw 
data were extracted from each eligible study by both the reviewers independently and 
disagreements were resolved through verification and discussion as well as by review by 
the third author (MM). Where necessary, we contacted the researchers to obtain 
additional information about study methods or outcome measures.  
 
Data were analysed using Review Manager (RevMan) 5.0 (the Cochrane Collaboration, 
2008; The Nordic Cochrane Centre, Copenhagen, Denmark) Coital incontinence as a 
specific outcome was analysed separately by generating two-by-two tables and 
expressed as odds ratios (OR) with 95% confidence intervals (CI) by comparing pre and 
postoperative results using the patients as their own controls.. Overall probability of 
improvement, no change and deterioration was calculated for all procedure and for 
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midurethral tapes. For continuous outcomes ie where a questionnaire was used for 
assessment of sexual function a standardised mean difference was used. TVT and TVT-
O/TOT were compared as they are the most commonly performed continence 
procedures and a meta-analysis conducted. Statistical heterogeneity was measured 
using the the chi squared and I2 statistics. A chi squared statistic larger than its degree of 
freedom, and an I2 statistic > 50% indicated the presence of significant heterogeneity in 
which case a random effects model for data analysis was used  
 
Results  
 
One hundred and sixty two publications evaluating the effect of continence surgery on 
sexual function were identified. Discussion with experts and a hand search of the 
references of the primary articles or specialist reviews/publications failed to retrieve any 
further studies. No relevant systematic reviews were identified.  
 
These 162 references were reviewed for inclusion and exclusion criteria. Figure 1 
summarises the process of literature identification as well as inclusion and exclusion. 
None of the articles in foreign languages (4) were suitable for inclusion as they were 
either review articles, abstract with insufficient information, commentaries. 46 articles 
were initially identified as being potentially suitable for the inclusion. Of these 3 were 
review articles, 7 included patients with prolapse or other procedures, 10 were 
abstracts or had insufficient data and 5 studies were repeat data from studies included 
in the review.  
 
21 articles were identified which assessed sexual function and/or coital incontinence 
following continence surgery in the absence of prolapse and formed the basis of this 
systematic review. These studies looked at several different interventions including TVT 
TOT and TVTO, Burch and autologous fascial sling. Table 1 shows the characteristics of 
the studies included in the review.  
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Overall Sexual function following Continence surgery 
 
18 studies which anlaysed 1578 women, assessed improvement, no change and 
deterioration in sexual function (Table 2). The combined analysis of all studies showed 
that in just over half of all women there was no change of overall sexual symptoms after 
surgery (55.5%). Combined the analysis of all studies also suggested significant albeit 
small odds of improvement of sexual problems (31.9%). The odds of improvement were 
at least twice as likely as the odds of deterioration (13.1%).  
 
16 studies (1252 women) out of the 21 looked at changes following midurethral tapes 
either alone or in comparison with other procedures. Data was extracted for 
midurethral tapes and overall improvement, no change and deterioration estimated. 
The interventions included ie TVT, TOT and/or TVTO. With Midurethral tapes the 
probability of no change was 56.7%. There was a 33.9 % chance of improvement and 
9.4% of deterioration. The chances of improvement were 3 times as likely as the 
chances of deterioration 
 
7 studies used a questionnaire for symptom assessment pre and postoperatively. By 
comparing the pre and postoperative scores for sexual function of all procedures pooled 
together there was no significant improvement of sexual function following surgery and 
the standardized mean difference was 0.62, 95% CI 0.00 ,1.24. The results are shown in 
Figure 2. Cayan et al (22) reported on 2 different procedures hence outcomes for the 2 
procedures are shown as 2 separate entries.  
 
For midurethral tapes alone there was a no significant improvement of sexual function 
with a standardized mean difference of 0.95, 95% CI 0.34, 1.56.  
 
Comparison of TVT vs TOT/TVTO 
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4 studies compared TVT (246 women) and TOT/TVT-O (290 women). These were all 
cohort studies with considerable heterogeneity of studies. The odds of improvement 
were similar for both procedures (OR 0.97; 95% CI 0.63, 1.49) (Figure 3). 
 
Coital incontinence following continence surgery 
 
11 out of 21 studies which analysed 1271 women assessed coital incontinence before 
and after surgery. The results suggest evidence for significant reduction in coital 
incontinence post surgery (OR 0.12; 95% CI 0.08, 0.17) ( Figure 4). When assessing the 
reduction in coital incontinence following midurethral tapes alone the results were 
similar (OR 0.13; 95% CI 0.09, 0.17).  
 
Discussion and Conclusion 
 
Coital incontinence is significantly reduced following continence surgery (OR 0.11; 95% 
CI 0.07, 0.17).The current evidence for stress incontinence surgery and its impact of 
sexual function is limited. Despite the fact that the pooled results suggest  a 2 to 3 times 
greater likelihood of improvement compared to deterioration in sexual function, at least 
half of all women undergoing surgery for stress incontinence are likely to experience no 
change in sexual function. There is no difference is sexual function following the two 
most commonly performed procedures for SUI ie the TVT and TOT/TVT-O (OR 0.97; 95% 
CI 0.63, 1.49).  
 
We need to be cautious when interpreting these results as there were several 
methodological problems with the quality of the primary research particularly related to 
heterogeneity of studies, use of different outcome measures and the absence of well 
designed randomised controlled trials. The heterogeneity of the studies was related to 
the variations in age as well as the inclusion and exclusion criteria and the previous 
surgical history of the participants. The variations in age alone is likely to have a 
considerable impact(13) and is associated with a reduced inclination to respond to the 
P a g e  136 | 187 
 
 
 
 
sexual function questions than younger women. In addition increasing age is also known 
to be an independent risk factor for worsening sexual function(35). None of the studies 
comment on the impact of complications of surgery may have had on sexual function ie 
tape erosion, bladder injury, denovo detrusor overactivity or failure of the procedure.   
 
One of the biggest problems with the primary studies that formed the basis of the 
review is that the cohort studies have looked at an intervention for a problem (ie stress 
incontinence) and the outcome of interest (sexual function/coital incontinence) is 
separate to what the intervention is used for. This makes it difficult to establish the 
association between the outcome and the primary pathology in the individual series. 
Though two RCTs (31;32) were included in the review they were designed to assess 
primarily SUI following surgery as opposed to sexual function. As with the other studies 
they did not assess what proportion of the sexual dysfunction was associated with 
urinary incontinence, hence it is difficult to confirm that the response to surgery was a 
result of curing of the SUI. Only one study established the sexual dysfunction related to 
urinary incontinence and the subsequent response (3). However this study used a 
questionnaire (ePAQ(36)) which though validated for urinary incontinence is not 
currently validated for sexual dysfunction in women with pelvic floor problems.  
 
The analysis of sexual function in the different studies was done by different methods. 
Some assessed improvement, no change and deterioration however most studies do not 
clarify which aspects contributed to this difference. Very few studies correlated the 
failure of the procedure to deterioration in sexual function however in those that did, 
the more successful the surgery the greater the improvement in sexual function. This 
suggests deterioration in sexual function could be related to a failure of the procedure 
to treat the actual incontinence. However this does not explain the ‘no change’ 
following surgery. This is possibly because other factors contribute to ‘worsening’ or ‘no 
change’ in sexual function even with improvement in SUI such as an alteration of vaginal 
anatomy by manipulation of vaginal mucosa, narrowing and elevation of the vaginal 
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walls, dyspareunia, lack of libido, reduced sensation, anorgasmia, high post void 
residuals and de novo urgency post surgery. 
 
In addition for those studies where a questionnaires was used this was variable and 
most were not validated for use in pelvic floor dysfunction. The International 
Continence Society (ICS) in its 3rd Consultation on Incontinence (37) created a grading 
system of patient reported outcome measures for urinary and faecal incontinence and 
pelvic organ prolapse. The ICS graded commonly used questionnaires into grade A 
(highly recommended), Grade B (recommended) and grade C (with potential). 
Interestingly the Golombok Rust Inventory of Sexual Satisfaction (GRISS), the only grade 
A questionnaire was not used in any of the studies included in the review. A Few studies 
used a Grade B Questionnaire such as PISQ which is a validated condition specific 
questionnaire (13;14;31). However others used a grade C (FSFI, BFLUTS) or other 
questionnaire. Aside from the PISQ, questionnaires are not designed to assess changes 
in sexual health specifically caused by pelvic floor dysfunction. The use of non validated 
tools for assessment of sexual function may not reliably describe the changes in sexual 
function after continence surgery including midurethral tapes. None of the studies took 
into account the DSM classification of sexual dysfunction when assessing the impact of 
SUI or its treatment.  
 
The studies by Abdel Fatah(31), Pace(28) and El Enen(23) appear to show more 
significant improvement in sexual function compared to the other studies. However all 
three studies are well conducted, use a validated questionnaire for assessment of sexual 
function and have appropriate follow up of greater than 3 months. The study by Abdel 
Fatah is the largest single series and follow up was appropriate at 12 months. The 
average age of participants was 51.8. Pace et al also had a relatively large series of 101 
patients but follow up was at 3 months and the mean age of participants was higher at 
57. In the study by El Enen mean age of participants was younger (40.5 years) and follow 
up was at 12 months.   
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For conducting the meta-analysis of coital incontinence and change in overall sexual 
function, as there were no controls hence the patients’ preoperative results were used 
as controls for the postoperative outcomes. This is not an ideal situation and it is not 
therefore possible to obtain information on individual patients, but provides 
information for the group as a whole.  
 
When counselling women undergoing surgery for stress incontinence and concurrent 
sexual dysfunction they may be told that coital incontinence is likely to improve. Overall 
sexual function is likely to remain unchanged though there is a small possibility of 
improvement or even deterioration following surgery. The retropubic or obturator 
approach does not influence the impact on sexual function.  
 
Female sexuality is complex and multi factorial. To establish the accurate impact of 
surgery for stress incontinence it is important to establish the impact of SUI on sexual 
dysfunction in the individual studies and alterations following surgery by using 
questionnaires that assess both function and activity. Adequately powered Randomised 
controlled trials of interventions targeting sexual dysfunction and using validated 
questionnaires are needed to assess the clinical relevance of continence surgery in 
patients with urinary incontinence and associated sexual problems.  
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Figure 1 Flow chart of literature search and data extraction 
 
 
Total citations identified from initial search 
(n= 162) 
Citations excluded after removing 
duplicates and screening titles 
and/or abstracts (n= 112) 
Potential References reviewed for detailed 
evaluation (n = 46) 
 
Excluded studies (n = 25) 
Reason for exclusion 
Review =3 
Included prolapse/other procedures =7 
Insufficient data =10 
Repeat data=5 
 
Studies included in the Review (n =21) 
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Figure 2. Meta-analysis of impact of incontinence surgery on Sexual function 
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Figure 3. Comparison of TVT vs TOT/TVT-O for improvement 
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Figure 4. Meta-analysis of Impact of incontinence surgery on Coital Incontinence  
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Table 1. Characteristics of studies reviewed (n=21)  
 
 Study Characteristics Study 
design 
Interventi
on 
Sampl
e size 
Outcome  Follow up 
(mean) 
1 El Enen 
et al 
2009(23
) 
Inclusion: SUI, 
neurologically intact, 
no other surgical 
diseases 
Exclusion: UI 
Age mean : 40.5 
Parity:2.1 
Operative 
success:84% 
Prospective 
Cohort 
TOT 62 FSFI 
Improvement, no change 
deterioration in sexual  
function 
12 months 
2 Sentilhe
s et al  
2008(24
) 
Inclusion: USI  
Exclusion-prolpase, 
mixed incontinence  
Age Mean-TVT 54.4; 
TOT 54.3. 
Parity:2 
Operative success-not 
stated 
Retrospecti
ve cohort 
TVT (81)  
TOT (64) 
145 Lemack Q 
Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
42 months 
3 Jha et al 
2009(3) 
Inclusion: USI, Mixed 
incontinence 
Exclusion-prolapse  
Age Range-49.1 
Operative success:not 
stated 
Prospective 
cohort 
TVT 62 ePAQ 
Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
3 months 
4 Moran 
et al 
1999(25
) 
 
Inclusion: USI 
Exclusion: not 
specified Age Range-
46.1 
Parity:2 
Operative 
success:84% 
Prospective 
cohort 
Burch 52 Coital incontinence 18 months 
5 Murphy 
et al 
2008(26
) 
Inclusion: USI 
Exclusion:prolapse, 
concomitant surgery 
Age Range-54.8 
Parity:2.2 
Operative 
success:82.1 
Retrospecti
ve 
cohort 
TVT(36) 
TVTO 
(103) 
139 Improvement, no 
change, deterioration in 
sexual function 
 
14.7 
months 
6 Elzevier 
et al  
Inclusion: SUI 
Exclusion: prolapse  
Age Mean-TOT 52 
Prospective 
Cohort 
TOT (44)  
TVTO (34) 
78 Lemack Q 3 months 
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2008(27
) 
TVTO 52 
Operative success:not 
stated 
Improvement, no 
change, deterioration in 
sexual function 
Coital incontinence 
7 Pace et 
al  
2008(28
) 
Inclusion: USI 
Exclusion: prolapse, 
Urge incontinence  
Age Range-TVT-55 
TOT 59 
Parity: 2 
Operative 
success:97.1% 
Prospective 
Cohort 
TVT (35) 
TOT (66) 
101 FSFI 
Improvement, no change 
deterioration in sexual 
function 
 
3 months 
8 Cayan et 
al  
2007(22
) 
Inclusion: SUI 
Exclusion: prolapse  
Age Mean-48.1 sling 
48.3 burch 
Parity: 3 
Operative 
success:Sling 84.9% 
Burch 69.3% 
Prospective Sling (53) 
Burch (41) 
94 FSFI 
Improvement, no change 
deterioration in sexual 
function 
 
 
6 months 
9 Jha et al 
2007(13
) 
Inclusion:USI 
Exclusion: prolapse, 
DOA Age Range-54.2 
Parity :3 
Operative 
success:97% 
Prospective 
Cohort 
TVT/TVT-
O 
54 PISQ 31 
Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
 
6 months 
1
0 
Ghezzi 
et al 
2005(14
) 
Inclusion: USI 
Exclusion: prolapse, 
DOA 
Age Range-51 
Parity : 2 
Operative 
success:98% 
Prospective 
Cohort 
TVT 53 PISQ 12 
Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
 
6 months 
1
1 
Elzevier 
et al 
2004(15
) 
Inclusion: USI 
Exclusion: prolapse, 
DOA Age Range-50.5 
Operative success: 
Not stated 
Retrospecti
ve 
TVT 65 Lemack 
Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
 
3 months 
1
2 
Yeni et 
al 
2003(12
) 
Inclusion: SUI 
Exclusion: Prolapse 
surgery 
Age Range-38.34 
Operative 
success:90.6% 
Prospective TVT 32 FSFI 
Coital incontinence 
 
6 months 
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1
3 
Glavind 
et al  
2004(17
) 
Inclusion: SUI 
Exclusion: Not stated  
Age Range-Not stated 
Operative 
success:92% 
Retrospecti
ve Cohort 
TVT 
IVS 
48 Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
 
3 months 
1
4 
Mazouni 
et al 
2004(10
) 
Inclusion: SUI 
Exclusion: Not stated  
Age Range-57.8 
Operative 
success:87.2% 
 
Prospective 
cohort 
TVT 55 Improvement, no change 
deterioration in sexual 
function 
 
> 6 weeks 
1
5 
Maaita 
et al 
2002(18
) 
Inclusion:USI 
Exclusion: prolpase  
Age Range-52.6 
Operative 
success:93.5% 
 
Prospective TVT 43 Improvement, no change 
deterioration in sexual 
function 
 
6 months 
1
6 
Byung et 
al 
2009(29
) 
 
Inclusion: USI 
Exclusion: DOA, 
Prolapse Age : 52.4 
Parity : 2.5 
Operative 
success:82.8% 
 
Retrospecti
ve 
TVT (94) 
TOT (57) 
151 Improvement, no change 
deterioration in sexual 
function 
Coital incontinence 
 
>8 weeks 
1
7 
Hasse et 
al 
1988(30
) 
Inclusion:USI 
Exclusion: 
concomitant surgery  
Age Range-49 
Operative 
success:87.7% 
 
Prospective Burch 14 Improvement, no change 
deterioration in sexual 
function 
 
6 months 
1
8 
Abdel 
Fatah 
2010(31
) 
Inclusion:USI 
Exclsusion: Prolapse, 
comorbidities  
Age Range: 51.8 
Operative 
success:91% 
 
RCT TOT 
TVT-O 
199 PISQ 12 
Improvement, no change 
deterioration in sexual 
function 
 
12 months 
1
9 
Ward et 
al 
2008(32
) 
 
Inclusion: USI 
Exclusion: DOA, 
prolapse , previous 
surgery for prolapse 
or incontinence, 
voiding dysfunction 
Age Range-50 
RCT TVT (98) 
Colposusp
ension 
(79) 
177 BFLUTS 
Improvement in sexual 
function 
Coital incontinence 
 
 
60 months 
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Parity:2 
Operative success: 
TVT 75% 
Colposuspension 69% 
 
2
0 
Yoon 
Kim et al 
2008(33
) 
Inclusion: SUI,  
Exclusion: Prolapse  
Age mean : 44.9 
Parity:2.8 
Operative 
success:91.4% 
 
Prospective 
cohort 
TVT/TOT/
Monarc 
/SPARC 
32 FSFI 6 months 
2
1 
Marszal
ek et al  
2007(34
) 
Inclusion: SUI,  
Exclusion: not stated  
Age mean : 59.9 
Parity:2.1 
Operative 
success:82.7% 
 
Prospective 
cohort 
TVT 52 Improvement, no change 
deterioration in sexual 
function 
 
18 months 
SUI: Stress urinary incontinence; USI: urodynamic stress incontinence; DOA: detrusor 
overactivity; OAB: overactive bladder; FSFI: Female Sexual Function Index; PISQ 12: 
Prolpase and Incontinence Sexual Function Questionnaire (short form) ; PISQ 31: 
Prolpase and Incontinence Sexual Function Questionnaire; ePAQ: electronic pelvic floor 
assessment Questionnaire; BFLUTS: Bristol  
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Table 2. Change in sexual function following all Incontinence surgery 
 
S 
No 
Study Procedure 
(Total 
cases) 
Improvement  % 
(n)  
No 
change % 
(n) 
Deterioration % 
(n) 
1 El Enen et al TOT (62) 11 (7) 86 (53)  3 (2) 
2 Sentilhes et al  TVT/TOT 
(145) 
31.2 (45) 53.9 (78) 14.9 (22) 
3 Jha et al 2009 TVT (62) 50 (31) 42 (26)  8 (5) 
4 Murphy et al  
                      
TVT (36) 
TVT-O 
(103) 
38.9 (14) 
37.1 (38) 
52.8 (19) 
61 (63) 
 8.3 (3) 
 1.9 (2) 
5 Elzevier et al 
2008  
                                
TOT  (44) 
TVT-O 
(34) 
18.2 (8) 
20.6 (7) 
68.2 (30) 
73.5 (25) 
13.6 (6) 
  5.9 (2) 
6 Pace et al  TVT/TOT 
(101) 
90.1 (91) -- 9.9 (10) 
7 Cayan et al   Sling (53)                
Burch (41) 
24.5 (13) 
12.2 (5) 
28.3 (15) 
24.4 (10) 
47.2 (25) 
63.4 (26) 
8 Jha et al 2007 TVT/TVT-
O (54) 
37 (20) 53.7 (29) 9.3 (5) 
9 Ghezzi et al TVT (53) 34 (18) 62.2 (33) 3.8 (2) 
10 Elzevier et al 
2004 
TVT (65) 26.1 (17) 72.3 (47) 1.6 (1) 
11 Glavind et al  TVT/IVS 
(48) 
25 (12) 60.4 (29) 6.6 (7) 
12 Mazouni et al TVT (55) 1.8 (1) 74.4 (41) 23.8 (13) 
13 Maaita et al TVT (43) 5 (6)  71 (31) 14 (6) 
14 Byung et al  TVT (94)                 
TOT (57) 
21.3 (20)    
15.8 (9) 
64.9 (61) 
66.7 (38) 
13.8 (13) 
17.5 (10) 
15 Hasse et al Burch (14) 7 (1) 93 (13) -- 
16 Abdel Fatah et al   TOT/ TVT-
O (199) 
94 (188) 1.4 (3) 4.3 (8) 
17 Ward et al   Burch  
(79)              
TVT (98) 
47 (37) 
54 (53) 
-- 
-- 
-- 
-- 
18 Marszalek et al TVT (52)  33.3 (17) 52.4 (28) 14.3 (7) 
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7.6 Paper 6 Impact of treatment of Overactive Bladder with 
anticholinergics on Sexual Function. 
Swati Jha 
 
Abstract: 
Purpose 
To establish if an improvement in OAB symptoms by treatment with anticholinergics is 
associated with a corresponding improvement in sexual function. 
Methods 
This was a prospective observational Questionnaire study using ePAQ – PF (electronic 
Pelvic assessment questionnaire- pelvic floor), PISQ 12 and PGI-I for Overactive bladder 
and Sexual function. Sexually active women with overactive bladder were included in 
the study.  Prolapse and voiding dysfunction were exclusion criteria for the study. All 
women were followed up for 6 months and were treatment naïve. Sexual function 
before and after treatment was compared.  The data were analysed using SPSS.  
Formal ethical approval was obtained.  
Results 
34 women were included in the study. Only 8% of women commenced on 
anticholinergics had an improvement in sexual function, compared to 66% who 
experienced an improvement in OAB symptoms.  Women who did experience a benefit 
in sexual function did so in the first 3 months of treatment of their overactive bladder 
and always noted an improvement in OAB symptoms.  
Conclusions 
Treatment of the overactive bladder symptoms does not guarantee improvement in 
sexual function. 
 
Introduction  
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Overactive bladder (OAB) has a prevalence of 20 % in the general population and an 
increasing prevalence with advancing age. It significantly affects health-related quality 
of life and daily functioning. OAB with or without incontinence negatively affects 
women's sexual health, reducing sexual desire and ability to achieve orgasm [1] and 
several studies have shown an adverse effect on sexual function[2-7]. However there is 
limited knowledge about the impact of treatment of overactive bladder on sexual 
function. Given the profound effect of OAB on sexual health, this should be routinely 
assessed by clinicians treating this condition, and addressed by researchers.  
This study aims to identify if treatment with anticholinergics and a corresponding  
improvement in OAB symptoms is associated with an alteration in sexual function, and if 
so what aspects of sexual function are changed/improved.  
Methods 
 
This study had formal ethical approval by the Yorkshire and Humber Research and Ethic 
committee and was registered with the host institution (Sheffield Teaching hospitals) 
Research and development department (STH 15315). The study was funded by a joint 
grant from BAUS and BSUG which was sponsored by Pfizer.   
 
This was a prospective observational Questionnaire study. This research followed a 
quantitative methodology. Women were recruited to the study for 24 month. They were 
then followed up for 6 months. The total duration of the study was 30 months.   
Power calculations were done and assuming 20% improvement in PISQ scores to be 
clinically significant, would require 74 responders (assuming a 20% drop out rate) on any 
one anticholinergic followed up for a one year period. Given there were approximately 
10 different anticholinergics in use this would need a multicenter study to prove 
effectiveness of individual anticholinergics. This was therefore a pilot feasibility study.   
Women were recruited from the Urogynaecology unit at a tertiary teaching hospital. 
Potential recruits for this study were identified by the author by review of referral letters 
to secondary care received from GPs or other clinicians prior to attendance. When 
patients attended, they were asked to complete a pelvic floor assessment questionnaire 
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to assess the severity of symptoms as part of routine clinical care. This was undertaken 
using the electronic pelvic floor assessment questionnaire (ePAQ)[8], which enables a 
comprehensive assessment of the pelvic floor.  
 
The ePAQ-PF is an electronic Pelvic Floor Assessment Questionnaire which has been 
specifically designed to assess patients with pelvic floor problems. It is an interactive, 
web-based health related quality of life questionnaire that measures urinary, bowel, 
vaginal and sexual symptoms and their related impact. It has been validated as a patient 
related outcome measure (PROM) having undergone extensive psychometric testing in 
both primary and secondary care settings. 10 specialist urogynaecology departments 
throughout the UK have adopted the questionnaire for routine use in clinical 
assessment and follow-up. The questionnaire has an interactive element which hides 
irrelevant questions (e.g. level of impact) if the symptom is not reported, reducing 
burden to the responder. Accidental non-response is avoided as an answer is required 
before progressing to the next question and there is the option of skipping questions if 
subjects would rather not answer. This assesses pelvic floor function in 4 dimensions: 
Urinary, Bowel, Vaginal & Sexual and subdivided into 19 psychometrically robust & 
clinically meaningful domains scores, each score being transformed on a range from 0 
(indicating best health status) to 100 (worst health status). The domain score is 
calculated using the simple formula: Domain Score = total of raw scores for each item in 
the domain / maximum possible score × 100. The Urinary dimension include overactive 
bladder as one of its domains. 
 
The sexual dimension provides 3 domain scores for the different aspects of pelvic floor 
symptomatology that may impact on sexual function: (1) Urinary, (2) Bowel & (3) 
Vaginal. The 2 final sexual domain scores are (4) Dyspareunia and (5) General sex life. 
The score for the urinary domain of the sexual dimension is derived from 4 items shown 
below. Each item is scored on an ordinal scale from 0-3, where 0 represents ‘Never’ and 
3 represent ‘All of the time’. These 4 items included;  
(1) Overall impact of bladder problems on sex life 
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(2) Anxiety related to bladder problems during sex 
(3) Avoidance of sex by the patient because of their bladder problems 
(4) Partners avoiding sex because of the patient's bladder problems 
Items not contributing to this score but analysed by the ePAQ also include orgasm 
incontinence, penetration incontinence & post-coital UTI.  
Patients were identified as being suitable for the study if they scored over 33% bother 
on the OAB domain of the urinary Dimension and the Urinary domain of the Sexual 
function Dimension.  
Sexually active women diagnosed to have OAB on the ePAQ (electronic Pelvic Floor 
Assessment Questionnaire) and commencing anticholinergics for the first time were 
invited to participate in the study. These women were asymptomatic for prolapse. A 
POP-Q assessment was performed and Aa, Ba, Ap and Bp was above -1 (i.e no anterior 
or posterior wall prolapse) with no utero-cervical descent for all potential recruits. A 
confirmed urodynamic diagnosis of detrusor overactivity (DOA) was not a criteria for 
referral and recruitment was based on symptomatology. Voiding dysfunction (post-void 
residual of >20% of the voided volume) was ruled out in all recruited women. Pre-
treatment data collected included age, ethnicity, parity, BMI, menopausal status, 
hysterectomy status and previous vaginal operations performed.  
 
Data were collected on the status of bladder symptoms and sexual function before, 3 
months after and 6 months after treatment with anticholinergics. The anticholinergics 
were Tolterodine, Solifenacin, Oxybutynin and Kentera Patch.  
 
The PGI- I asks a patient to rate the response of her condition to therapy and is simple, 
direct, easy to use, and intuitively understandable to the clinician. They are single item 
questions which rate the outcome from ‘very much worse’ to ‘very much improved’ 
over a 5 point Likert scale. The construct validity of the PGI-I has been widely 
established for treatment response.  
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Sexual function was assessed using PISQ 12[9]. The PISQ 12 (The Pelvic Organ Prolapse 
Urinary Incontinence Sexual Questionnaire 12) is a condition-specific sexual function 
questionnaire for women with POP and/or UI that is shown to be valid and reliable. It 
consists of 12 questions and is reliable and responsive to change in sexually active 
women with POP and/or UI. In addition, the PISQ-12 is easy to understand and use, and 
is rapidly completed by the respondent. It has been used to assess the effect of non-
surgical therapy, as well as pelvic floor reconstructive surgery on sexual function in 
women with POP/UI. Of the twelve questions, nine are general sexual-function question 
and three directly pertain to women with UI/POP.  
 
The data were analysed using SPSS (IBM SPSS Statistics 20). The aim was to analyse and 
establish the impact of a 20 point improvement in OAB symptoms on bladder symptoms 
and correlate to changes in sexual function. Patient Global Impression of improvement 
(PGI-I) data were collected post treatment. Wilcoxan Signed rank test was used to 
compare pre and post treatment responses in PISQ. Linear regression was used to 
assess the relationship between the PISQ parameters analysed and changes in OAB 
scores following treatment. Significance was set at a p value of < 0.05. Chi square test 
was performed for Patient Global Impression of Improvement for OAB symptoms and 
Sexual function after treatment.  
 
Results  
 
In total 34 women were recruited of whom 24 completed the study to at least 6 months 
and their data was analysed. Table 1 shows the demographic data of the women recruited.  
The mean BMI of women recruited was 26.8 (SD 5.6) and mean age was (40.9) (SD 9.4)  
 
Wilcoxon signed rank test for PISQ at baseline and repeated at 3 months and 6 months 
showed no significant improvement in scores with a p value of 0.909 at 3 months and 
0.458 at 6 months. The data was also extracted by excluding women who were 
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menopausal (7/24) to see if this contributed to the impact on Sexual function. The 
results did not show any difference and changes in PISQ scores remained statistically 
insignificant pre and post treatment at 3 and 6 months.  
 
Linear Regressions failed to show any association of any of the PISQ domains to changes 
in OAB scores following treatment. 
 
Table 2 shows mean PISQ scores at baseline and at 3 and 6 months post 
commencement of treatment.  
 
PGI I for OAB showed that (16/24) women had an improvement in OAB symptoms on 
anticholinergics. This is similar to expected levels of improvement/cure on medical 
treatment for OAB. Of these women only 8% (2/24) experienced an improvement in 
sexual function. Women who experienced no improvement in their OAB symptoms 33% 
(8/24) did not experience any improvement in their sexual function. Using Chi square 
test improvement in OAB symptoms were not associated with a statistically significant 
improvement in sexual function (p=0.43).  
 
Discussion 
 
In women with OAB, treatment of the bladder symptoms does not guarantee 
improvement in sexual function. Only 8% of women commenced on anticholinergics have 
an improvement in sexual function, compared to 66% who will experience an 
improvement in OAB symptoms. Improvement in sexual function is only seen in women 
who have an improvement in OAB symptoms. Overall changes in the different aspect s of 
sexual function are not significant on anticholinergic treatment.  
 
The main strengths of the study are that demographic data was collected and patients 
were followed up for a sufficient duration ie 3 and 6 months to be able to see differences 
in sexual function. All patients were treatment naïve. Prolapse, which can impact on 
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sexual function independently was an exclusion criteria. We analysed women who were 
premenopausal separately as menopause can impact on sexual function as an 
independent variable.  The other strength of the study was that patient selection was 
based on identifying patients who had sexual dysfunction related to urinary incontinence.  
The main weakness of the study was sample size. This was related to identifying patients 
who fulfilled all the criteria. Most patients attending a tertiary urogynaecology clinic for 
OAB are not treatment naïve so had been tried on at least one and sometimes more 
anticholinergics. This precluded their recruitment to the study. We also found a 
significant proportion of women recruited did not experience an improvement in their 
OAB symptoms post-treatment. These patients acted as a control group.  
 
The other weakness of our study was that women were on a range of anticholinergics. It 
could be that these different agents impact on sexual function in different ways. Ideally 
the study would be performed with a single anticholinergic.  
 
There have been several studies published which have found improvement in sexual 
function scores by treatment with anticholinergics with corresponding improvement in 
OAB scores [5, 6, 10].  
 
In the study by Rogers et al [10], women with symptoms of OAB were recruited however 
they were not identified as having problems of sexual dysfunction prior to treatment. 
Analysis of patients was using health related Quality of life measure rather than a 
questionnaire specific for pelvic floor dysfunction.   
 
The study by Sand et al [6] assessed the effect of Transdermal oxybutynin on sexual 
function. Assessment of patients was using the King's Health Questionnaire and Beck 
Depression Inventory-II. They also found an improvement in different aspects of sexual 
function including coital incontinence and effect on relationship with partners.   
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Patel et al [5] similarly demonstrated an improvement in sexual function with 
improvement in OAB. This study too like the previous two failed to use a condition specific 
questionnaire like PISQ to assess changes in sexual function.  This study advances the 
understanding of sexual problems in women with OAB and opportunities for intervention 
with pharmacotherapy. This study allows us to give more realistic expectations to our 
patients when commencing treatment for OAB.  
 
This has been very poorly studied in the past and thus prevents us from providing 
reliable evidence based information to our patients when treating the condition. This 
study also advances the understanding of the effectiveness of pharmacotherapy in 
improving sexual quality of life and sexual function and highlights the complex 
mechanisms of sexual dysfunction. Bladder function may contribute to some extent to 
sexual function but overall impact on sexual function is multifactorial with emotional, 
psychological, partner related as well as physical factors all playing an important role. 
This study highlights this issue and it is likely this was why improvements in sexual 
function were not noted with improvements in bladder function alone.  
 
There are still many unanswered questions relating to OAB and sexual function. Though 
improvement in OAB is likely with anticholinergics, this does not guarantee resolution or 
improvement in sexual dysfunction. Larger, well conducted trials of women on 
anticholinergics with sexual dysfunction related to their urinary incontinence are 
required to better answer whether anticholinergics do actually positively affect sexual 
function.   
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Table 1: Demographic data of women recruited to the study( N=34) 
Demographic data N (%) 
Ethnicity C = 30 (88) 
As = 2 (6) 
BA =2 (6) 
Menopausal 7(20) 
HRT 5 (15) 
Hysterectomy 5(15) 
Previous vaginal Surgery 2 (6) 
 
C= White Caucasian; As= Asian; BA= Black Afrocarribean   
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Table 2 Baseline, 3 month and 6 month PISQ in all recruits and postmenopausal 
women  
 
 Baseline PISQ 3mth PISQ 6 mth PISQ 
All women 30.15 30.25 39.50 
Postmenopausal 
women  
30.50 35.00 36.00 
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7.7 Paper 7 Impact of Pelvic Floor Muscle Training on Sexual 
function of women with Urinary Incontinence and a comparison 
of electrical stimulation versus standard treatment (IPSU Trial): a 
randomised controlled trial 
 
Swati Jha, Stephen J Walters, Oscar Bortolami, Simon Dixon, 
Abualbishr Alshreef 
 
 
Abstract 
Aims  
To evaluate the clinical and cost-effectiveness of electric stimulation plus standard 
pelvic floor muscle training compared to standard pelvic floor muscle training alone in 
women with urinary incontinence and sexual dysfunction.  
Methods  
Single centre two arm parallel group randomised controlled trial conducted in a Teaching 
hospital in England. Participants were women presenting with urinary incontinence and 
sexual dysfunction. The interventions compared were electric stimulation versus 
standard pelvic floor muscle training. Outcome measures included Prolapse and 
Incontinence Sexual function Questionnaire (PISQ) physical function dimension at post-
treatment (primary); other dimensions of PISQ, SF-36; EQ-5D, EPAQ, resource use, 
adverse events and cost-effectiveness (secondary outcomes). 
Results  
114 women were randomised (Intervention n=57; Control group n=57).   64/114 (56%) 
participants had valid primary outcome data at follow-up (Intervention 30; Control 34). 
The mean PISQ-PF dimension scores at follow-up were 33.1 (SD 5.5) and 32.3 (SD 5.2) 
for the Intervention and Control groups respectively; with the Control group having a 
higher (better) score. After adjusting for baseline score, BMI, menopausal status, time 
from randomisation and baseline oxford scale score the mean difference was -1.0 (95% 
CI: -4.0 to 1.9; P=0.474).There was no differences between the groups in any of the 
secondary outcomes at follow-up. Within this study, the use of electrical stimulation 
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was cost-effective with very small incremental costs and quality adjusted life years 
(QALYs).   
Conclusions  
In women presenting with urinary incontinence in conjunction with sexual dysfunction, 
physiotherapy is beneficial to improve overall sexual function. However no specific form 
of physiotherapy is beneficial over another.  
 
Introduction  
 
Urinary incontinence (UI) is defined by the International Continence Society as the 
‘complaint of involuntary leakage of urine on effort or exertion, or on sneezing or 
coughing’ (1). It is usually caused by weakness or damage to muscles and connective 
tissues of the pelvic floor, compromising urethral support, or by weakness of the 
urethral sphincter itself. Epidemiological studies suggest that UI affects up to 41% of the 
female population (2). It is a health burden and impacts not only on social, 
psychological, occupational, domestic and physical health but also on sexual well-being. 
The proportion of women suffering from UI who have sexual dysfunction is significant 
(3) (4-7) and has been reported to range from 26% (3) to 83% (8). The taboo nature of 
sexual dysfunction means that symptom reporting has been infrequent and is often 
underreported. In addition, there is a lack of awareness of availability of treatment. 
Pelvic Floor Muscle Training (PFMT) is now accepted as the first line treatment for 
urinary incontinence (9) and the National Institute of Clinical Excellence (NICE) 
recommend that a trial of supervised PFMT of at least 3 months’ duration should be 
offered to all women with stress or mixed UI prior to any surgical intervention(10) 
.There is good evidence that daily pelvic floor muscle training continued for 3 months is 
safe and effective with an improvement in urinary incontinence expected in 40–60% of 
women (11). The aim of therapy is to improve the strength and efficacy of pelvic floor 
contraction. 
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The reports on the impact of PFMT on sexual function of women with UI is limited. The 
current available evidence suggests that supervised PFMT has a beneficial effect on 
overall sexual function. To date there has been no study assessing the impact of PFMT on 
sexual function of women with urinary incontinence using a validated condition specific 
questionnaire. In addition there have been no studies comparing the impact of electrical 
stimulation versus standard PFMT on sexual function of women with UI.  
This study aims to evaluate the clinical and cost-effectiveness of electric stimulation plus 
standard pelvic floor muscle training (the Intervention) compared to standard pelvic 
floor muscle training (usual care control treatment) in women with predominant stress 
urinary incontinence and sexual dysfunction. 
 
Methods  
 
Trial design 
 
Single centre two arm parallel group randomised controlled trial 
 
Setting 
 
Teaching hospital in England 
 
Participants 
 
Women referred to secondary care, within the hospital or community, with urinary 
incontinence who, following clinical assessment or urodynamic studies, are deemed to 
require PFMT. All women were reviewed and examined by a urogynaecologist (2 
clinicians recruiting to the study) to ensure they fulfilled the inclusion and exclusion 
criteria. Women were identified to have urinary incontinence on the basis of their 
presenting complaint and questionnaire completion.   
Women were eligible for inclusion in the trial if:  
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• Sexually active, over the age of 18yrs and with urinary incontinence attending for 
PFMT.   
• Women scoring greater than 25% on the urinary domain of the sexual function 
dimension, and/or greater than 33% for the degree of bother for the same symptom  
Women gave written (personally signed and dated) informed consent.  
• Were able to understand, and are willing to comply with the requirements of the 
protocol. 
The following exclusion criteria were applied:  
• Women with prolapse as their predominant problem. 
• Women who have had any previous incontinence surgery.  
• Women who have a Grade 3 or above muscle strength as measured using the 
modified Oxford Scale on vaginal examination. 
• Women with vaginal discharge or UTI. 
• Women fitted with an implanted pacemaker. 
• Women fitted with a copper coil IUD 
• Women who were pregnant. 
• Women with undiagnosed pelvic pain. 
• Women with a known sensitivity to the electrodes or the electrode gel. 
• Women with inflammation or infection of the vulva and vagina. 
• Women who had experienced recent haemorrhage or haematoma. 
• Women with Atrophic vaginitis. 
• Any other medical condition or abnormality (e.g. malignancy or complication) 
that in the opinion of the investigator would impact upon the safety or efficacy of the 
study treatment or any study assessments. 
• The patient was already enrolled in another interventional trial. 
• Non-English speaking women or with a specific language problem. 
Potential participants were identified by review of referral letters received from GPs or 
other clinicians. 
 
Interventions 
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PFMT (Pelvic Floor Muscle training) was the control and PFMT plus electrical stimulation 
was the intervention. The technique for PFMT was as recommended by NICE(12). This 
comprised at least 8 contractions performed three times a day. This was supervised by 
the Women’s Health Physiotherapy team and included 3 members. They were all 
trained in the provision of PFMT and were members of the Association of Chartered 
Physiotherapists in Women's Health (ACPWH).  
 
Outcomes 
 
Assessments were made at baseline (prior to commencing PFMT), and approximately 6 
months randomisation  The primary outcome was the self-reported Prolapse and 
Incontinence Sexual function Questionnaire (PISQ-31)(13) physical function dimension, at 
six months post-randomisation.  Secondary outcomes included the other dimensions of 
PISQ-31 (Behavioral Emotive dimension and Partner-Related dimension scores); SF-36 
domain scores(14); EQ-5D score(15); ePAQ(16) urinary & sexual domain scores, adverse 
events resource use, and cost-effectiveness  
 
The PISQ is a 31 item questionnaire with responses measured on a 5-point Likert scale. It 
evaluates sexual function of women with either urinary incontinence and/or pelvic organ 
prolapse. The PISQ identifies 3 separate and distinct domains of sexual function plus and 
overall total score. These include Behavioural Emotive (15 items), Physical (10 items) and 
Partner Related (6 items). Whereas the Behavioural Emotive domain evaluates sexual 
desire, frequency of sexual activity, and orgasmic capabilities, the Physical Domain 
assesses more directly the effect of urinary incontinence on sexual function. The partner 
Related Domain on the other hand assesses the patient’s perception of her partner’s 
response to the effect of her pelvic floor disorder on their sexual functioning, as well as 
her partner’s sexual functioning. Scores are calculated by totalling the scores for each 
question, from 0 (always) to 4 (never), with the exception of question 5, which is scaled 
from 0 (always) to 5(do not masturbate). Individual domain scores are calculated by 
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adding the scores for the individual items in each domain. The total PISQ-31 score ranges 
from 0 to 125; the physical domain scores range from 0 to 40; Behavioural emotive 0 to 
61; Partner related 0 to 24. Higher scores on all domains indicate better sexual 
functioning. 
 
The SF-36 is a generic health related quality of life, which is capable of producing eight 
domain scores including, social functioning, emotional role limitations, mental health and 
general health perceptions. Each domain is scored from zero to 100, with higher scores 
indicating better health. The SF-36 one of the most popular health related quality of life 
instruments in the world and has been shown to have good measurement properties 
across a wide range of conditions. 
 
The EQ-5D is a five–item generic health related quality of life instrument that produces a 
single preference weighted utility score ranging from -0.57 to 1.00 (good health). It is 
principally used to generate quality adjusted life years (QALYs) for use in economic 
evaluation and is recommended by the National Institute for Health and Clinical 
Excellence (NICE) for use in its technology appraisal programme. 
 
The e-PAQ is an interactive web-based computerised interview, designed to assess & 
analyse pelvic floor symptoms in women It comprehensively measures symptoms as well 
as their impact on quality of life. It immediately processes response data, providing an 
instantaneous measure of pelvic floor health that can be printed out & used during the 
clinical episode. The e-PAQ provides 34 domain scores in 4 dimensions: Urinary, Bowel, 
Vaginal & Sexual (all scored on a scale of 0 - 100). 
 
Sample size  
 
The primary outcome was the mean PISQ-31 physical dimension score at 6-months post 
randomisation. The 10 item physical dimension of the PISQ-31 is scored on a 0 to 40 scale 
with higher scores indicating better sexual functioning.  
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From a study of sexual function, in 54 women, following surgery for urodynamic stress 
incontinence (17), the mean PISQ-31 Physical score pre-operation was 31.0 (SD 6.2) and 
35.2 (SD 4.8) a mean improvement in sexual functioning of 4.2 points following surgery. 
Studies have shown a total change of 5.5 (5.3-5.8) points in the total score and 2 point 
difference in individual domains is a Minimally Important Difference for the PISQ score 
(18). On this basis assuming a three-point difference is of clinical and practical importance 
and a standard deviation of five-points then to have an 80% power of detecting a 3-point 
mean difference in PISQ-31 physical dimension scores at 6-month between the 
Intervention and standard control treatment group as statistically significant at the 5% 
(two-sided) level would require 45 patients per group (90 in total). If 20% of patients drop 
out and are lost to follow-up then the study will need to recruit and randomize 57 per 
group (114 in total).  
 
Randomisation  
 
Women scheduled to undergo PFMT (Pelvic Floor Muscle Training) for predominant stress 
incontinence were randomised to either 1) Standard PFMT or 2) PFMT plus Electrical 
Stimulation.  
Allocation was through block randomisation (with a variable block size an integer multiple 
of two) stratified by menopausal status (Pre or post-menopausal). The study statistician 
generated a randomisation schedule using the STATA software. Nottingham University 
Clinical Trials Research Unit CTRU) Set-up and hosted a web based randomisation system, 
for a two arm trial with 114 participants, stratified by menopausal status.  
 
The research administrator arranged for the patient information sheets and consent 
forms to be made available at each appropriate clinic where it was expected potential 
patients would be recruited.  
 
Blinding  
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In order for the physiotherapist to perform the study procedures, they were aware of 
which group the patient has been randomised to. The woman were not blinded to the 
treatment they received. The 2 Clinicians were also blinded to the treatment the patient 
was randomised to when they attended for a final visit.  
 
Statistical Methods  
 
The statistical analysis was performed on an intention-to-treat-basis. A P-value of less 
than 0.05 was regarded as being statistically significant. The primary outcome mean 
post-randomisation PISQ-31 physical function score was compared between the 
Intervention and Control groups using a two independent samples t-test (unadjusted 
analysis) and a multiple linear regression analysis, adjusting for baseline score, BMI, 
menopausal status, time from randomisation and baseline Oxford Scale score.  A 95% 
confidence interval for the treatment effect was also reported. Secondary outcomes 
(other dimensions of the PISQ-31, SF-36, EQ-5D and EPAQ) were analysed in a similar 
way to the primary outcome. 
The mean change in the PISQ scores was calculated using a paired t test.  
Multiple imputation was used to impute missing data on the primary outcome. Data was 
imputed using chained equations, (regression) with 20 imputations using baseline, follow-
up, menopausal status, time from randomisation, body mass index, diastolic blood 
pressure, SF36 physical score, SF-36 mental score, and baseline oxford scale.  
 
Safety and Harms analysis 
 
Serious adverse events (SAEs) and adverse events (AEs) were summarised and assessed 
for similarity between the treatment groups.  Both SAEs and AEs were reported on an 
intention to treat basis (i.e. according to the group to which the participants was 
randomised). 
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Cost Effectiveness 
 
A cost-effectiveness analysis was undertaken alongside the trial using recommended 
methods (19-21).  The analysis takes the NHS perspective and includes costs and 
outcomes up to the patient’s final visit.  The first visit for all patients was allocated a 60 
minute appointment, the second visit for patients receiving electrical stimulation was also 
allocated a 60 minute appointment and all other appointments were allocated 30 
minutes.  Based on NHS Reference costs, 60 minute appointments were valued at £52 
and the 30 minute appointments at £42.  In addition, patients receiving electrical 
stimulation were also allocated an equipment and consumables cost of £16.31, based on 
equipment costs of £54.59, a life span of 10 years and utilisation rate of 80%.  Quality-
adjusted life years (QALYs) were calculated from the EQ-5D scores using the trapezium 
rule, using the actual time of follow-up. 
 
Analyses of total costs and QALYs used adjustments for baseline covariates via seemingly 
unrelated regression (22). Multiple imputation was used to replace missing data.  Costs 
and QALYs gained were compared between the groups and then used to plot data on the 
cost-effectiveness plane.   A value of £20,000 per QALY was used to determine the 
probability that the intervention is cost-effective under current funding conditions.  
Sensitivity analysis was undertaken using alternative cost sources for the PFMT visits and 
the Sf-6D for the calculation of QALYs. 
 
Results 
 
198 women were assessed for eligibity of whom 114 were randomised to standard 
PFMT or electrical stimulation. Participants were recruited between 01.12.2012 and 
30.11.2015 and followed up at 4-6 weekly intervals. The trial stopped recruitment once 
the sample size was reached. The flow of participants through the trial is shown in 
Figure 1. The study achieved its pre-specified target sample size of 114 participants. Of 
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the 114 participants randomised, sixty nine completed the study or had primary 
outcome reported. Sixty four participants had complete primary outcome data (PISQ-31 
Physical dimension score) at the end of follow up. On the control group of the 37 
patients completing the study or having primary outcome, 33 were on intention to treat 
(ITT) and completed the study, one did not complete study but was included anyway on 
ITT analysis, 3 completed the study but did not provide primary outcome data. On the 
experimental group, of the 32 patients completing the study or having primary outcome 
30 were on ITT and completed the study while two completed the study but did not 
provide primary outcome data. The patient that withdrew later on (Id=R038) however 
was included anyway on the ITT analysis given that provided a primary outcome value 
(collected at visit 4).  
 
Baseline demographic data and health related quality of life data for the control and 
intervention arms are summarised in Tables 1 and 2 respectively. These were comparable 
in the two groups and no significant differences noted. Table 2 compares the baseline 
characteristics of the 64 participants (34 control, 30 experimental) who had valid post-
randomisation follow-up outcome data and were included in the ITT analysis with the 
characteristics of the 50 (out of 114) participants (23 control, 37 experimental) who were 
also randomised but had no valid follow-up outcome data. The baseline characteristics of 
the 64 participants who provided valid outcome data were similar between the 
intervention and control groups suggesting that the baseline balance between the 
randomised groups had been maintained despite the 44% attrition in participants. 
 
A small but statistically significant change (improvement) in functioning was observed for 
overall PISQ outcomes following PFMT when both treatment options were combined 
(Table 3). This was in the Physical factors related to sexual activity rather than 
behaviour/emotive or partner related domains. However when comparing the Control 
group and the Intervention group the unadjusted and adjusted mean difference was not 
statistically significant (Table 4).  
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Sensitivity analysis on the primary outcome was carried out and the analysis was repeated 
for complete cases, imputing data for all participants. This shows similar results to the 
primary analysis suggesting the observed results are consistent and fairly robust to the 
missing outcome data and loss to follow-up. 
 
No treatment effect was observed between the control and intervention group on the 
EQ-5D, SF36 single scores and component summaries EPAQ sex life scores or Oxford 
scores on all analyses.  
 
Subgroup analysis by menopausal status demonstrated no statistical evidence of any 
subgroup effects or interactions between the treatment and control group.  
 
Overall 5 Adverse Events (AEs) were observed on 4 subjects (One subject experienced 2 
AEs) however none of these were related to the study and included road traffic accidents, 
surgery for other health problems and accidents resulting in the requirement for a plaster. 
There was no statistically significant difference in the number of visits between groups, 
but due to the longer appointment time for the second visit and the cost of the 
equipment, the mean cost of the electrical stimulation group was £32 higher (£100 vs 
£131, p<0.001). Mean QALYs were 0.15 higher in the electrical stimulation group 
(p<0.001) and when combined with the mean cost difference, leads to an incremental 
cost per QALY gained of £213.  There is a >99% chance of electrical stimulation being 
cost-effective compared to the standard PFMT.  The sensitivity analyses did not 
materially change these results. 
 Within this trial, the use of electrical stimulation is likely to be cost-effective.  This 
conclusion is driven by a very small incremental cost associated with the addition of 
electrical stimulation.  There is also a small and statistically significant gain in QALYs 
measured via the EQ-5D. 
 
Discussion and Conclusion 
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Main Findings 
 
In women presenting with sexual dysfunction in conjunction with urinary incontinence, 
phsyiotherapy is beneficial to improve overall sexual function. However no specific form 
of PFMT is beneficial over another. The effects of Electrical stimulation and standard 
PFMT on patient reported outcomes at follow-up are broadly similar with no reliable 
statistical evidence of any differences in primary or secondary outcomes.  However, 
small differences in costs and QALYs were identified which suggest that electical 
stimulation is cost-effective. 
 
Strength and Limitations  
 
This is the only study to compare PFMT alone to PFMT with electrical stimulation and 
assess its impact on sexual function. The trial design being an RCT was well suited to 
compare the 2 treatments.  Similar to previous studies, the IPSU trial has confirmed that 
PFMT either on its own (23-25) or with electrical stimulation improves overall sexual 
function But whereas previous studies assessing the impact of PFMT on sexual function 
have failed to use validated questionnaires for analysis (25-28) the IPSU trial used the 
PISQ a validated questionnaire for the assessment of sexual function in women with pelvic 
floor dysfunction. In addition most of these trails were observational studies with very 
small sample sizes and underpowered to establish the benefit or make comparisons 
between treatments.  
 
Another advantage is that the IPSU trial also assesses the cost effectiveness of the 
intervention.  
 
The main limitation of the IPSU trial is that the number of women analysed was smaller 
than the numbers needed to reach meaningful conclusions. In addition there was no 
blinding of the patients and physiotherapists, but it was felt to be impractical to 
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completely blind treatment. It was accepted that bias may be introduced as a 
consequence. This bias may arise as the treatment expectations following different 
modalities of treatment and the subjective clinical outcomes may be over-estimated or 
under-estimated depending on how women perceived their her prior problems and 
expected outcomes. Our clinical practical experience suggests that this bias would be 
minimal and its measurement would be beyond the objectives of this trial. Clinician bias 
is eliminated by patients performing ePAQ and PISQ at the end of the study as this 
provides objective evidence of the degree of change. 
 
A new version of the PISQ was developed after this study was commenced, the PISQ IR 
(29). Using the previous version of the questionnaire has however allowed analysis of the 
3 domains of sexual function.  
 
In terms of the economic analysis, a key drawback is that the trial does not examine the 
long-term effects of treatment or assess electrical stimulation’s position within a 
treatment pathway. Ideally, the results of this research should be combined with those of 
other RCTs and considered within a wider health technology assessment study, such as 
that undertaken by Imamura and colleagues (2010). 
 
Interpretation 
 
The current theory as to why PFMT may improve sexual function is varied. The pelvic floor 
muscles are directly responsible for the amount of sensation a woman feels during 
intercourse, and for the amount of grip felt by her partner. Rhythmic contractions of the 
pelvic floor contribute to arousal and many women's ability to achieve orgasm. Women 
may be able to reach orgasm more easily, after a pelvic floor exercise program. Exercise 
improves muscle tone and improves circulation, and this is particularly important for the 
smaller muscles of the pelvic floor, which are responsible for engorging the clitoris when 
women are aroused. This may explain why the improvement is in the physical aspect of 
sexual function as opposed to other aspects.  
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Previous studies have shown no difference in this benefit when used for purposes of 
urinary incontinence alone (30). This study reaffirms that there is no difference in PFMT 
alone compared to electrical stimulation and irrespective of the method adopted it is 
beneficial.  Whilst our economic analysis shows that the use of electrical stimulation is 
cost-effective, in the absence of clear clinical benefits the policy implications of these 
results are uncertain. 
 
Practical and research recommendations 
 
In women presenting with urinary incontinence and concurrent sexual dysfunction, PFMT 
is an effective treatment. The modality of PFMT does not impact on outcomes. Given the 
safety of this intervention it would be reasonable for all women to trial a course of PFMT 
before being referred to secondary care.  In terms of research, these results need to be 
considered in combination with other evidence, preferably through a systematic review 
and cost-effectiveness analysis.   
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Figure 1: CONSORT Flow chart: Participant flow in the IPSU 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Assessed for eligibility (n= 198) 
Excluded (n= 84) 
   Not meeting inclusion criteria (n=36  ) 
   Declined to participate (n=26 ) 
   Other reasons (n=22  ) 
Analysed (n=34) 
 Excluded from analysis (no primary 
outcomes) (n=3) 
Lost to follow-up (Unable to attend) (n= 12) 
Discontinued intervention (Investigator 
decision) (n=4) 
Allocated to Control (n= 57) 
 Received allocated intervention (n= 53 ) 
 Did not receive allocated intervention 
(adverse effect) (n= 4 ) 
Lost to follow-up (Unable to attend) (n=18) 
Discontinued intervention (Investigator 
decision) (n=6) 
   Allocated to intervention (n=57) 
 Received allocated intervention (n=56  ) 
 Did not receive allocated intervention 
(adverse effect) (n=1) 
    Analysed (n=30) 
 Excluded from analysis (no primary 
outcome) (n=2) 
 
Allocation 
Analysis 
Follow-Up 
Randomized (n=114) 
Enrolment 
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Table 1 Demographics and characteristics of participants at baseline 
 
 Group 
Standard physiotherapy Electrical Stimulation Total 
n % n % n % 
Age Mean (SD) 45.5 (9.8) --- 45.8( 9.4) --- 45.6(9.5
) 
-- 
Menopausal Status No 
Yes 
Total 
41 72 40 70 81 71 
16 28 17 30 33 29 
57 100 57 100 114 100 
Parity 0 2 4 0 0 2 2 
 1 11 19 13 23 24 21 
 2 32 56 24 42 56 49 
 3 6 11 10 18 16 14 
 4 3 5 8 14 11 10 
 5 2 4 2 4 4 4 
 8 1 2 0 0 1 1 
 Total 57 100 57 100 114 100 
Ethnicity English/Welsh/Scottish/North
ern Ireland/British 
56 98 56 98 112 98 
 Any Asian Background 0 0 1 2 1 1 
 Any other black/African/ 
Caribbean 
1 2 0 0 1 1 
 Total 57 100 57 100 114 100 
Hysterectomy No 49 86 47 82 95 84 
 Yes 8 14 10 18 18 16 
 Total 57 100 57 100 113 100 
Regular Menstrual Cycle No 7 12 9 16 16 14 
 Yes 27 47 23 40 50 44 
Dysmenorrhoea No 30 53 23 40 53 47 
 Yes 5 19 8 14 13 11 
Dyspareunia No 48 84 48 84 96 84 
 Yes 4 7 7 12 11 10 
Oxford Scale grade 0 1 2 5 9 6 5 
 1 23 40 14 25 37 33 
 2 30 53 33 58 63 55 
 3 0 0 1 2 1 1 
 Not Done 3 5 3 5 6 6 
 Total 57 100 57 100 114 100 
BMI Mean (SD) 28.4 (5.5) -- 30.7 (7.4) -- 29.5 
(6.6) 
-- 
 Group 
Standard physiotherapy 
(n=57) 
Electrical Stimulation 
(n=57) 
Total 
(n=114) 
PISQ behaviour emotive domain N (%) 55 (96.5%) 50 (87.7%) 105 (92.1%) 
Mean (SD) 38.2 (8.6) 34.1 (10.2) 36.2 (9.6) 
PISQ Physical Factor N (%) 55 (96.5%) 49 (86.0%) 104 (91.2%) 
Mean (SD) 29.7 (5.7) 27.7 (5.6) 28.7 (5.8) 
PISQ Partner related  N (%) 54 (94.7%) 49 (86.0%) 103 (90.4%) 
Mean (SD) 20.1 (2.0) 19.0 (3.1) 19.6 (2.6) 
PISQ Total Score N (%) 54 (94.7%) 48 (84.2%) 102 (89.5%) 
Mean (SD) 88.2 (12.7) 80.7 (14.3) 84.7 (14.0) 
EQ5D Score N (%) 55 (96.49%) 51 (89.47%) 106 (92.98%) 
Mean (SD) 0.79 (0.20) 0.78 (0.15) 0.78 (0.18) 
SF36 Physical Component scale N (%) 55 (96.5%) 51 (89.5%) 106 (93.0%) 
Mean (SD) 16.4 (39.1) 20.2 (36.6) 18.2 (37.8) 
SF36 Mental component scale N (%) 55 (96.5%) 51 (89.5%) 106 (93.0%) 
Mean (SD) 18.8 (37.8) 22.7 (37.4) 20.7 (37.5) 
ePAQ PF : General Sex Life N (%) 52 (91.2%) 56 (98.2%) 108 (94.7%) 
Mean (SD) 41.4 (27.4) 50.9 (25.3) 46.3 (26.6) 
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Table 2: Baseline characteristics by treatment group and missing data status 
Characteristic Missing PISQ physical dimension      Complete PISQ physical dimension      
 Control  Intervention  All  Control  Intervention  All  
 (n=23)  (n=27)  (n=50)  (n=34)  (n=30)  (n=64)  
 n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) n Mean (SD) 
Age 23 45.0 (9.9) 27 44.7 (9.7) 50 44.8 (9.7) 34 45.7 (9.8) 30 46.7 (9.1) 64 46.2 (9.4) 
BMI 21 28.3 (5.8) 24 31.1 (6.4) 45 29.8 (6.2) 33 28.4 (5.4) 28 30.4 (8.2) 61 29.3 (6.9) 
PISQ behaviour/emotion factor 21 37.1 (9.6) 21 32.5 (11.8) 42 34.8 (10.9) 34 38.8 (8.1) 29 35.2 (8.9) 63 37.2 (8.6) 
PISQ physical factor 21 28.4 (6.0) 21 26.5 (5.5) 42 27.4 (5.7) 34 30.5 (5.5) 28 28.5 (5.7) 62 29.6 (5.6) 
PISQ partner related factor 20 20.1 (2.1) 21 19.0 (3.1) 41 19.6 (2.7) 34 20.2 (2.0) 28 19.0 (3.2) 62 19.6 (2.6) 
PISQ total score 20 86.0 (13.6) 21 78.1 (15.1) 41 81.9 (14.8) 34 89.5 (12.2) 27 82.7 (13.6) 61 86.5 (13.2) 
EQ5D score 21 0.79 (0.13) 22 0.77 (0.18) 43 0.78 (0.16) 34 0.79 (0.24) 29 0.79 (0.13) 63 0.79 (0.19) 
SF-36 Physical Component Scale 21 15.9 (38.7) 23 10.6 (36.7) 44 13.1 (37.3) 34 16.8 (39.9) 28 28.0 (35.2) 62 21.9 (38.0) 
SF-36 Mental Component Scale 21 16.6 (37.9) 23 11.4 (36.2) 44 13.9 (36.7) 34 20.1 (38.2) 28 32.1 (36.4) 62 25.5 (37.5) 
ePAQ PF: General sex life    18 44.1 (27.1) 26 50.1 (24.6) 44 47.6 (25.5) 34 39.9 (27.8) 30 51.7 (26.3) 64 45.5 (27.5) 
____________________________________________________________________________________________________________________
_________ 
Characteristic  
Missing PISQ physical 
dimension   
Complete PISQ physical 
dimension   
  Control Intervention All Control 
Interventi
on All 
  (n=23) (n=27) (n=50) (n=34) (n=30) (n=64) 
Ethnicity English / Welsh / Scottish / Northern Irish / British 23 (100.0%) 27 (100.0%) 
50 
(100.0%) 33 (97.1%) 
29 
(96.7%) 
62 
(96.9%) 
 Any other Asian background 0 (0.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (3.3%) 1 (1.6%) 
 Any other Black / African / Caribbean Background 0 (0.0%) 0 (0.0%) 0 (0.0%) 1 (2.9%) 0 (0.0%) 1 (1.6%) 
        
Parity 0 2 (8.7%) 0 (0.0%) 2 (4.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
 1 4 (17.4%) 6 (22.2%) 10 (20.0%) 7 (20.6%) 7 (23.3%) 
14 
(21.9%) 
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 2 11 (47.8%) 9 (33.3%) 20 (40.0%) 21 (61.8%) 
15 
(50.0%) 
36 
(56.3%) 
 3 2 (8.7%) 6 (22.2%) 8 (16.0%) 4 (11.8%) 4 (13.3%) 8 (12.5%) 
 4 2 (8.7%) 6 (22.2%) 8 (16.0%) 1 (2.9%) 2 (6.7%) 3 (4.7%) 
 5 1 (4.3%) 0 (0.0%) 1 (2.0%) 1 (2.9%) 2 (6.7%) 3 (4.7%) 
 8 1 (4.3%) 0 (0.0%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
Hysterectomy No 20 (87.0%) 23 (85.2%) 43 (86.0%) 28 (82.4%) 
24 
(80.0%) 
52 
(81.3%) 
 Yes 3 (13.0%) 4 (14.8%) 7 (14.0%) 5 (14.7%) 6 (20.0%) 
11 
(17.2%) 
Menopausal No 18 (78.3%) 21 (77.8%) 39 (78.0%) 23 (67.6%) 19 (63.3%) 
42 
(65.6%) 
 Yes 5 (21.7%) 6 (22.2%) 11 (22.0%) 11 (32.4%) 11 (36.7%) 
22 
(34.4%) 
        
        
Regular menstrual cycle No 4 (17.4%) 7 (25.9%) 11 (22.0%) 3 (8.8%) 2 (6.7%) 5 (7.8%) 
 Yes 11 (47.8%) 11 (40.7%) 22 (44.0%) 16 (47.1%) 12 (40.0%) 
28 
(43.8%) 
Dysmenorrhoea No 14 (60.9%) 12 (44.4%) 26 (52.0%) 16 (47.1%) 11 (36.7%) 
27 
(42.2%) 
 Yes 2 (8.7%) 6 (22.2%) 8 (16.0%) 3 (8.8%) 2 (6.7%) 5 (7.8%) 
Dyspareunia No 18 (78.3%) 23 (85.2%) 41 (82.0%) 30 (88.2%) 25 (83.3%) 
55 
(85.9%) 
 Yes 2 (8.7%) 3 (11.1%) 5 (10.0%) 2 (5.9%) 4 (13.3%) 6 (9.4%) 
Oxford scale grade 0 1 (4.3%) 3 (11.1%) 4 (8.0%) 0 (0.0%) 2 (6.7%) 2 (3.1%) 
 1 7 (30.4%) 8 (29.6%) 15 (30.0%) 16 (47.1%) 6 (20.0%) 
22 
(34.4%) 
 2 12 (52.2%) 11 (40.7%) 23 (46.0%) 18 (52.9%) 22 (73.3%) 
40 
(62.5%) 
 3 0 (0.0%) 1 (3.7%) 1 (2.0%) 0 (0.0%) 0 (0.0%) 0 (0.0%) 
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Table 3 Overall change in PISQ following physiotherapy (both types of treatment 
combined) 
 
Outcome 
 n 
Mean change 
(SD) 95% CI 
p-
value 
PISQ 
behaviour/emotion 
factor 63 2.3 (6.8) 0.6 to 4.0 0.009 
PISQ physical 
factor 
62 3.2 (6.2) 1.6 to 4.8 <0.001 
PISQ partner 
related factor 
62 0.5 (2.2) -0.1 to 1.0 0.094 
PISQ total score 61 5.9 (11.8) 2.9 to 8.9 <0.001 
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Table 4: Primary Outcomes: mean difference of PISQ domains between Control and Intervention 
 
 Control Intervention Unadjusted Adjusted* 
Outcome n 
Mean 
(SD) n 
Mean 
(SD) 
N 
analysi
s 
mean 
difference 95% CI 
p-
value 
N 
analysi
s 
mean 
difference 
95% 
CI 
p-
value 
PISQ physical 
factor 34 
33.1 
(5.5) 30 
32.3 
(5.2) 64 -0.8 
-3.5 to 
1.9 0.572 60 -1 
-4.0 
to 1.9 0.474 
PISQ 
behaviour/emotio
n factor 
34 40.8 
(8.7) 
30 37.4 
(11.2) 
64 -3.4 -8.4 to 
1.6 
0.176 60 1.9 -2.1 
to 5.9 
0.345 
PISQ partner 
related factor 
34 20.4 
(2.0) 
30 19.6 
(3.0) 
64 -0.8 -2.1 to 
0.4 
0.202 59 0.4 -0.6 
to 1.5 
0.412 
PISQ total score 34 94.2 
(12.5) 
30 89.2 
(15.8) 
64 -5 -12.1 
to 2.1 
0.165 59 1.1 -5.9 
to 8.2 
0.748 
 
*Adjusted for baseline score, BMI, menopausal status, time from randomisation and oxford scale 
The PISQ-physical factor is scored on a 0 to 40 scale with a higher scoring indicating better sexual functioning 
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8. Conclusions and areas for future research 
 
Sexual well-being is complex and dependent on various inter-related factors including 
physical and mental well-being. It is an important determinant of emotional well-being, 
self-worth, and overall quality of life of women. However, urinary incontinence has a 
negative impact on sexual function. The impact of prolapse on sexual function was 
found to be similar to the impact of urinary incontinence. In women with urinary 
incontinence, urodynamic diagnosis does not correlate with the nature of underlying 
sexual problems, orgasm or penetration incontinence. Worsening urinary incontinence 
is associated with a more deleterious effect on sexual function. 
 
Through the work presented I have demonstrated the impact of various treatment 
strategies of urinary incontinence on sexual function. PFMT is associated with an 
improvement in sexual function but different modalities of treatment i.e. adding 
electrical stimulation to standard PFMT did not alter outcomes.  
 
Medical treatment of overactive bladder did not guarantee improvement in sexual 
function and when improvements were noted this was within the first 3 months of 
treatment.  
 
In most patients undergoing surgery for SUI, coital incontinence improves. There is 
potential for overall sexual function to deteriorate after surgery and this should be 
emphasized during the consent process for surgery. This is important to avoid 
disappointment and unhappiness with the surgery and to ensure realistic expectations. 
 
Although problems relating to sexual health are complex involving both psychological 
and physical factors. Consideration should be given to the impact of urinary 
incontinence and treatment offered as part of management of sexual dysfunction and to 
enquire about these symptoms before and after treatment routinely as part of the 
package of care being provided.  
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More recent forms of treatment for women with urinary incontinence include B3 
agonist Betmiga, intravesical Botox, Percutaneous Tibial Nerve stimulation (PTNS) and 
Sacral nerve stimulation (SNS). Further work into the impact these treatments have on 
sexual function is required and was outside the remit of this thesis.  
 
Most of the research into sexual health in women suffering urinary incontinence does 
not seek to identify what proportion of the problems are linked directly to the urinary 
incontinence and therefore the actual impact of treatment of this condition on their 
sexual health is difficult to gauge. Furthermore its importance in treatment outcomes 
and satisfaction has not been evaluated and would form an important future area of 
research. Good quality research into sexual function in women with urinary 
incontinence aimed at quantifying what aspects of a woman’s sexual function is affected 
by the urinary incontinence per se is required. This will allow improvement in 
management strategies and provision of more realistic expectations to patients of the 
impact that specific treatments are likely to have.  
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Pfizer UK Overactive Bladder / Detrusor Overactivity 
Competitive Grants Programme 2008 
 
RESEARCH PROPOSAL 
 
Study Title 
Impact of treatment of Overactive Bladder on Sexual Function 
 
Statement declaring your clinical or outcomes research study  
An observational questionnaire study of women with Overactive Bladder being treated 
with anticholinergic comparing sexual function before and after treatment.   
 
Objectives  
Statement of objectives 
To assess the impact of treatment of overactive bladder on sexual function. 
 
Specific aim/hypothesis 
 
To establish if an improvement in OAB symptoms by treatment with anticholinergics is 
associated with a corresponding improvement in sexual function. This will be done by 
comparing sexual function before and after treatment.   
 
Relevance of proposed study to "Advancing the Understanding of Overactive 
Bladder / Detrusor Overactivity” 
 
Several Studies have shown OAB to adversely affect sexual function1-6, but there is 
limited knowledge about the impact of treatment of overactive bladder on sexual function. 
This study aims to identify if an improvement in OAB symptoms is associated with an 
alteration in sexual function and if so what aspects of sexual function are improved.  
 
Description  
Experimental/research design  
 
This is a prospective observational Questionnaire study.  
 
Methodology (including methods of statistical analysis)  
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Sample Size 
We accepted a 20% improvement in sexual function to be clinically significant. To 
estimate this with +/-10% i.e. 95% confidence limits from 10% to 30% will require 62 
responders to the study. Assuming a 20% drop out rate the sample size required is 74 
responders. 
 
Data collection 
 
Sexually active women diagnosed to have OAB on the ePAQ (electronic Pelvic Floor 
Assessment Questionnaire) and commencing anticholinergics for the first time will be 
potential recruits for the study. These women will be asymptomatic for prolapse. A POP-
Q assessment will be performed and Aa, Ba, Ap and Bp should be above -1 (i.e no 
anterior or posterior wall prolapse) with no utero-cervical descent. Women may or may 
not have a urodynamic diagnosis of detrusor overactivity (DOA) but will have no voiding 
dysfunction (post-void residual of <100mls). Pre-treatment data collected will include age, 
ethnicity, parity, BMI, menopausal status, hysterectomy status and previous vaginal 
operations performed.  
Data will be collected on the status of bladder symptoms and sexual function before, 3 
months after and 6 months after treatment with anticholinergics. The anticholinergics will 
include Tolterodine and its formulation, Solifenacin, and Oxybutynin and its formulation. 
The impact of a 20 point improvement in OAB symptoms on bladder symptoms will be 
analysed and correlated to changes in sexual function. Patient Global Impression of 
improvement (PGI-I) data will be collected post treatment.  
 
Tools/ Questionnaire 
 
The ePAQ and the PGI-I are validated and reliable condition specific questionnaires used 
in the assessment of women with incontinence and related problems.  
The instrument used to assess pelvic floor symptoms will be the electronic pelvic floor 
symptoms assessment questionnaire (e-PAQ) which provides symptoms assessment in 4 
dimensions: Urinary, Bowel, Vaginal & Sexual. Each dimension provides 5 
psychometrically robust & clinically meaningful symptom domain scores, each score 
being transformed on a range from 0 (indicating best health status) to 100 (worst health 
status), The domain score is calculated using the simple formula: Domain Score = total of 
raw scores for each item in the domain / maximum possible score × 100. The sexual 
dimension provides 3 domain scores for the different aspects of pelvic floor 
symptomatology that may impact on sexual function: (1) Urinary, (2) Bowel & (3) 
Vaginal. The 2 final sexual domain scores are (4) Dyspareunia and (5) General sex life. 
The score for the urinary domain of the sexual dimension is derived from 4 items shown 
below. Each item is scored on an ordinal scale from 0-3, where 0 represents ‘Never’ and 3 
represent ‘All of the time’. These 4 items included;  
(1) Overall impact of bladder problems on sex life 
(2) Anxiety related to bladder problems during sex 
(3) Avoidance of sex by the patient because of their bladder problems 
(4) Partners avoiding sex because of the patient's bladder problems 
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Items not contributing to this score but analysed by the ePAQ also include orgasm 
incontinence, penetration incontinence & post-coital UTI. The impact of treatment of 
OAB on each of these parameters will be evaluated.  
The PGI- I asks a patient to rate the response of her condition to therapy and is simple, 
direct, easy to use, and intuitively understandable to the clinician. They are single item 
questions which rate the outcome from ‘very much worse’ to ‘very much improved’ over 
a 5 point Likert scale. The construct validity of the PGI-I has been widely established for 
treatment response. The PGI-I is incorporated into the ePAQ and is the last item on the 
questionnaire when it is being completed following treatment.  
 
Analysis 
 
The data will be analysed using SPSS. Wilcoxan Signed rank test will be used to compare 
pre and post treatment responses. Linear regression will be used to assess the relationship 
between the parameters analysed and changes in OAB scores following treatment. 
Significance has been set at a p value of < 0.05. 
By comparing the improvement in the scores of OAB and sexual function to the PGI-I the 
minimally important difference (MID) for each domain of the ePAQ will be calculated.  
 
Potential problems and strategies for overcoming them 
 
The potential problems include 
1. Patients may not be able to attend for Follow up appointments, resulting in a high 
drop out rate.  
The ePAQ, which is the tool being used for assessment of patients, can be used by on-
line completion. An initial survey has shown that 70% of women have access to the 
internet, hence this will enable a follow up of patients, even when they are unable to 
attend clinic.  
 
2. The Questionnaire burden 
Patients often find it tedious to complete a multitude of questionnaires. For this study, 
women only have to complete a single questionnaire which assesses all aspects of 
pelvic floor function including urinary, sexual, bowel and prolapse symptoms. The 
PGI-I is also incorporated into the questionnaire and this reduces the burden of the 
questionnaire. 
 
3. Change in anticholinergics 
Women commenced on anticholinergics quite often change medications. For the 
purposes of this study it is the improvement in OAB symptoms rather than the type of 
anticholinergic they are on that we are interested in.  
 
4. Patients with no improvement 
Not all women will experience an improvement in their OAB symptoms post-
treatment. These women will act as a control group to compare with those who do 
Pfizer UK Overactive Bladder / Detrusor Overactivity Competitive Grant Programme 2008 
 
 
 4
experience a benefit in their OAB symptoms.  
 
Expected outcome 
 
We anticipate an improvement in sexual function with a corresponding improvement in 
OAB symptoms. This study will help determine which domains of sexual function are 
improved by a corresponding improvement in OAB symptoms.   
 
Study relevance to past work 
We have done work looking at the impact of surgical correction of Stress incontinence 
and shown all domains of sexual function7 to be improved. This same study showed the 
impact on sexual function in women diagnosed to have mixed incontinence was far less 
marked and did not influence all domains of sexual function even though the 
improvement in their stress incontinence was similar to those with pure stress 
incontinence. There has been work in the past which suggest an association of penetration 
incontinence with SUI and orgasm incontinence with OAB. This has never been 
confirmed in a formal study and in fact the small amount of data we have from studies 
done by the chief investigator would suggest this to be inaccurate8. 
There is also very little data relating to the impact of treatment with anticholinergics on 
OAB. A review of literature did not demonstrate any primary published studies looking at 
this clinical problem. There is therefore an urgent need for this study to be done.  
 
 
Initial results to support study (if applicable)  
 
The above mentioned study demonstrated only two domains (orgasm incontinence and 
patient avoidance of intercourse) of sexual function improved with surgical treatment of 
the women with mixed incontinence and this is related to the fact that the overactive 
bladder component is untreated with surgical correction7. Another study done by the 
principal investigator showed that OAB was as likely to be associated with penetration 
incontinence as orgasm incontinence8.  There is very little evidence in literature to show 
the change/ improvement in sexual function symptoms following treatment of OAB.  
 
This study aims to assess the impact of treatment of OAB with anticholinergics on the 
different domains of sexual function.  
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Description of the laboratory facilities and equipment to be used  
 
The urogynaecology department of the Birmingham Women’s hospital is a tertiary 
referral unit with upto 1000 referrals a year. This is a large stand alone trust catering for 
Women’s health with facilities to investigate and treat patients at a tertiary level. The 
Department offers specialist care to women of all ages in a friendly welcoming 
environment, providing a high standard of care to women in South Birmingham and 
beyond. 
 
The service is provided by 2 consultants, 3 urogynaecology specialist nurses, as well as a 
urogynaecology subspecialist trainee, research fellow and 2 specialist registrars. The unit 
has a strong ethos in managing bladder problems, conservatively, whilst also offering 
proven surgical options when necessary. The unit offers an individualised, patient focused 
service, from referral to discharge and the current services include 
 The ongoing evaluation, investigation and treatment of urinary incontinence and 
pelvic floor dysfunction 
 Transperineal & transvaginal ultrasound scans 
 Laboratory urodynamics 
 Video Urodynamics  
 Ambulatory Urodynamics  
 Complimentary investigations (urethral pressure profile and pad testing)  
 Specialist combined clinics with a Colorectal surgeon with an interest in functional 
bowel disease and Urologist with an interest in female urology 
 An OASIS clinic 
 Development of an interest in sensory urgency  
 One of our current research interests is developing a nurse based service as a 2 year 
pilot funded through a pharmaceutical grant 
 
The ongoing research in the Unit include a number of Drug trials of which two are 
currently funded by Pfizer. Of these, I am personally collaborating the SOPHIA study. 
 
The equipment to be used involves the use of two computers on which patients are able to 
complete the ePAQ which is the questionnaire being used to assess OAB symptoms and 
sexual function pre and post treatment. Within the department we also have facilities to 
conduct urodynamics studies and ensure a normal void profile using the uroflowmeter and 
bladder scan. 
 
For patients unable to attend the Follow up clinic, the follow Up Questionnaire can be 
completed on Line as the ePAQ has been used in clinical practice by on line completion.  
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Description of the partner institutions and departments to be involved (if applicable)   
 
NA 
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Title  
Impact of physiotherapy on sexual function in women with urinary incontinence (UI)  
and a comparison of electrical stimulation versus standard physiotherapy:  
A prospective pragmatic parallel group randomized controlled trial (RCT) 
 
Short Title  
Impact of physiotherapy on the sexual function of women with urinary incontinence. 
 
1. ABSTRACT 
 
Aims 
This study aims to evaluate the effect of physiotherapy on sexual function of women with 
urinary incontinence. It also compares 2 different methods of pelvic floor muscle training 
comparing electrical stimulation to standard physiotherapy as a prospective parallel group 
randomised controlled trial (RCT). The clinical and cost effectiveness of these 2 
interventions on the sexual function of women with urinary incontinence and the response to 
treatments over a 6-month period will be compared.  
2. BACKGROUND AND INTRODUCTION 
Urinary incontinence (UI) is defined by the International Continence Society as the 
‘complaint of involuntary leakage of urine on effort or exertion, or on sneezing or coughing’ 
(Abrams et al. 2009). It is usually caused by weakness or damage to muscles and 
connective tissues of the pelvic floor, compromising urethral support, or by weakness of the 
urethral sphincter itself. Stress incontinence i.e. the ‘complaint of involuntary leakage of 
urine on effort or exertion, or on sneezing or coughing’ is the commonest cause of urinary 
incontinence in women and epidemiological studies have shown it to be most common 
between 45 and 54 years (Rortveit & Hunskaar 2006), with urge incontinence becoming 
more prevalent in older women.  
 
Epidemiological studies suggest that UI affects up to 41% of the female population 
(Hannestad et al. 2004). It is a health burden and impacts not only on social, psychological, 
occupational, domestic and physical health but also on sexual well being. The proportion of 
women suffering from UI who have sexual dysfunction is significant(Korda, Braun, & 
Engelmann 2007) (Aslan et al. 2005;Handa et al. 2004;Jha et al. 2009;Salonia et al. 2004) 
and has been reported to range from 26% (Korda, Braun, & Engelmann 2007) to 83% (Clark 
& Romm 1993). The taboo nature of sexual dysfunction means that symptom reporting has 
been infrequent and is often underreported. In addition, there is a lack of awareness of 
availability of treatment. 
  
Pelvic Floor Muscle Training (PFMT) is now accepted as the first line treatment for urinary 
incontinence (Berghmans et al. 1998) and the National Institute of Clinical Excellence 
(NICE) recommend that a trial of supervised pelvic floor muscle training of at least 3 months’ 
duration should be offered to all women with stress or mixed UI prior to any surgical 
intervention (National Institute of Clinical Excellence 2006). There is good evidence that 
daily pelvic floor muscle training continued for 3 months is safe and effective with an 
improvement in urinary incontinence expected in 40–60% of women (Bo 2003).  
 
The exact mechanism by which PFMT improves incontinence was postulated by Bo (Bo 
2004) who stated this may be achieved by three mechanisms: 1) women learn to 
consciously pre-contract the Pelvic Floor Muscles (PFM) before and during increases in 
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abdominal pressure (such as coughing, physical activity) to prevent leakage; 2) strength 
training builds up long-lasting muscle volume and thus provides structural support; and 3) 
abdominal muscle training indirectly strengthens the PFM. The first can be placed in a 
behavioral construct, while the two latter both have the aim of changing neuromuscular 
function and morphology, thus making the PFM contraction automatic; however the aim of 
therapy is to improve the strength and efficacy of pelvic floor contraction. 
 
Whereas there are several studies reporting on response of sexual function following  
incontinence surgery (Berthier et al. 2008;Brubaker et al. 2009;Cayan et al. 2008;Elzevier, 
Venema, & Nijeholt 2004;Ghezzi et al. 2006;Jha et al. 2007), the reports on the impact of 
physiotherapy on sexual function of women with SUI is limited. The current available 
evidence suggests that supervised PFMT has a beneficial effect on overall sexual function. 
An observational study assessing the impact of PFMT on sexual function showed all 
aspects of sexual function to be improved (Zahariou, Karamouti, & Papaioannou 2008). All 
domains of the FSFI (Female Sexual Function Index) significantly improved with median 
total FSFI scores increasing from 20.3 to 26.8. This is one of the few studies to quantify, 
using a validated questionnaire, the improvement in sexual function of women with SUI, 
undergoing successfully a 12-month supervised PFMT program. Unfortunately the Female 
Sexual Function Index is not validated for use in women with urinary incontinence.  
 
Beji (Beji, Yalcin, & Erkan 2003) showed similar results with an improvement in sexual 
desire, performance during coitus and achievement of orgasm in women who received 
pelvic floor muscle rehabilitation but also failed to use a validated questionnaire when 
assessing the impact of PFMT on sexual function.  
 
Bo Talseth, & Vinsnes (2000) also showed physiotherapy improved some aspects of sex 
life, but failed to look at different domains of sexual function.  Rivalta et al. (2009) looked at 
the impact of biofeedback, electrical stimulation, PFMT and vaginal cones in combination in 
3 women with urinary incontinence and associated sexual dysfunction. More recently Rivalta 
et al. (2010) found in a group of 16 women that sexual function was treated and quality of 
life improved by a complete pelvic floor rehabilitation program ie biofeedback, functional 
electrical stimulation, pelvic floor muscles exercises, and vaginal cones.  
 
Benefits were demonstrated however numbers were too small and the benefit of individual 
interventions difficult to assess. All these studies were of a small size and underpowered to 
answer the relevant question. In addition, they fail to use a validated questionnaire and have 
made no comparisons with different types of physiotherapy. 
 
Neuromuscular electrical stimulation has been shown to be safe and effective in the 
treatment of women with urinary incontinence both stress (Sand et al. 1995;Smith, III 1996) 
and urgency (Siegel et al. 1997;Smith, III 1996). It is at least as effective as PFMT (Bo, 
Talseth, & Holme 1999). In patients with sexual dysfunction electrical stimulation has been 
found to be of benefit particularly those with vulval pain disorders (Dionisi et al. 2008;Nappi 
et al. 2003). lGiuseppe, Pace & Vicentini (2007) demonstrated that in women with UI and 
who scored low on the Female Sexual Function Index (FSFI) showed an improvement in 
urinary leakage and also in their sexual life following treatment by neuromuscular electrical 
stimulation. This was an observational study with relatively small numbers and made no 
comparisons with alternative forms of physiotherapy. 
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The current theory as to why PFMT may improve sexual function is varied. The pelvic floor 
muscles are directly responsible for the amount of sensation a woman feels during 
intercourse, and for the amount of grip felt by her partner. Rhythmic contractions of the 
pelvic floor contribute to arousal and many women's ability to achieve orgasm. Women may 
be able to reach orgasm more easily, after a pelvic floor exercise program. Exercise 
improves muscle tone, which means that the muscle is tighter, so is stretched more by an 
erect penis. Strong, firm muscles have more nerve endings, and more nerve endings mean 
more sensations during sex. Exercise improves circulation, and this is particularly important 
for the smaller muscles of the pelvic floor, which are responsible for engorging the clitoris 
when women are aroused.  
 
To date there has been no study assessing the impact of physiotherapy on sexual function 
of women with urinary incontinence using a validated condition specific questionnaire. There 
have been no studies comparing the impact of electrical stimulation versus standard PFMT 
on sexual function of women with urinary incontinence.  
 
3. METHODOLOGY  
 
ETHICS  
The study is registered with the R&D office of the Sheffield Teaching Hospitals NHS 
Foundation Trust.  Research ethical approval and NHS research governance approval will 
be sought and gained prior to commencement of the project.  
 
AIMS & OBJECTIVES  
1. To evaluate the effect of physiotherapy on sexual function of women with UI 
2. To compare standard physiotherapy with electrical stimulation 
3. To evaluate the cost effectiveness of one treatment versus the other. 
 
Research Question 
1. Does physiotherapy improve sexual function in women with urinary incontinence? 
2. Does standard PFMT versus PFMT in conjunction with electrical stimulation in the 
treatment of urinary incontinence improve clinical and patient-centred outcomes related to 
sexual function? 
 
Null Hypothesis  
There is no change in sexual function of women following physiotherapy for urinary 
incontinence.  
There is no difference in sexual function following treatment with standard PFMT versus 
standard PFMT with electrical stimulation. 
 
TRIAL DESIGN  
A prospective pragmatic parallel group randomized controlled trial (RCT). 
(Appendix 1: flow chart of study design).  
As the study compares two different forms of treatment this would be the most appropriate 
design.  
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STUDY POPULATION 
 
Population  
Women referred to secondary care with urinary incontinence who, following clinical 
assessment or urodynamic studies, are deemed to require physiotherapy (Pelvic floor 
Muscle training) are potential recruits for this study. Potential participants will be identified 
by review of referral letters received from GPs or other clinicians.  
 
SETTING  
The Jessop Wing of the Royal Hallamshire Hospital, Sheffield, UK will be recruiting patients 
for this study. A feasibility assessment has been performed to ensure that the Gynaecology 
outpatients department is referred the appropriate number of patients to recruit to this study 
in the estimated time frame. On average 30 patients are referred each month for stress 
incontinence to the physiotherapy department. Of these 15 are premenopausal sexually 
active women. Assuming 50% women agree to be recruited into the study, recruitment could 
be achieved in 16-18 months but we are allowing for 2 years allowing for any delays or 
issues that could potentially cause recruitment to be slower than anticipated.  
 
INCLUSION AND EXCLUSION CRITERIA 
 
Inclusion criteria  
 Women must have given written (personally signed and dated) informed consent.  
 Women who are able to understand, and are willing to comply with the requirements 
of the protocol. 
 Women who are sexually active and are between the age of 18yrs and 
premenopausal with urinary incontinence attending physiotherapy for PFMT.   
 Women who score either greater than 25% on the urinary domain of the sexual 
function dimension, and/or greater than 33% for the degree of bother for the same 
symptom  
 
Exclusion criteria  
 Women with a prolapse as their predominant problem. 
 Women who have had any previous incontinence surgery.  
 Women who have a Grade 3 or above muscle strength as measured using the 
modified Oxford Scale on vaginal examination. 
 Women with vaginal discharge or UTI. 
 Women fitted with an implanted pacemaker. 
 Women who are pregnant. 
 Women with undiagnosed pelvic pain. 
 Women with a known sensitivity to the electrodes or the electrode gel. 
 Women with inflammation or infection of the vulva and vagina. 
 Women who have experienced recent haemorrhage or haematoma. 
 Women with Atrophic vaginitis. 
 Any other medical condition or abnormality (e.g. malignancy or complication) that in 
the opinion of the investigator would impact upon the safety or efficacy of the study 
treatment or any study assessments. 
 The patient is enrolled in another interventional trial. 
 Non-English speaking women or with a specific language problem. 
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RANDOMISATION 
  
Women scheduled to undergo PFMT for predominant stress incontinence will be 
randomised to either 1) Standard PFMT or 2) PFMT plus Electrical Stimulation.  
 
Allocation will be through block randomisation (with a variable block size an integer multiple 
of two). The study statistician will generate a randomisation schedule using the STATA 
software. A series of consecutively numbered opaque sealed envelopes will be created that 
will contain the treatment allocations. These sealed envelopes will be opened by the 
research administrator at the time of randomisation in the next consecutive order revealing 
which arm the patient is randomized to. The numbers on the envelope will become the 
patient’s identification number for the duration of the study. The randomization envelopes 
will be labeled from 001-150 which would allow for any screen failure patients who decide 
not to take part in the study once randomization has been performed or who do not meet the 
inclusion/exclusion criteria at visit 1 when performed by the physiotherapist. The envelopes 
will be opened in strict numerical order.  
The research administrator will sign/date the randomisation form to confirm it was opened in 
consecutive order and also record the date, patient's NHS number/details on the 
randomization form and in the medical notes. The Research administrator will be 
independent from the physiotherapists who are performing the study procedure so bias will 
not be affected.   
The research administrator will arrange for the patient information sheets and consent forms 
to be made available at each appropriate clinic where it is expected potential patients will be 
recruited.  
Randomization envelopes will be stored in a locked cabinet when not required. 
 
BLINDING 
 
In order for the physiotherapist to perform the study procedures, they will be aware of which 
group the patient has been randomised to. 
 
The woman will not be blinded to the treatment they will receive. We believe that it would be 
impractical to blind treatment, but accept that bias may be introduced as a consequence. 
This bias may arise as the treatment expectations following different modalities of treatment 
and the subjective clinical outcomes may be over-estimated or under-estimated depending 
on how she would view her prior problems and expected outcomes. Our clinical practical 
experience suggests that this bias would be minimal and its measurement would be beyond 
the objectives of this trial. Clinician bias is eliminated by patients performing ePAQ and 
PISQ at the end of the study as this provides objective evidence of the degree of change.  
 
4. STUDY PROCEDURES 
 
All potential patients will be seen in clinic by their hospital Doctor where a full history will be 
obtained and the necessary investigations will be performed including a vaginal examination 
using the modified Oxford scale, which is routine hospital procedure. 
 
The patient will have completed e-PAQ (interactive questionnaire) either at home or at the 
time of this visit and their Doctor will decide on a plan of care.  
 
ANNEXE 4. RFPB APPLICATION: PB-PG-0110-19276 
Impact of Physiotherapy on Sexual function of women with Stress Urinary Incontinence and a 
comparison of electrical stimulation versus standard physiotherapy: 
 
Impact of Physiotherapy on Sexual function of women with SUI.  
Version 1: Dated 17th May 2010.   
 
9 
If the clinician is referring the woman for physiotherapy and they meet all the 
inclusion/exclusion at this point they will be invited to participate in the study. All patients 
invited into the study will be given the approved patient information letter and consent form 
to take home and review/sign. All consent forms will be returned to the study administrator in 
a pre-paid envelope once signed by the patient. 
 
114 women (57 to each arm) will be randomly allocated to each treatment arm. Pelvic floor 
symptoms, including incontinence severity before and after treatment will be assessed using 
the ‘Electronic Pelvic Floor Assessment Questionnaire’ (ePAQ). Changes in sexual function 
will be assessed using the ‘Prolapse and Incontinence Sexual function Questionnaire’ 
(PISQ). SF-36 domain scores; EQ-5D score; ePAQ urinary & sexual domain scores before 
and after physiotherapy and a comparison in the two groups. 
 
Incontinence severity will be assessed using ePAQ, and different aspects of sexual function 
will be assessed by the PISQ, including physical, behavior, emotive and partner related 
domains. Assessments will be made at baseline and on completion of treatment.  
SPSS will be used for analysis of results. 
 
Note  
It is normal practice at the Jessop Wing, Sheffield for women to be invited to a 
physiotherapy group session where they will receive information about the normal routine 
treatment they can expect to receive along with advice on how to perform pelvic floor 
exercises. Once the physiotherapist receives the referral letter from the medical staff the 
patient will be sent a letter inviting them to attend this group session. This session provides 
women with an opportunity to ask questions about the study. 
 
Consent and Randomization  
Once the research administrator has received the consent form from the patient the 
randomization envelope will be opened in consecutive number order (starting at 001) to 
identify which group the patient will be randomized to. The research administrator will 
sign/date the randomisation form to confirm it was opened in consecutive order and record 
the date, patient's NHS number/details on the randomization form and in the medical notes.  
The research administrator will then contact the patient to notify them of their clinic 
appointment and which treatment they will receive.  
 
Group 1 = Standard Pelvic Floor Muscle Training.  
Patients will receive a minimum of 4 and up to 6 sessions with assessments by the 
physiotherapist being performed at each visit on a monthly basis. 
 
Group 2 = Pelvic Floor Muscle Training with Electrical Stimulation.  
Patients will receive a minimum of 4 sessions and up to 6 sessions with assessments by the 
physiotherapist being performed at each visit on a monthly basis. 
 
Neuromuscular stimulation is the electrical stimulation of muscle and nerve fibres. A small 
hand held machine will be attached to an internal vaginal electrode and used at home by the 
patient on a daily basis. Treatment sessions last 20 minutes and the treatment continues for 
3-6 months. Electrotherapy will be chosen when the pelvic floor is generally graded between 
0-2 on the Oxford scale. Alongside this and as a means of assessing progress, 
Electromyography (EMG) will be used (which may show high resting baselines). This 
increases patient awareness during a voluntary contraction. EMG is a technique for 
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evaluating physiologic properties of muscles and is used to achieving biofeedback and is an 
integral component of electrical stimulation. This will show the activity of the muscle on a 
screen which increases interest and challenge to the treatment of electrical stimulation 
Two physiotherapists will be involved in this study, one will treat group 1 patients and one 
will treat group 2.  
 
The following procedures will be performed on each group of patients: 
 
Visit 1:  
Physiotherapy visit. (Week 0.) 
Group 1 Patients:  
 Perform subjective and objective assessment using standard department 
assessment tool.  
 Perform a vaginal examination using the modified Oxford scale.  
 Identify/document problems with the patient  
 Identify goals and agree an action plan with the patient. 
 Review e-paq results with the patient.  
 Review frequency / volume chart with the patient 
 Document a personalized exercise plan:  
 
Advice and education on posture, core stability and on performing pelvic floor exercises will 
be given. Exercises will include slow and fast contractions. 
NICE guidelines recommend 8 PFM contractions repeated three times a day. All exercises  
should be patient specific and based on the initial assessment of the pelvic floor. 
 
 Perform bladder re-education as necessary 
 Arrange the next appointment and provide the patient with contact details. 
 Complete the ‘Case Report Form’ (CRF) and ‘Source Data’. 
 
Group 2 patients: As above +  
 Discuss treatment option of electrotherapy to commence at the next visit. 
 
Visit 2: 
 
Physiotherapy Visit. (week 3 +/- 1 week)  
 
For Both Groups. 
 Review symptoms with the patient. 
 Review goals and establish new ones with the patient. 
 Review & encourage personalized exercise programme with the patient 
 Discuss with the patient problems identified by e-paq / pisq in sexual domain.  
 Arrange the next appointment. 
 Complete ‘Case Report Form’ (CRF) and ‘Source Data’. 
 Obtain Adverse Events data and document in Case Report Form. 
 
Group 2 only: 
 EMG assessment and commence electrotherapy 
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Maintenance visits 3/4/5/6 (performed at 3 weekly intervals +/_1 week 
 
i.e week 6/9/12/15/18. +/- 1 week) 
 
For Both Groups: 
 Review symptoms with the patient. 
 Review goals and establish new ones with the patient. 
 Assess any change in symptoms subjectively  
 Assess if managing daily treatments with the patient 
 Discuss/review exercises in relation to ‘activities of daily living’ with the patient 
 Encourage patient to continue treatment and pelvic floor exercises. 
 Discuss any sexual problems 
 Review/resolve any questions  
 Arrange the next appointment. 
 Complete the ‘Case Report Form’ (CRF) and ‘Source Data’. 
 Record any Adverse events  
 
Group 2 only: 
 Assess if using neuromuscular stimulator correctly. 
 Change programme if necessary  
 
Those patients experiencing benefit will continue using the device for a minimum of 3 
months to a maximum of 6 months with assessments by the physiotherapist being 
performed at each visit. The program may be changed depending on the progress made 
with their urinary incontinence as per departmental protocol.  
 
At the end of the treatment phase patients whose symptoms have improved will be 
discharged and patients who have experienced no or minimal improvement will be 
referred back to their hospital gynaecologist for further treatment. 
 
End of study visit:  
The study can complete in both groups only after a minimum of 4 visits (visit 4/5/6 or week 
12/15/18). 
 Complete the ‘Case Report Form’ (CRF) and ‘Source data’. 
 
ADVERSE EVENTS 
An adverse event (AE) is any untoward medical occurrence in a patient or clinical 
investigation subject administered a pharmaceutical product or device and which does not 
necessarily have to have a causal relationship with the treatment. 
Although no serious adverse events are anticipated, it is possible that these may occur and a 
system for reporting these promptly is required.  
All Adverse Events (AE’s) or Serious Adverse Events (SAE’s) occurred during the trial either 
observed by the investigator or reported by the participant, whether or not attributed to the 
study, will be reported on the Case Report Form (CRF). AEs/SAEs considered to be related 
to the trial by the investigator will be followed up until resolution or the event is considered 
stable. The investigator may be asked to provide follow-up information. 
All related AEs/SAEs that result in a participant’s withdrawal from the trial or are present at 
ANNEXE 4. RFPB APPLICATION: PB-PG-0110-19276 
Impact of Physiotherapy on Sexual function of women with Stress Urinary Incontinence and a 
comparison of electrical stimulation versus standard physiotherapy: 
 
Impact of Physiotherapy on Sexual function of women with SUI.  
Version 1: Dated 17th May 2010.   
 
12
the end of the trial should be followed up until a satisfactory resolution occurs. 
The Chief Investigator shall submit, once a year throughout the clinical trial, or on request, a 
safety report to the Ethics Committee that includes all AEs/SAEs. 
In order to elicit details of any AEs/SAE’s, at each visit the patient should be asked a non-
leading question such as: “Do you feel different in any way since the last assessment / 
visit?” 
 
5. OUTCOMES 
 
1. Primary Outcomes  
Self reported PISQ-31 Physical dimension score, at six months in women undergoing 
physiotherapy for urinary incontinence and a comparison in the two randomized groups.  
 
2. Secondary Outcomes  
PISQ-31 Behavioral Emotive dimension and Partner-Related dimension scores; SF-36 
domain scores; EQ-5D score; ePAQ urinary & sexual domain scores before and after 
physiotherapy and a comparison in the 2 groups. 
Assessments will be at Baseline (prior to commencing Physiotherapy), 3 and 6 month (post 
commencement of Physiotherapy) intervals.  
 
The PISQ is a 31 item questionnaire with responses measured on a 5-point Likert scale. It 
evaluates sexual function of women with either urinary incontinence and/or pelvic organ 
prolapse. The PISQ identifies 3 separate and distinct domains of sexual function. These 
include Behavioural Emotive, Physical and Partner Related. Whereas the Behavioural 
Emotive domain evaluates sexual desire, frequency of sexual activity, and orgasmic 
capabilities, the Physical Domain assesses more directly the effect of urinary incontinence 
on sexual function. The partner Related Domain on the other hand assesses the patient’s 
perception of her partner’s response to the effect of her pelvic floor disorder on their sexual 
functioning, as well as her partner’s sexual functioning. Scores are calculated by totaling the 
scores for each question, from 0 (always) to 4 (never), with the exception of question 5, 
which is scaled from 0 (always) to 5(do not masturbate). Individual domain scores are 
calculated by adding the scores for the individual items in each domain.  
 
The SF-36 is a generic health related quality of life, which is capable of producing eight 
domain scores including, social functioning, emotional role limitations, mental health and 
general health perceptions. Each domain is scored from zero to 100, with higher scores 
indicating better health. The SF-36 one of the most popular health related quality of life 
instruments in the world and has been shown to have good measurement properties across 
a wide range of conditions. 
 
The EQ-5D (Dolan 1997) is a short generic health related quality of life instrument that 
produces a single score. It is principally used to generate quality adjusted life years (QALYs) 
for use in economic evaluation and is recommended by the National Institute for Health and 
Clinical Excellence (NICE) for use in its technology appraisal programme. 
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6. SAMPLE SIZE CALCULATION 
 
For the purposes of sample size estimation the primary outcome will be the mean PISQ-31 
physical dimension score at 6-months post randomisation.   
From a study performed by the group who developed the PISQ 32, they found the mean and 
Standard Deviation in the 3 dimensions of the PISQ in women with UI to be: 
 
Behavioral Emotive       39.2+/- 9.1 
Physical                       34.1+/- 5.3 
Partner-Related           19.2+/-  3.1 
Total PISQ                   92.6+/- 13.5 
 
The above study looking at PISQ scores in women with urinary incontinence found these 
values in women with no urinary incontinence (who served as controls for the study), to be  
 
Behavioral-Emotive    43.7+/-7.0  
a difference of 4.5 points compared to women with UI 
Physical    36.8+/-2.5  
a difference of 2.7 points compared to women with UI 
Partner-Related    20.5+/-1.7 
Total PISQ     100.1+8.8 
 
To have an 80% power of detecting a 3-point mean difference in PISQ-31 physical 
dimension scores at 6-month between the Electrical stimulation/Biofeedback and standard 
treatment group as statistically significant at the 5% (two-sided) level with s.d  of 5 will 
require 45 patients per group (90 in total). If 20% of patients drop out and are lost to follow-
up then the study will need to recruit and randomize 57 per group (114 in total).  With 90 
patients we will be able to show a difference of 2.2 units in a non-randomised before and 
after comparison with baseline and 6 month scores for the overall effect of both treatments  
 
If we assume a standard deviation of 9.0 points for the PISQ-31 behavioral Emotive 
dimension score at 6-months, with a sample size of 45 patients the study would have 80% 
power to detect a difference of 5.5 or more points in mean 6-month PISQ-31. Following 
randomization, with 45 patients per group we will also have 80% power to detect a 
difference of 5.5 or more points in mean 6-month post randomisation PISQ-31 Behavioural 
emotive domain scores between the groups as statistically significant at the 5% (two-sided) 
level.  
 
7. ANALYSIS OF DATA 
 
As the trial is a pragmatic parallel group randomised, with a usual (control) treatment arm, 
data will be reported and presented according to the revised CONSORT Statement for 
reporting of pragmatic randomized controlled trials (Moher, Schulz, & Altman 
2001;Zwarenstein et al. 2008). The statistical analysis will be performed on an intention-to-
treat-basis. All statistical exploratory tests will be two-tailed with alpha = 0.05. Baseline 
demographic (e.g. age, parity, previous history urinary incontinence, current smoking 
history) and health related quality of life data (PISQ-31, ePAQ, SF-36 and EQ-5D scores) 
will be assessed for comparability between the treatment groups.   
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The primary aim is to assess the impact of physiotherapy on sexual function of women with 
urinary incontinence and compare standard PMFT treatment plus electrical stimulation 
versus standard PMFT treatment. The primary outcome will be the patient’s self-reported 
PISQ-31 Physical dimension score, at three months post randomization. Statistical methods 
appropriate for analysing patient reported outcome measures as described in Walters 
(Walters S.J. 2009) will be used.  A two independent samples t-test will be used to compare 
mean PISQ-31 Physical dimension scores, at three months post randomization between the 
two groups (standard PMFT treatment plus electrical stimulation versus standard PMFT 
treatment). A 95% confidence interval (CI) for the mean difference in PISQ-31 Physical 
Symptom dimension scores between the electrical stimulation treatment and standard 
groups will also be calculated. In the event of differences between the electrical stimulation 
treatment and standard groups with respect to baseline demographic, physical, and health-
related quality of life measurements, multiple linear regressions will be used to adjust the 
treatment effect for these variables. The ordinary least squares estimated adjusted 
regression coefficient estimate for the treatment group parameter along with its 95% 
confidence interval (CI) will then be reported alongside the simple unadjusted estimate. 
Secondary outcomes such as the mean PISQ-31 Behavioural Emotive dimension and 
Partner-Related dimensions; ePAQ dimension scores, and SF-36 outcomes at three month 
follow-up will be compared before and after treatment and between the two groups using a 
two independent samples t-test. A 95% confidence interval (CI) for the mean difference in 
this parameter between the treatment groups will also be calculated.  
For the repeated PISQ-31 and other secondary outcomes at baseline, 3 and 6 months a 
summary measure such as the Area Under the Curve (AUC) will be calculated for each 
patient(Matthews et al. 1990). Two independent samples t-test will be used to compare 
mean AUC between the groups. A 95% confidence interval (CI) for the mean difference in 
AUCs between the groups will also be calculated. 
No interim analysis of the data is planned. No sub-group analysis will be performed. All data 
will be analyzed with SPSS for Windows software (SPSS; Chicago, IL). Further analyses will 
be undertaken in addition to the ITT trial-based evaluation. Missing primary outcome data 
(3-month post randomization PISQ-31 Physical Symptom dimension scores) will be imputed 
through a variety of methods including: Last observation carried forward (LOCF); horizontal 
mean imputation and regression imputation as described by Walters (Walters S.J. 2009); to 
check the robustness and sensitivity of the ITT analysis. 
The economic evaluation will take the form a cost-utility analysis and will take a NHS and 
Personal Social Services perspective (although no PSS costs are thought possible in this 
patient group). Costs will be based around the number and type of physiotherapy sessions 
undertaken (i.e. with and without electrical stimulation). Differences in the use of any 
equipment (including portable electrical stimulation equipment) will also be recorded. All 
other costs will be captured by a patient questionnaire at 6 months. Unit costs for the two 
types of sessions will be constructed through a small micro-costing exercise of 100 
sessions, and will examine differences in length of time and necessary equipment and 
consumables. Other unit costs will come from NHS Reference costs, the British National 
Formulary and ‘Unit costs of health and social care’.  The EQ-5D will be scored using the 
‘Dolan’ tariff, with QALYs then estimated using linear interpolation between data points. 
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The focus of the economic analysis will be to estimate the probability that the intervention is 
cost-effective at funding thresholds of £20,000 and £30,000 per QALY. This will be 
supported by plots on the cost-effectiveness plane and cost-effectiveness acceptability 
curves. Missing data will be imputed using multiple imputation. Deterministic sensitivity 
analysis will be used to examine any service issues identified by the Trial Steering Group. 
8. PATIENT INPUT 
 
A lay summary of the protocol was reviewed by 4 patient groups as described below and 
feedback requested. The suggestions made by each were addressed and incorporated into 
the design of the protocol.  
 
Service User Representative 
A patient who had already received treatment for this condition was approached to join the 
study group as a representative of Service users. Having used the physiotherapy services 
successfully, she has been involved in the protocol development and is a named applicant 
on the RfPB application. Her chief role has been to provide information and feedback into 
the design of the study especially in relation to the lay summary and she will be actively 
involved in monitoring the progression of the study and speaking to potential patients who 
are considering consenting to the study.  
 
Physiotherapy Patients Group 
This is a patient group run by the hospital Women’s Health Physiotherapy team and 
includes women who are receiving physiotherapy as a treatment for incontinence. This 
group of patients comprised women who could be potential recruits for the study hence this 
group provided a patient perspective to the protocol.  
 
The Jessop Wing Readers panel  
This panel comprises of a lay panel that provide feedback on the overall design and content 
of the information leaflets produced for the department of Obstetrics and Gynaecology. They 
reviewed the protocol individually and provided advice and guidance on the wording of the 
protocol and supporting documents.   
 
Sheffield Teaching Hospitals NHS Foundation Trust Patient Representative 
This group plays an important role in different aspects of the Trust Management including: 
 
 Attending and participating in Directorate Management Team meetings as a full, active 
member as and when there are issues of interest on the agenda. 
 Attending any other relevant Directorate meetings. 
 Attending quarterly meetings of the Patient Representative Group 
 Representing the views of the patient carer population.   
 
Members of this group reviewed the lay summary and provided feedback individually.  
 
In addition to feedback into the design of the protocol each of the above groups were asked 
the following:  
1. If they felt the research was worthwhile? 
2. If they would be willing to be involved as recruits?  
3. If they wished to be informed of the results? 
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4. If they would be willing to be involved in a service users trial steering 
committee?  
 
All those providing feedback felt the research was worthwhile and needed to be performed.  
82% who were approached said they would have been willing to participate if they were 
approached. 
Those wishing to be informed of the results have provided their contact details and will be 
informed in due course of the results.  
Those willing to be on a trial steering committee will be contacted again once funding has 
been made available and a Trial Steering Committee will be set-up..  
 
Changes made following PPI input:  
1. The service user representative felt that women with previous surgery were less 
likely to benefit from physiotherapy as they would probably have had physiotherapy 
prior to their primary surgery. It was therefore agreed that previous continence 
surgery would be an exclusion criteria as this could lead to bias. 
2. A member of the physiotherapy patients group highlighted that pelvic floor tone and 
sexual function can be influenced by age as an independent variable. This could 
impact on the results if women recruited were of different ages. The initial protocol 
included women up to the age of 60, but following this feedback it was agreed that 
premenopausal women alone would be included in the study. 
3. The Jessop Wing Readers Panel suggested changes in the wording of the flowchart 
of the study. They also recommended adding to the patient information leaflet that 
treatment would not be delayed if they chose not to be in the study. This statement 
will be incorporated into the patient information sheet (PIS).   
4. Sheffield Teaching Hospitals NHS Foundation Trust Patient Representatives 
suggested adding a statement regarding the time frame for the return of the 
questionnaire to facilitate the study and enhance compliance. This will be added to 
the PIS.  
 
9. QUALITY CONTROL 
All monitoring and auditing procedures which are the responsibility of the Sponsor, Sheffield 
Teaching Hospitals NHS Foundation Trust Research Department and other Regulatory Authorities 
will be adhered to. The Trial Management Group (TMG) will also meet on a monthly basis to 
discuss the performance of the study in relation to the timelines, recruitment and any safety issues 
identified during the performance of the study. 
 
Trial Management Group (TMG) 
The TMG is an informal group of trial personnel who have input into the monitoring and 
supervision of the trial. It will be the responsibility of the Chief Investigator to perform the role 
of study manager and they will also Chair the (TMG) who will consist of the other recruiting 
PI’s, Physiotherapists’, Research Administrator and Directorate Research co-ordinator. 
The Trial Management Group (TMG) will meet on a regular basis to discuss the 
performance of the study in relation to the timelines, recruitment and any safety issues 
identified during the performance of the study. The role of the TMG is to assist the study 
manager in the day-to-day running of the trial.  
 
The Trial Steering Committee (TSC) 
It is role of the Steering Committee (TSC) is to provide overall supervision of the trial and in 
particular, the progress of the trial, adherence to protocol, patient safety and consideration 
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of new information. Day to day management of the trial is the responsibility of the Chief 
Investigator (CI). The TSC will be required to make executive decisions about the trial, for 
example, whether a trial should continue or not following advice by the ethics committee.  
The Trial Steering Committee (TSC) will act independently of the Trial Management Group 
and will consist of the following people:  
 Mr Andrew Farkas: Consultant Gynaecologist and Clinical Director of Obsterics, 
Gynaecology and Neonatology 
 Miss Angela Driscoll. R&D Co-ordinator from the Research Department within the 
Sheffield Hospital NHS Foundation Trust. 
 The Service User Representative. 
 
10. DURATION OF STUDY  
 
It is anticipated this will be 42 months (including study set-up): 
 Study set-up including ethics submission/governance. 6 months 
 Recruitment 6-30 months 
 Minimum follow up 6 months (30-36 months)  
 Final data analysis and preparation of results for dissemination 6 months (36-42 months)  
 
11. PROJECT MANAGEMENT  
 
It will be the responsibility of the Chief Investigator to disseminated all study related 
information and procedures to all participants in the team along with information relating to 
protocol amendments or safety issues.  
A research administrator will be employed to support the physiotherapists with the research 
administration of this protocol. As this protocol mimics current practice funding will not be 
available to fund the physiotherapists. However, funding will be requested to enable the 
physiotherapist to obtain training in GCP/research governance and to attend the meetings of 
the trial management group (TMG). 
The research administrator will help to support the physiotherapist by organising the 
clinics/appointments, randomisation, maintaining the site file, study documentation, 
completion of Case Report Forms (CRF) and data entry into the study database etc... 
 
The Directorate Research Co-ordinator has assisted in the design of the protocol and co-
ordinated the RfPB application and will support  the study set-up, ethical and governance 
approval, provide research training to the research administrator and physiotherapists, and 
will be ensure accrual data is maintained. 
 
It is the policy within the Jessop Hospital-Sheffield that the Jessop Wing Research 
Executive provides administrative support to all studies performed within the Directorate of 
Obstetrics, Gynaecology and Neonatology. This resource is funded and will be available to 
assist with the ethics and governance requirements of the study.  
 
12. DATA MANAGEMENT 
Services will be bought from the Sheffield University Clinical Trials Research Unit to design 
and maintain the database and perform the analysis. 
A database system built to a specification agreed between Sheffield CTRU and the Chief 
Investigator will be developed. The system will be accessible remotely via a web browser, 
with the data stored securely on a central server. Access will be controlled by the use of 
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assigned logins and encrypted passwords. The system will have a full electronic audit trail 
and will be regularly backed up. If required point of entry checks will be included in the 
system. The data will be available in CSV format ready for import into standard 
spreadsheets and statistical analysis packages. On-going support will be provided for minor 
modifications and trouble-shooting. All activities will be performed in accordance with 
Sheffield CTRU Standard Operating Procedures. 
Support after database set-up is limited to providing minor modifications and trouble-
shooting only e.g. one or two additional field or changes to coding where simple. This does 
not include addition of new questionnaires or new CRF pages after the database has been 
set-up and data entry has commenced. 
 
Data management mainly comprises of the production of regular data quality reports 
(including missing data, out of range values, incongruent values, etc.) and basic summary 
statistics (recruitment rates, basic analyses). This role will be performed by the Chief 
Investigator.  
 
Other funding will be requested for the following: 
 Consumables  
 Physiotherapist training and time to participate in the TMG 
 PPI aspects 
 Steering committee remuneration 
 Service User Representative remuneration 
 Postage 
 NeuroTrace 4 continence devices along with periform vaginal probes. 
 
13. EXPERTISE OF THE TEAM: 
Swati Jha. (Chief Investigator).  
 Consultant Obstetrician & Gynaecologist, Sheffield Teaching Hospital NHS Foundation 
Trust. 
 Recruiting PI 
 Member of Study Management Group 
 
Mr. Stephen Radley. (Recruiting Investigator).  
 Consultant Obstetrician & Gynaecologist, Sheffield Teaching Hospital NHS Foundation 
Trust. 
 Recruiting Patients. 
 Member of Study Management Group 
 
Professor Stephen Walters. (Co- Investigator).  
 Health Services Research, School of Health & Related Research, University of Sheffield. 
 Professor of Medical Statistics and Clinical Trials 
 Sample size calculation and Data analysis 
 
Professor Simon Dixon. (Co-Investigator). 
 Professor of Health Economics 
 Responsible for the economic evaluation 
 Health Services Research, School of Health & Related Research, University of 
Sheffield. 
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Maria Goodwin. (Co-Investigator).  
 Womens Health Physiotherapist. Sheffield Teaching Hospital NHS Foundation Trust. 
 Performing physiotherapy to group 2 patients. 
 Member of Study Management Group 
 
Kate Reece. Womens Health Physiotherapist.  
 Physiotherapist. Sheffield Teaching Hospital NHS Foundation Trust. 
 Performing physiotherapy to group 1 patients 
 Member of Study Management Group 
 
Philippa Watmough-Cownie: Service User Representative.  
 Provide patient perspective on study 
 Speak to patients with any questions regarding the study 
 Member of Study Management Group 
 
To be appointed. Research Administrator. 
 To support the physiotherapist with the day-to-day management of the study. Responsible 
for study documentation, Site file maintenance, organisation of study clinics, CRF 
completion, data base entry, communication with patients in relation to clinic appointments 
etc. 
 Member of Trial Steering Committee 
 
Mrs Clare Pye. Directorate Research Co-ordinator.  
 Assisted with the design of the protocol and application form. Co-ordinated the RfPB 
application and will facilitate study set-up within the directorate including ethics, governance, 
accrual etc... 
 Provide training as required to other members of the TMG 
 Member of Study Management Group 
 
Support Services 
Departments which will be used to facilitate study: 
 Department of Obstetrics, Gynaecology & Neonatology 
 Department of Physiotherapy 
 Department of Research & Development  
 Yorkshire & Humber Research Design Service 
 Sheffield University Clinical Trial Research Unit 
 
14. TAKING THE WORK FORWARD 
 
Depending on the outcomes, future counselling and management of patients with coexisting 
urinary incontinence and sexual dysfunction could be affected. Current practice is that 
women with sexual dysfunction in association with urinary incontinence are referred for 
electrical stimulation. There is no evidence to support this practice. Electrical stimulation has 
a cost implication to the NHS as devices are required. These devices need regular 
maintenance and servicing and have a limited life span. In addition, EMG machines are 
needed to perform the procedure. There are also training implications, as all 
physiotherapists are trained to teach PFMT, however not all physiotherapists are trained to 
carry out electrical stimulation.  
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If the results fail to show benefit this expenditure may be avoided. If however there is benefit 
demonstrated from electrical stimulation there will be a case for investing in this form of 
treatment in future.  
 
The results will therefore guide further evidence based management of these patients while 
resulting in potential cost savings to the NHS.   
 
15. ETHICAL ISSUES 
Non-English speaking women or women with a specific language problem will not be 
recruited as the validated questionnaires used in this study are not available in other 
languages and to arrange for them to be translated and validated at this stage of the 
protocol design into other languages would be a major piece of work.  
 
16. FUNDING  
Funding is being applied for from the Research for Patient Benefit Scheme (RfPB).  
 
17. COSTING SCHEDULE 
Refer to finance form.  
 
18. INTELLECTUAL PROPERTY 
None anticipated  
 
19. DISSEMINATION 
The work will be published in Medline indexed peer reviewed Journals i.e. IUGA Journal, 
Neurology Urodynamics and the BJOG. It will be presented at National and International 
meetings such as the UKCS, ICS and IUGA.   
 
Patients and Jessop reader group members comprising the advisory steering group for the 
study will be informed of the results as will all patients recruited into the study and Reader 
Group members who have expressed an interest in the results and are not members of the 
advisory steering group. 
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Appendix 1: Study flowchart 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Patient referred for urinary 
incontinence 
Clinical assessment using ePAQ +/- 
UDS:  
Predominant Stress incontinence + 
Fulfils the Inclusion criteria 
 
Patient referred for Physiotherapy & 
given Patient information sheet/ 
consent form and PISQ 
Consent form and PISQ returned by 
patient in post:  
Randomisation performed.  
Exclusion criteria: prolapse/ previous 
SI surgery/ Not sexually active/ post 
menopausal 
Standard PFMT 
Patient informed of clinic appointment 
and treatment group allocation by 
Study administrator.  
Standard PFMT + Electrical 
stimulation  
 
Comparison of the two methods  
 
 
Change in sexual function following 
physiotherapy 
Commented [j1]: I have added + fulfils inclusion criteria in the 
box above 
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Appendix 2: PISQ  
The PISQ is a 31 item questionnaire with responses measured on a 5 point Likert scale. It 
evaluates sexual function of women with either urinary incontinence and/or pelvic organ 
prolapse.  
The PISQ identifies 3 separate and distinct domains of sexual function. These include 
Behavioural Emotive, Physical and Partner Related. Whereas the Behavioural Emotive 
domain evaluates sexual desire, frequency of sexual activity, and orgasmic capabilities, the 
Physical Domain assesses more directly the effect of urinary incontinence on sexual 
function. The partner Related Domain on the other hand assesses the patient’s perception 
of her partner’s response to the effect of her pelvic floor disorder on their sexual functioning, 
as well as her partner’s sexual functioning.  
Scores are calculated by totalling the scores for each question, from 0 (always) to 4 (never), 
with the exception of question 5, which is scaled from 0 (always) to 5(do not masturbate). 
Individual domain scores are calculated by adding the scores for the individual items in each 
domain.  
Behaviour emotive domain includes questions 1,2,5,6,7,8,9,10,12,22,23,24,26,27 and 29. 
The physical domain includes questions 11,13,16,17,18,19,20,21,25,and 30. The partner 
related domain comprised  questions 3,4,14,15,28, and 31. 
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Appendix 3: The Modified Oxford Scale 
 
Grade 0: No discernible PFM contraction 
 
Grade 1: a flicker, or pulsing under the examining finger- a very weak contraction 
 
Grade 2: a weak contraction - an increase in tension in the muscle without any discernible 
lift or squeeze 
 
Grade 3: a moderate contraction – characteristised by a degree of lifting of the posterior 
vaginal wall and squeezing on the base of the finger (pubovisceralis) with in drawing of the 
perineum. A grade 3 or higher grade contraction are generally discernible on visual perineal 
inspection. 
 
Grade 4: a good PFM contraction producing elevation of the posterior vaginal wall against 
resistance and in drawing of the perineum. If two fingers (index and middle) aare placed 
laterally and/or vertically and seperated, a grade 4 contraction can squeeze them together 
against resistance. 
 
Grade 5: a strong contraction of the PFM; strong resistance can be given against elevation 
of the posterior vaginal wall and approximation of the index and the middle finger as above. 
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Appendix 4: ePAQ 
 
The e-PAQ is an interactive web-based computerised interview, designed to assess & 
analyse pelvic floor symptoms in women. It comprehensively measures symptoms as well 
as their impact on quality of life. It immediately processes response data, providing an 
instantaneous measure of pelvic floor health that can be printed out & used during the 
clinical episode.  
 
e-PAQ provides 19 domain scores in 4 dimensions: Urinary, Bowel, Vaginal & Sexual (all 
scored on a scale of 0 - 100).  
 
The impact of the problem on Quality of life is also estimated. The domains of relevance for 
this study will be the urinary and vaginal domains, and the impact of these symptoms on 
quality of life.  
 
Appendix 5: SF- 36 
 
The SF-36 is a generic health related quality of life, which is capable of producing eight 
domain scores including, social functioning, emotional role limitations, mental health and 
general health perceptions.    Each domain is scored from zero to 100, with higher scores 
indicating better health.  The SF-36 one of the most popular health related quality of life 
instruments in the world and has been shown to have good measurement properties across 
a wide range of conditions. 
 
Appendix 6: EQ-5D 
 
The EQ-5D is a short generic health related quality of life instrument that produces a single 
score.  It is principally used to generate quality adjusted life years (QALYs) for use in 
economic evaluation and is recommended by the National Institute for Health and Clinical 
Excellence (NICE) for use in its technology appraisal programme. 
 
 
